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1. Introduction 
The rational of the research performed during this PhD project was to apply 
the peptide-based approach defined "Chemical Reverse Approach" previously 
developed at the Interdepartmental Laboratory of Peptide & Protein Chemistry 
& Biology of the University of Florence (Department of Chemistry "Ugo 
Schiff", Department of Pharmaceutical Sciences, and Department of 
Neurology) for the identification and characterization of antigen-antibody 
interaction in order to dissect the molecular mechanisms of autoimmune 
responses in disease conditions. 
In particular final aim of this PhD was the design, synthesis, and set-up of 
specific immunoassays, i.e., SP-ELISA, as new peptide-based diagnostic tools 
for particular disease phases of Coeliac Disease and Multiple Sclerosis. 
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1.1. Introduction to the immune system 
The human immune system has evolved over millions of years from both 
invertebrate and vertebrate organisms to develop sophisticated defense 
mechanisms to protect the hosts from microbes and their virulence factors. 
From invertebrates, humans have inherited the innate immune system, an 
efficient defense system that uses germ line-encoded proteins to recognize 
pathogens. Upon contact with pathogens, macrophages and natural killer (NK) 
cells may kill pathogens directly or may activate a series of events that both 
slow the infection and recruits the more recently evolved arm of the human 
immune system, the adaptive immune system. 
The adaptive immune system consists of dual limbs of cellular (T-
lymphocytes) and humoral (B-lymphocytes) immunity. B-lymphocytes 
produces antibodies (Abs) that are able to bind, neutralize and kill foreign, 
dangerous molecules, termed antigens (Ags). In infected cells, the Antigen 
Presenting Cell (APC) exposes peptide fragments, derived from hydrolysis of 
all the proteins present into the cell, to the T-lymphocytes attack by a special 
class of cell-surface glycoproteins, e.g. the Major Histocompatibility Complex 
(MHC) molecules
1
, as shown in Figure 1.1. 
 
 
Figure 1.1MHC-I bound antigen is scanned by T-cell receptor. 
                                                        
1 Rose, N.; Mackay, I., The Autoimmune Diseases, Elsevier Academic Press, 4thEdition., 
Elsevier Academic Press, 4
th
 edition, 2006. 
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Depending on the antigen presented and the type of MHC molecule, several 
types of immune cells can be activated. Both B and T lymphocytes derive 
from a common stem cell and the proportion and distribution of these 
immunocompetent cells in various tissues reflect cell traffic, homing patterns 
and functional capabilities. Cytokines are the soluble proteins that direct, focus 
and regulate specific B- versus T- lymphocyte immune response, thus 
triggering humoral or cell mediated pathways, as summarized in Figure 1.2. 
 
 
Figure 1.2. Mechanism of the immune response. 
Coupled with finely tuned specific recognition mechanisms that maintain 
tolerance (non reactivity) to self antigens, T- and B- lymphocytes bring both 
specificity and immune memory to vertebrate host defenses. One of the 
classically accepted features of the immune system is the capacity to 
distinguish self from non self.Most animals do not mount immune responses to 
self antigens under ordinary circumstances and thus are tolerant to self. 
Whereas self recognitionplays an important role in shaping both the T cell and 
B cell repertoires of immune receptors and in recognition of nominal antigen 
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by T cells, the development of potentially harmful immune response to self 
antigens is, in general, precluded
2
. 
 
1.2 Antigen-Antibody interaction 
The modern definition of antigenencompasses all substances that can be 
recognized by the adaptive immune system thus acting as an immunogen. An 
antigen is generally a protein molecule that often protrudes from the cell 
surface eliciting an immune response leading to the production of specific 
antibodies. Antibodiesare host proteins found in plasma and extracellular 
fluids that serve as the first response to pathogens. Also referred to as 
Immunoglobulins (Igs), because they contain a common structural domain 
found in many proteins, antibodies are composed of four polypeptides. Two 
identical copies of both a heavy (∼55 kD) and light (∼25 kD) chain are held 
together by disulfide bonds as well as noncovalent interactions, and the 
resulting molecule is often represented by a schematic Y-shaped molecule of 
∼150 kD (Figure 1.3). 
 
Figure 1.3. The basic structural molecule of an antibody. 
 
                                                        
2Kasper, D.L. ; Braunwald, E.; Fauci, A.S.; Hauser, S.L.; Longo, D.L.; Jameson J.L., 
Principles of internal Medicine, Mcgraw Hill Medical, 16
th
Edition, 2005. 
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Antibodies perform two essential roles: 
1. Epitope or antigen binding with the arms of the Y. Each arm or 
monovalent antibody fragment (fragment antigen-binding,Fab1) 
domain contains a binding site. 
2.  The fragment crystallizable (Fc) domain of the Y imparts to the 
antibody the biological effector functions such as natural killer cell 
activation, activation of the classical complement pathway, and 
phagocytosis. 
 
Antibodies can bind to different targets, allowing the immune system to 
recognize an equally wide diversity of antigens. Ag-Ab interaction is central to 
the antibodies' natural biological function and this property is usedboth for a 
research or therapeutic aim. Antibodies binds only a determinant or an epitope 
region of a macromolecule, which can also contain multiple determinants. The 
part of the antibody that binds to the antigenic determinant is termed the 
"antigen combining site", e.g.the paratope. Small molecules cannot induce an 
adaptive immune response by themselves. In fact, molecules with molecular 
weight below 5000Da are usually non effective immunogens. However, many 
of these small non immunogenic molecules, when covalently linked to a large 
molecule, i.e. a protein, can stimulate an immune response. These molecules, 
which are non-immunogenic by itself, are termed haptens, and the large 
molecules to which can be covalently attached, generally proteins, are termed 
carriers. Once the hapten-carrier complex is formed, a specific antibody 
response can occur. This is the case of human little gastrin where conventional 
gastrin/carrier protein conjugates prepared via classical crosslinking reactions 
generally lead to strong anti-gastrin responses in terms of antisera titers
3
. 
For simplicity, the binding of antibody with a simple hapten, which has only 
one antigenic determinant site, is used to illustrate the antigen–antibody 
                                                        
3Moroder, L.; Kocher, K.; Papini, A.M.; and Dufresne, M., Chemistry of peptides and 
proteins, 1993, 783-791. 
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interaction. As shown in Equation 1, the interaction depends on the 
equilibrium or affinity constant (K¼ka/kd), which is the ratio of the 
association (ka) and dissociation rate constant (kd), and the concentrations of 
the reactants, i.e. [antibody] and [antigen]. 
 
Equation 1. Equation of Antigen-Antibody interaction. 
 
In general, the K values for antibody–antigen interaction are in the range of 
106–109 L.mol-1, but they may vary from 103 to 1014 (L.mol-1). 
 
1.2.1 Classes and functions of antibodies 
In mammals there are five classes of antibodies, each characterized by a 
different function, IgG, IgA, IgM, IgD, and IgE.  
IgG antibodies are the most common and the most important. They circulate in 
blood and other body fluids, defending against invading bacteria and viruses. 
IgGs move easily across cell membranes and in humans this mobility allows 
the IgGs in a pregnant woman to pass through the placenta to her fetus, 
providing a temporary defense to the unborn child. 
IgA antibodies are present in tears, saliva, and mucus, as well as in secretions 
of the respiratory, reproductive, digestive, and urinary tracts. IgA function is to 
neutralize bacteria and viruses and prevent them from entering the body or 
reaching the internal organs. 
IgMs are present in blood and are the largest antibody form, combining five 
Y-shaped units. Their function is similar to IgGs in defending against antigens 
but cannot cross membranes because of the size. IgMs are produced in an 
initial attack by a specific bacterial or viral antigen, while IgGs are usually 
produced in later infections caused by the same agent. 
INTRODUCTION 
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IgDs may play a role in eliminating B-lymphocytes generating self-reactive 
autoantibodies. 
IgE antibodies trigger the body to respond against foreign matter like pollen, 
spores, pet dander and fungus. They are present in lungs, skin and mucous 
membranes. IgE levels are typically high in people with allergies. They may 
also be present where there are allergic reactions to drugs and food, i.e. milk. 
 
 
 
Figure 1.4. Classes of antibodies. 
 
1.2.2 Epitopes in antibodies 
The specificity of the antibody response refers to its ability to recognize a 
specific epitope in the presence of other epitopes. The binding site of an 
antibody can usually lodge an antigenic epitope of approximately 6 amino 
acids. The epitopes composed by linear (continuous) amino acid sequences are 
termed linear epitopes. Linear epitopes can be accessible to antibodies if they 
are exposed on the external surface of the antigen or in a conformationally 
extended regionsof the folded protein antigen. Differently, in conformational 
epitopes, the antibody interacts with amino acids not sequentially linked but 
spatially close one to each other, because of the protein folding. Antigen-
INTRODUCTION 
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antibody binding is reversible, and follows the basic thermodynamic principles 
of any reversible bimolecular interaction
4
. 
The binding energy between an antibody molecule and the antigen determinant 
is termed affinity. Thus, antibodies with paratopes recognizing epitopes 
perfectly, will have higher affinity for the antigen in question.On the contrary 
antibodies for which the antigen fit is less perfect, will have fewer non-
covalent bonds established into the complex, and the binding strength will be 
lower.Avidity can be regarded as the sum of all different affinities. 
Mathematically, affinity and avidity are expressed as an association constant 
(K, L/mol) calculated under equilibrium conditions
5
. 
 
1.3 Molecular mechanisms of autoimmunity 
Autoimmunity represents the end result of the breakdown of one or more of 
the basic mechanisms regulating immune tolerance. Since Paul Ehrlich (who 
was the first to postulate the existence of mechanisms preventing the 
generation of self-reactivity), several ideas concerning the nature of this 
inhibition have developed in parallel with the progressive increase in 
understanding the immune system. Currently, three general pathways are 
thought to be involved in the maintenance of selective unresponsiveness to 
autoantigens: sequestration of self-antigens, rendering them inaccessible to the 
immune system; specific unresponsiveness (tolerance or anergy) of relevant 
T or B cells; and limitation of potential reactivity by regulatory mechanisms. 
Derangements of these normal processes might predispose to the development 
of autoimmunity. Microbial superantigens, such as staphylococcal protein A 
and staphylococcal enterotoxins, are substances that can stimulate a broad 
range of T and/or B cells based upon specific interactions with selected 
                                                        
4Harlow, E.;and Lane,D., “Using Antibodies, a laboratory manual”, Cold Spring Harbor 
Laboratory Press, NY, 1999. 
5Crowther, J.R.,"ELISA Theory and Practice Methods in Molecular Biology" Vol.42, 
Editor John M. Walker, HUMANA PRESS, 1995. 
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families of immune receptors irrespective of their antigen specificity. If 
autoantigen-reactive T and/or B cells express these receptors, autoimmunity 
might develop. Alternatively, molecularmimicry or cross reactivity between a 
self antigen and a microbial molecule with a very similar structure and/or 
conformation to mammalian surface glycoproteins and/or glycolipids, might 
lead to activation of autoreactive lymphocytes.  Molecular mimicryhas been 
reported in type I diabetes mellitus, rheumatoid arthritis, and multiple 
sclerosis
6
. The most commonly identified triggering agents are pathogens 
having carbohydrate sequences (considered the antigens) in common with the 
peripheral nervous tissue. 
 
 
Figure 1.5.Molecular mimicry7. 
The human stomach pathogen Helicobacter pylori exposes lipopolysaccharide 
(LPS) containing Lewis antigens mimicking human glycan structures 
interacting with human dendritic cells: these are thought to induce a 
suppression of the immune response thus facilitating a chronic H. Pylori 
infection. Moreover, LPS biosynthetic pathway can be considered 
evolutionarily connected to bacterial protein N-glycosylation
8
. 
 
                                                        
6 Oldstone, M. B. A., Cell, 1987, 50, 819-820. 
7 Oldstone, M.B.A., The FASEB J., 1998, 12, 1255-1265. 
8
  Hug, I.; and Feldman, M.F., PloS Pathogens, 2010,6(3),e1000829. 
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1.4 The Autoimmune Diseases 
Autoimmune diseases are syndromes caused by the activation of T and/or B 
cells, with no evidence of other causes such as infections or malignancies. The 
essential feature of an autoimmune disease is that tissue injury is caused by the 
immunologic reaction of the organism with its own tissues. In some 
autoimmune disorders a pathologic immune response is localised to specific 
antigens confined to a particular organ system. Alternatively, systemic 
autoimmune diseases are characterized by an immune response to ubiquitous 
intracellular antigens in which the relationship between immune specificity 
and disease manifestations may not be obvious. Multiple factors can contribute 
to the genesis of clinical autoimmune disease syndromes including genetic 
susceptibility, environmental immune stimulants such as drugs, infectious 
agent triggers, and loss of T regulatory cells, as shown in Figure1.6. 
 
 
Figure1.6. Possible causes of immune regulation failure in Systemic lupus 
erythematosusand rheumatoid arthritis autoimmune diseases9. 
 
Genetic evaluation has shown that the occurrence in type1 diabetes, 
rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus is 
approximately 15 to 30% of pairs of monozygotic twins, whereas in the case 
of coeliac disease is 60%. Autoimmune diseases affect approximately 8% of 
                                                        
9
Chavele, K.M.; and Ehrenstein, M.R., FEBS Lett., 2011, 585(23), 3603–3610. 
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the population, 78% of whom are women. Theyoften cause chronic 
debilitating illnesses thus having a high social impact
10
. 
 
1.4.1 Aberrant PTMs triggering autoimmunity 
Alterations in antigen presentation may also contribute to autoimmunity. This 
may occur by epitope spreading, in which protein determinants (epitopes) not 
routinely seen by lymphocytes (crypticepitopes) are recognized as a result of 
immunologic reactivity to associated molecules. Growing evidences indicate 
that post-translational modifications (PTMs), either native or aberrant, may 
play a fundamental role for specific autoantibody recognition in autoimmune 
diseases
11
. In autoimmune diseases in which the antigens have not yet been 
characterised, several molecules (not only carbohydrates) could modify by a 
covalent bond a self-protein antigen, which will become a non-self one 
triggering an abnormal antibody response
12
. Aberrant glycosylation of self-
antigens (proteins), deamidation, biotinylation and lipoylation, as well as 
transamidation and other modifications can be responsible of influencing the 
level of epitope production, and the generation of neoepitopes, leading to 
autoimmune responses. 
 
Figure 1.7. Examples of common PTMs triggering autoimmune mechanisms. 
                                                        
10Lipman, N.S.; Jackson, L.R.; Trudel, L.J.; and Weis-Garcia, F., ILAR J., 2005,46(3), 258-
268. 
11Doyle, H.A.; and Mamula, M.J.,Trends. Immunol.2001, 22, 443-449. 
12S. Mouritsen, M. Meldal, I. Christiansen-Brams, H. Elsner, O. Werdelin, Eur. J. 
Immunol., 1994, 24, 1066-1072. 
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The modified regions are termed neo-antigenic epitopes and can be recognized 
by different specific antibodies. Therefore, glycopeptides with simple sugars 
or synthetic peptides reproducing other modifications can be suitable tools to 
investigate the antigen fine specificity of specific T cells. 
 
1.5 The role of glycosylation in autoimmune diseases 
Interest in glycobiology has dramatically increased amongst immunologists 
during the last few years due to the fact that oligosaccharides also play a 
central role in adhesion and homing events during inflammatory processes, 
comprise powerful xenotransplantation antigens, and may provide targets for 
tumor immunotherapy. Additionally, alterations in glycosylation are now 
known to occur in a number of autoimmune diseases
13
.  
Interestingly, for the first time Lolli et al. in 2005
14
, Schwarz et al. in 2006
15
, 
and more recently Brettschneider et al. in 2009
16
, demonstrated that 
glucosylation could be one of the PTMs responsible of triggering autoAbs in a 
relapsing-remitting form of multiple sclerosis (MS). Almost all of the key 
molecules involved in the innate and adaptive immune response are 
glycoproteins and in the cellular immune system, specific glycoforms have 
been reported to be involved in folding, quality control, and assembly of 
peptide-loaded MHC antigens and the T cell receptor complex. 
Oligosaccharide structures play also a key role in antigenicity of a number of 
clinically relevant antigens such as blood group determinants. Moreover, 
oligosaccharides attached to glycoproteins in the junction between T cells and 
APCs help to orient binding faces, providing protease protection, and 
                                                        
13a)Delves, P.J., Autoimmunity. 1998, 27(4), 239-53; b) Rudd, P.M.; Elliott, T.; 
Cresswell, P.; Wilson, I.A.; Dwek, R.A., Science, 2001, 291(5512), 2370-2376. 
14Lolli, F.; Mulinacci, B.; Carotenuto, A.; Bonetti, B.; Sabatino, G.; Mazzanti, B.; D’Ursi, 
A. M.; Novellino, E.; Pazzagli, M.; Lovato, L.; Alcaro, M. C.; Peroni, E.; Pozo-Carrero, M. 
C.; Nuti, F.; Battistini, L.; Borsellino, G.; Chelli, M.; Rovero, P.; Papini. A.M. Proc. Natl. 
Acad. Sci., U.S.A. 2005, 102(29), 10273-10278. 
15 Schwarz, M.;Spector, L; Gortler, M; et al., J. Neurol. Sci., 2006, 244, 59-68. 
16
Brettschneider, J., Jaskowski, T.D.; Tumani, H., J. Neuroimmunol., 2009, 217, 95-101. 
INTRODUCTION 
18 
restricting nonspecific lateral protein-protein interactions. Last but not least, in 
the humoral immune system, all of the immunoglobulins and most of the 
complement components are glycosylated. 
 
1.5.1 Protein glycosylation 
Protein glycosylation is a phenomenon shared by all domains of life. Over 
70% of the eukaryotic proteome is thought to be glycosylated. Protein 
modification by enzymatic glycosylation, is an event that reaches beyond the 
genome and is controlled by factors greatly differing among cell types and 
species. Gangliosides, glycosphingolipids, and glycoproteins found on the 
surface of oligosaccharides provide cells with distinguishing surface markers 
that can serve in cellular recognition and cell-to-cell communication. The 
defining event in the biogenesis of peptide-linked oligosaccharides is clearly 
the formation of sugar-amino acid bond. This, in most instances, determines 
the nature of the carbohydrate units that will subsequently be formed by the 
cellular enzymatic machinery, which in turn influences specific protein’ 
biological activity. 
Protein glycosylation is structurally divided into O- and N-linked 
glycosylation. In the former, the first sugar of the oligosaccharide is attached 
to the hydroxyl group of Ser, Thr, Hyl, or Hyp residues, whereas in the latter it 
is attached to the terminal amide group of Asn residues. Although more and 
more bacterial and archaeal N-glycosylation systems are becoming known, the 
best characterized system is the N-glycosylation pathway of eukaryotes and 
especially of Saccharomyces cerevisiae
17
. Mechanisms for glycan attachment 
to proteins and further studies will shed more light on the variety of 
glycosylation pathways. 
 
 
                                                        
17
Dwek, R.A., Chem. Rev., 1996, 96, 683–720. 
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1.5.2 Bacteria transferring sugar moieties in host proteins 
We now know that carbohydrates are involved in a wide range of biological 
processes, including host-pathogen interactions and the immune response and 
that glycoproteins are a common feature in all domains of life. Bacteria 
surfaces are decorated with glycans. Today, many pathways by which 
prokaryotes can promote glycosylation mechanisms have been reported. 
Considering the huge diversity of prokaryotic glycoproteins discovered in 
recent years it is clear that glycosylation in these organisms is the normal 
rather than the exception. In this sense, the discovery of a general N-
glycosylation system in Campylobacter jejuni represents the starting point a 
great deal of progress in understanding prokaryotic glycosylation
18
. 
 
1.5.3. N-linked protein glycosylation 
Asn N-linked glycosylation of proteins is a fundamental and extensive co-
translational modification that results in the covalent attachment of the first 
sugar of an oligosaccharide onto Asn residue of polypeptide chains. The 
biosynthetic machinery responsible for this elaborate protein modification 
follows a similar overall progression, whereby an oligosaccharide is assembled 
in a stepwise fashion on a polyisoprenyl-pyrophosphate carrier and then 
ultimately transferred to proteins. Glycosylated proteins in both eukaryotes 
and prokaryotes contain the Asn-Xaa-Ser/Thr sequon. In both systems, 
glycosylation is abolished when the Xaa amino acid is Pro, suggesting that 
local conformation plays an important role in the glycosylation reaction, 
catalyzed by oligosaccharil transferase (OT). 
                                                        
18
Szymanski, C.M.; Wren, B.W., Nat Rev Microbiol.,2005, 3, 225-37. 
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Figure 1.8.N-Glycosylation in Eukaryotes. 
There is evidence that the local secondary structure around the site of 
glycosylation in eukaryotes may be a vital determinant in this enzymatic 
process where glycosylation induces conformational switch from an Asn-turn 
to a β-turn structure. Bacteria utilize a wide variety of amino- and deoxy-
sugars that are not found in eukaryotic systems, for example C. jejuni 
heptasaccharide is structurally very different from the tetrasaccharide in 
eukaryotic N-linked glycosylation
19
. These modified proteins might have 
important roles in pathogenic pathways, as well as aberrant glycosylation of 
self-antigens promoted by bacteria could be the first event of  tolerance loss to 
develop an autoimmune disorder. 
 
1.6 Serologic Biomarkers for autoimmune diseases diagnostics 
A biomarker is an anatomical, physiological, and/or biochemical parameter, 
which should be easily determined and used as indicator of normal 
physiological or pathogenic processes. Molecules present in tissues and 
biological fluids can be identified as biomarkers and used to set up 
diagnostic/prognostic tools, as well as for monitoring the efficacy of a 
therapeutic treatment
20,21
. In particular, autoantibody detection is extremely 
valuable to follow up patients when disease exacerbations or remissions 
                                                        
19Weerapana, E.; and Imperiali, B., Glycobiol., 2006, 16(6), 91R-101R. 
20Roland, P.; Atkinson, J.A.; and Lesko, L., J. Clin. Pharm. Ther.,2003, 73, 284-291. 
21
Baker, M.,Nature Biotech.,2005, 23, 297-304. 
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correlates with antibody titer. As a consequence, antibodies present in patients’ 
serum can be used as disease biomarkers
22,23
 as a non-invasive alternative 
diagnostics. Unfortunately, in autoimmune diseases only very low specific 
antibodies were demonstrated to be detectable in serum, possibly because 
proteins used in the assays cannot reproduce the real autoantigen. Moreover, 
an entire protein should contain more than one epitope specific for different 
autoantibodies. These observations account, at least in part, for the limited 
success got in the discovery of biomarkers for autoimmune diseases using 
proteomic analysis and/or protein microarrays.
 
 
1.6.1  The“Chemical Reverse Approach” and autoimmune 
diseases 
In autoimmune diseases diagnostics, specific identification of autoantibodies 
by protein antigens isolated from biological material or reproduced by 
recombinant technologies has sometimes failed. Native protein antigens 
(particularly if underexpressed) can be difficult to be fully sequenced or cannot 
often be successfully reproduced using recombinant techniques. In any case 
protein folding and exposition of the epitope can be also a difficult task. 
Moreover, proteins may be difficult to isolate with correct co- or post-
translational modifications. Synthetic peptides derived from native protein 
sequences and reproducing specific epitopes, or mimicking immunogenic 
modifications could be even more effective and specific than native proteins in 
antibody detection. 
To identify and optimise synthetic peptides as antigenic probes for fishing out 
autoantibodies circulating in biological fluids as biomarkers, an innovative 
“Chemical Reverse Approach” has been developed for the first time in the 
Laboratory of Peptide and Protein Chemistry and Biology of the University of 
                                                        
22 Leslie, D.; Lipsky, P.;and Notkins, A.L.,J. Clin. Invest., 2001, 108, 1417-1422. 
23Alcaro, M.C.; Lolli, F.; Migliorini, P.; Chelli, M.; Rovero, P.; and Papini, 
A.M.,Chem.Today,2007, 25 (5), 14-16. 
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Florence, (PeptLab). This approach was defined “Reverse” because the 
screening of the synthetic antigenic probe is guided by autoantibodies 
circulating in autoimmune disease patients’ blood. “Chemical” because 
autoantibody recognition drives selection and optimisation of the “chemical” 
structure from defined peptide libraries
24
. Autoantibodies circulating in 
patients’ biological fluids drive the selection of synthetic post-translationally 
modified peptides mimicking new epitopes in antigens. Peptide epitopes 
identified by this approach, if selectively and specifically recognizing 
autoantibodies in a statistical significant number of patients, can be used as 
antigenic probes in immunoenzymatic assays to detect disease biomarkers in 
an efficient way. Therefore, screening of focused libraries of unique modified 
peptide molecules canbe a valuable strategy to develop optimised peptide 
antigens containing the minimal epitope with the correct modification to detect 
at the best autoantibodies specific of the autoimmune disease under 
investigation
25
. As a proof-of-concept this approach has been successfully 
applied for the identification of autoantibodies as biomarkers of an 
autoimmune mediated form of MS (the most difficult disease since protein 
antigens are localized in the central nervous system), Reumathoid Arthritis 
(RA), and more recently Rett Syndrome (RS) using simple peptide-based 
Enzyme Linked Immunosorbent Assays (ELISA). In the case of RA, a key 
step in setting up the commercially available ELISA was represented by 
identification of deiminated sequences of filaggrin that are recognized in a 
high percentage of RA sera
26,27
. Sensitivity of the assay was increased 
modifying the peptide structure to optimally expose the citrulline moiety. In 
fact a cyclic citrullinated peptide allows detection of antibodies with high 
                                                        
24Papini, A.M. J. Pept. Sci. (2009), 15, 621-628. 
25Lolli, F.; Rovero, P.; Chelli, M.; and Papini, A.M. Expert Rev. 
Neurotherapeutics.,2006,6 (5), 781-794. 
26Sebbag, M.; Simon, M.; Vincent, C.; Masson-Bessiere, C.; Girbal, E.; Durieux, J.J.; and 
Serre, G.; J. Clin. Invest., 1995,95, 2672-2679. 
27
Serre, G., Joint Bone Spine,2001, 68, 103-105. 
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specificity in RA patients
28,29
. These ELISAs are now considered a gold 
standard for RA diagnosis and follow up.  
 
1.6.2. ELISA for diagnostics 
In the field of autoimmune diseases, a number of autoantibody detection 
techniques have been developed. Over the past years, autoimmunity diagnosis 
has gone through a very dynamic period, associated with the introduction of 
new tests deriving from the identification of new families of autoantibodies 
and the demonstration of their usefulness into the clinic. The Radio-
ImmunoAssay (RIA) has been traditionally used in autoantibody detection and 
it is based on labelled targets providing a radioactive signal. Today RIA is 
largely supplanted by ELISA, because in ELISA the antigen-antibody reaction 
is measured using a colorimetric signal instead of a radioactive signal thus 
avoiding requirements for special radioactivity instrumentation and 
precautions. ELISA is a versatile tool that is used for diagnosis of different 
kind of diseases, from viral infections to immune mediated diseases and  it can 
be used to detect and quantify any antigen or antibody that one may desire to 
look for. It stands for “Enzyme Linked Immunosorbent Assay” and that means 
a test which uses an immunosorbent (a substance that either is or reacts with 
an immune compound to bind to it) linked to an enzyme. Depending on 
whether one is looking for antigens or antibodies, antibodies or antigens, 
respectively, are chemically bound to the surface of wells of the ELISA plates. 
The design of different types of immune assays is possible. The employ of a 
wide range of methods to detect and quantitate antigens or antibodies makes 
the ELISA one of the most powerful of all the immunochemical techniques. 
The main three classes of immunoassays that can be performed are: the 
                                                        
28 Schellekens, G.A.;. de Jong, B.A.; van den Hoogen, F.H.; van de Putte, L.B.; and van 
Venrooij, W.J.,J. Clin. Invest.1998,101, 273-281. 
29Method for the diagnosis of rheumatoid arthritis". Inventors: Alcaro M.C.; Pratesi F.; 
Paolini I.; Chelli M.; Lolli F.; Papini A.M.; Rovero P.; and Migliorini P., Applicant 
Toscana Biomarkers Srl. Patent application number EP11167420.6. (2011). 
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antibody capture assays and the antigen capture assays and the antibody 
sandwich assays. Moreover, any immunoassay can be performed with four 
variations; the assay can be done in antibody excess, in antigen excess, as an 
antibody competition, or as an antigen competition
30
. 
 
1.6.3 Peptide-based ELISA 
Many small chemicals, such as peptides, can be used in ELISA helping to 
dissect and elucidate the properties of an antibody response. Peptides are 
particularly useful when the epitope sequence has been discovered inside the 
total protein. To this end, epitope mapping and Ala-scan are valid strategies to 
define the minimal epitopes recognised by the immune system. Moreover, 
peptide antigens can display enhanced recognition specificity eliminating or 
minimizing potential cross-reactivity between structurally homologous protein 
epitopes. Peptides have several advantages: they are relatively easy to produce 
and may retain chemical stability over time. Finally, reproduction of co- or 
post-translational modifications in peptides is a quite easy task to be achieved 
by a synthetic point of view, if compared to recombinant techniques
31
. 
The most frequently asked question concerning synthetic peptides is what 
sequence should be reproduced. The presence of Pro residues in synthetic 
peptides originally was suggested because β-turns often form portions of 
known epitopes, moreover in several papers it is reported that carboxy-
terminal sequences are often exposed and can be targeted by anti-peptide 
sequences. Similarly, many amino terminal regions are exposed, and these 
may also make good targets. Another potentially useful parameter for selecting 
peptide sequences is their “mobility”, i.e. regions that are more flexible are 
more likely to be epitopes respect to the more static ones.  
                                                        
30Harlow, E.; and Lane, D., Antibodies: A laboratory manual, CSH Ed. Cold Spring 
Harbor Laboratory Press, NY, 1999 
31Papini, A.M. “Peptide-based Immunoassays for Biomarkers Detection: a Challenge 
for Translational Research” Zervas Award Lecture 30th European Peptide Symposium, 
August 31-September 5 2008, Helsinki, Finland. 
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Theoretical ability to understand the immune response with defined peptide 
epitopes coupled to the correct set up of the ELISA experiments can have 
important advantages not only for diagnostic purposes but even to dissect the 
pathological pathways leading to the development of a disease. 
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PART A: Design and synthesis of modified peptide probes 
to study Coeliac Disease 
 
2. Coeliac Disease: an overview 
Coeliac disease (CD), also called gluten-sensitive enteropathy, as the other 
immune mediated diseases, has a complex and multifactorial aetiology and 
occurs in genetically susceptible individuals in association with environmental 
factors (gluten), leading to a chronic inflammatory condition and villous 
atrophy shown in Figure 2.1. 
 
 
Figure 2.1Marsh classification of intestinal coeliac lesions32. 
 
CD may present in early childhood soon after the introduction of gluten-
containing food.It is triggered by the gliadin fraction of wheat gluten and 
similar alcohol soluble proteins called prolamines
33
. The massive penetration 
of gliadin fractions across the intestine lumen has been observed in association 
with the disregulation of a human intestinal protein, zonulin. Zonulin regulates 
the intestinal permeability acting on the tight junctions and, during the acute 
phase of CD the lumen permeability dramatically increases. This discovery 
                                                        
32Fasano, A.; and. Catassi, C.,Gastroenterol., 2001, 120, 636-651. 
33
 Schuppan,D., Nutr. Clin. Care, 2005,8(2), 54–69. 
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suggests that increased levels of zonulin are a contributing factor for the 
development of the disease
34
. CD is classically characterized by 
gastrointestinal symptoms, but also atypical or silent forms are known 
(dermatitis, iron deficiency anaemia, osteoporosis, and many others), and 
sometimes is associated with other autoimmune disorders
35
. If a genetic 
predisposition is present the gluten intake leads to a complex immune 
response, both a cell-mediated form involving T cells and humoral form 
leading to the secretion of autoantibodies, mainly to gliadin and tissue 
transglutaminase, tTG
36
.  
 
 
Figure 2.2. Postulated mechanism for the pathogenesis of CD. 
 
In the pathway shown in Figure 2.2, HLA-DQ2 and DQ8 molecules bound to 
deamidated gliadin peptides are able to present gluten to T cells leading to the 
                                                        
34Fasano, A.; and Not, T. Lancet, 2000, 358, 1518-1519. 
35Schuppan, D.; and Ciccocioppo, R., Dig Liver Dis, 2002, 34, 13–15. 
36
 Murray, J.A., Am. J. Clin. Nutr.,1999, 69, 354-365 
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activation of gluten-specific CD4
+
 T-helper 1 (Th1) cells in the lamina 
propria, as shown in Figure 2.3. 
 
Figure 2.3. CD4+ T-cells recognize modifiedgliadin peptides  
presented by HLA-DQ2 or -DQ8 on the surface of APCs. 
 
 
The activated T-cells are able to secrete Th1 cytokines such as IFN-γ and 
TNFα, inducing the release and activation of Matrix Metalloproteinases 
(MMPs) by myofibroblasts, finally resulting in mucosal remodelling and 
villous atrophy. Additionally, Th2 cytokines driving the production of 
autoantibodies to deamidated gliadin peptides, tTG, and gliadin-tTG 
complexes are produced. Catalytically inactive extracellular tTG is transiently 
activated in response to innate immune signals such as exposure to a potent 
ligand of the toll-like receptor TLR-3
37
. Other cytokines, such as IL-18, IFN-α, 
or IL-21 seem to play a role in polarizing and maintaining the Th1 response. 
Furthermore, IL-15 links the adaptive immune system to innate immune 
responses
38
. These are central effector cells of the intestinal inflammation 
resulting in crypt hyperplasia and villous atrophy
39
. 
                                                        
37Siegel, M.; Strnad, P.; Watts, R.E.; Choi, K.; Jabri, B.; Bishr Omary, M.; and Khosla, C., 
PLOs One, 2008, 3(3), e1861. doi:10.1371/journal.pone.0001861  
38Schuppan, D.; Junker, Y.; and Barisani, D,Gastroenterol, 2009, 137, 1912–1933. 
39Halstensen, T.S.; Scott, H.; Fausa, O.; and Brandtzaeg, P., Scand. J. Immunol., 1993, 
38, 581–590. 
PART A 
29 
 
 
Autoantibodies in CD 
Untreated CD patients (on a wheat-containing diet) usually have increased 
levels of antibodies against gluten-derived peptides, several other food 
antigens, and autoantigens present in the mucosa. The autoantibodies in CD 
are primarily directed against the Ca
2+
-activated (extracellular) form of the 
enzyme tTG
40
. The autoantibodies to tTG are both of the IgA and IgG 
isotypes, but the IgA antibodies which are primarily produced in the intestinal 
mucosa demonstrate the highest disease specificity. 
The mechanism underlying the formation of the autoatibodies in CD is not 
completely understood. The production of anti-tTG IgA antibodies is likely to 
be dependent on cognate T-cell help to facilitate isotype switching of 
autoreactive B cells. Autoreactive T cells specific for tTG could provide the 
necessary help for B-cell production of anti-tTG IgA, but since tTG is 
expressed in the thymus such cells are unlikely to survive thymic selection. An 
alternative explanation could be that the complexes of gluten derived peptides 
and tTG allows the gluten-reactive T-cells to provide help to the tTG-specific 
B cells by a possible mechanism of intramolecular help. This model could 
explain why the serum anti-tTG antibodies in CD patients disappear when 
patients are following a gluten free diet
41
. 
 
HLA genes confer genetic susceptibility 
The high prevalence of CD (around 10%) among first-degree relatives 
indicates that the susceptibility to this disease is strongly influenced by 
inherited factors. The strong genetic influence in coeliac disease is supported 
                                                        
40 Dieterich, W.; Ehnis, T.; Bauer, M.; Donner, P.; Volta, U.; Riecken, E.O.; et al., Nat. 
Med., 1997, 3, 797-801. 
41
 Sollid, LM., Nat. Rev. Immunol., 2002, 2, 647–655. 
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by a very high concordance rate (around 75%) in monozygotic twins
42
. The 
genetic predisposition is mainly associated with HLA class II genes, 90% of 
celiac patients have HLA-DQ2 and HLA-DQ8 for a minority of patients is 
present
43
. The HLA-DQ2 and DQ8 molecules confer the genetic 
susceptibilityto coeliac disease by presenting disease-related peptidesto T cells 
in the small intestine thanks to the peculiarity of the aminoacide 
 residues in their binding site
44
, or by shaping theT-cell repertoire during T-cell 
development in the thymus
45
. 
 
 
Figure 2.4. HLA association in coeliac disease. 
 
Environmental features 
Gluten dietary intake is associated with alterations of small intestinal mucosa 
classified according the criteria introduced by Marsh
46
. Gluten can be defined 
                                                        
42Greco, L.;Corazza, G.; Babron, M.C.; Clot, F.; Fulchignoni-Lataud, M.C.; Percopo, S.; 
Zavattari, P.; Bouguerra, F.; Dib, C.; Tosi, R.; Troncone, R.; Ventura, A.; Mantavoni, W.; 
Magazzù, G.; Gatti, R.; Lazzari,R.; Giunta, A.; Perri, F.; Iacono, G.; Cardi, E.; de Virgiliis, 
S.; Cataldo, F.; De Angelis, G.; Musumeci, S.; and Clerget-Darpoux, F., Am. J. Hum. 
Genet., 1998, 62, 669–675. 
43
 a) Shaoul, R.;  and Lerner,A.  Autoimmun. Rev.,2007, 6(8), 559- 565;b) Sollid, L. M.; 
et al. J. Exp. Med., 1989, 169, 345–350; c) Lundin, K. E. A.; Scott, H.; Hansen ,T.; 
Paulsen, G.; Halstensen, T.S.; Fausa, O. Thorsby, E.; and Sollid, L. M., J. Exp. Med., 
1993, 178, 187–196. 
44Kim, C.Y.; Quarsten, H.; Bergseng, E.; Khosla, C.; and  Sollid, L.M. PNAS, 2004, 
101(12), 4175–4179. 
45
 Schuppan , D. Gastroenterol., 2000, 119, 234–242. 
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as the rubbery mass that remains when wheat dough is washed to remove 
starch granules and water-soluble constituents. Depending on the thoroughness 
of washing, the dry solid contain 75–85% protein and 5–10% lipids, most of 
the remainder is starch and non starch carbohydrates. Gluten is an extreme 
complex mixture of diverse proteins, gluten proteins can be divided into two 
main fractions according to their solubility in aqueous alcohols: the soluble 
gliadins and the insoluble glutenins. Due to their high content of Pro and Gln 
residues, the proteins of wheat gluten are collectively referred to as 
prolamines. The high content of Pro residues makes these prolamines 
particularly resistant to gastrointestinal digestion. This has important 
implications for their immunogenicity since gluten-derived peptides fulfil 
length requirements to be recognised by T cells. In particular, the gliadin 
fraction is referred to as the more toxic for CD patients. Gliadins are usually 
classified into α-, β-, and ω-gliadins whereas glutenins are classified acording 
to their high and low molecular weight (HMW and LMW)
47
. 
 
 
Figure 2.5. Characterization of gluten protein types. 
 
 
2.1 Tissue Transglutaminase, structural insights for antibody 
recognition 
The 76kDa enzyme tissue Transglutaminase belongs to a family of ubiquitous 
enzymes that are included in many pathways such as GTP hydrolysis in signal 
                                                                                                                                     
46 Marsh, M.N., Gastroenterol., 1992, 102, 330-354. 
47
Wieser, H. Food Microbiol., 2007, 24(2),115-119. 
PART A 
32 
trasducing
48
, cellular, and tissutal homeostasis, cellular cycle regulation, 
proliferation
49
, differentiation and apoptosis
50
. In erythrocytes as well as in 
other cells, the enzyme is latent during normal cell lifespam and is subjected to 
fine regulation, involving GTP and calcium. 
Activated tTG catalyzes PTMs of specific Gln residues within its substrate 
proteins. tTG catalyzes deamidation of Gln residues or protein cross linking 
through the formation of ε-(γ-glutamyl)-lysine isopeptide bonds between Lys 
exposed on its surface and Gln residues in gliadin-derived peptides
51
.  
 
 
Figure 2.6. Reactions catalyzed by tissue Transglutaminase. 
 
The increasing interest in transglutaminases because of their medical relevance 
led in the past few years to the production of numerous structural studies of the 
protein to clarify the basis of its regulation. The monomeric human tTG 
consists of four structural domains: the N-terminal β-sandwich; the core; and 
two C-terminal β-barrels. The structure of the human tTG was solved on the 
                                                        
48 a) Iismaa, S.E.; Wu,M.J.; Nanda, N.; Church, W.B.; and Graham, R.M.; J. Biol. Chem., 
2000, 275,18259-1826.5; b) Nakaoka,H.; Perez, K.; Baek, D.M.; Das, T.; Husain, A.; 
Misono, K.; and Graham, R.M. Science, 1994, 264, 1593-1596 
49 Haroon, Z.A.; Hettasch, J.M.; Lai, T.S.; Dewhirst, M.W.; and Greenberg, C.S., FASEB 
J., 1999, 13, 1787–1795. 
50a) Melino,G.; Annicchiarico-Petruzzelli, M.; Piredda, L.;. Candi, E.; Gentile,V.; Davies, 
P.J.; and Piacentini, M. Mol. Cell. Biol., 1994, 14, 6584-6596; b) Piacentini, M.; 
Rodolfo, C.; Farrace, M.G.; and Autuori, F., Int J Dev Biol.,2000, 44, 655–662. 
51
Qiao SW BE, Molberg O, Xia J, et al.. J. Immunol., 2004, 173, 1757–1762. 
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sequence of the human endothelial enzyme based on the alignment with the 
crystal structure of factor XIII. The ATP and GTP hydrolytic domain is 
localized in the N-terminus of tTG (amino acid residues 1-185). The predicted 
structure of this fragment contains a β-sandwich domain and part of the 
catalytic core region. The protein C-terminus also plays an important role in 
regulating the enzymatic activity. In the past years, since the first relevant 
findings published by Folk and Chung in 1973
52
, many research groups 
directed their efforts to characterize the tTG’ structure associated with its 
enzymatic function
53
. As shown in several works and in the PDB deposited 
tTG-structure
54
, the protein active site is characterized by the presence of the 
so called “Catalytic triad” Cys277, His335, and Asp358.  
 
 
Figure 2.7. Tissue Transglutaminase’ active site structure. 
In the presence of GDP, tTG shows a closed conformation with the 
transamidating catalytic triad on the core domain in a hidden position. When 
the enzyme is functioning as a Ca
2+
-dependent transglutaminase, the C-
                                                        
52Folk, J.E.; and Chung, S.I., Adv Enzymol Relat Areas Mol Biol., 1973, 38, 109–191.  
53 a) Gentile, V.; Saydak, M.; Chiocca, E.A.; Akande, O.; Birckbichler, P.J.; Lee, K.N.; 
Stein, J.P.; and Davies, P.J.,  J. Biol. Chem., 1991, 266, 478-83; b) Lai, T.S.; Slaughter, 
T.F.; Koropchak, C.M.; Haroon, Z.A.; andGreenberg, C.S.,J. Biol. Chem., 1996, 271, 
31191-5. 
54
 Liu, S.; Cerione, R. A.; and Clardy, J., P.N.A.S., 2002, 99, 2743–2747. 
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terminal beta barrels are displaced of 120Å and the structure becomes open 
and extended, at least transiently
55
. Pinkas et al.
56
 reported the tTG solved 
structure, at atomic resolution, in a complex with a molecule mimicking a 
natural substrate (i.e. gluten peptides deriving from proteolysis).  
 
 
Figure 2.8. Activated tTG displays an open conformation. 
 
The new structure exposes the active site undergoing to a very large 
conformational change with respect to previous tTG structures. Very few 
proteins have been observed to display this type of large-scale transformation. 
By the way this structural rearrangement could assume a significant role in the 
early stages of CD. Moreover, the open conformation described is likely to 
expose self-epitopes that are ordinarily inaccessible to the immune system. In 
this model, the catalytic Cys277 is located into a hydrophobic tunnel bridged 
by two Trp residues, i.e. Trp241 and Trp332. The other side of the tunnel is 
open and presumably serves as the binding site for a Lys residue or alternative 
nucleophilic substrates participating in the transamidation reaction. The 
enzyme displays selectivity for particular Gln residues. tTG identifies QxP and 
QxxF (where x can be Tyr, Trp, Met, Leu, Ile, Val) as consensus sequences, 
                                                        
55 Casadio, R.; Polverini, E.; Mariani, P.; Spinozzi, F.; Carsughi, F.; Fontana, A.; 
Polverino De Laureto,P.; Matteucci, G.; Bergamini, C.M.,Eur. J. Biochem., 1999, 262, 
672-679. 
56Pinkas, D.M.; Strop, P.; Brunger, A.T.; and Khosla, C.; PLoS Biology, 2007, 5(12), 
2788-2796. 
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wheras Gln followed directly by Pro will not be targeted. As shown in Figure 
2.9, the modification introduced by tTG in peptide substrates in example α2-
gliadin (57-89), allows the interaction between Glu residues, and the HLA-
DQ2 binding site
57,58
. 
 
 
Figure 2.9. Interaction between deamidated gliadin peptides and Lysβ71 residue in 
the DQ2 HLA pocket. 
 
Deamidated gluten peptides are presented to the CD4+T-cells by HLA-DQ2 or 
-DQ8 molecules on the cell surface of antigen-presenting cells. This is thought 
to be the event triggering the T-cell autoimmune response in CD. It is evident 
that the role of tTG in the pathogenesis of coeliac disease, even if not 
completely understood, clearly encompasses more than simply being the target 
of the autoantibodies in the disease. 
 
Antigenic domains in tissue Transglutaminase 
The enzyme tTG is a highly sensitive and specific target of autoantibodies in 
CD. The characterization of tTG antigenic domains is a crucial step in 
understanding the autoimmune role and onset in the CD’ pathogenesis, since 
                                                        
57Shan, L.; Molberg, O.; Parrot, I.; Hausch, F.;Filiz, F. ; Gray, G.M.; Sollid, L.M; Khosla, 
C., Science, 2002, 297, 2275–2279. 
58Costantini,S.; Rossi, M.; Colonna, G.; and Facchiano, A. M., J. Mol. Graph. 
Model.,2005, 23(5), 419-43. 
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the pathogenic role and exact binding properties of these autoantibodies to tTG 
are still unclear. Sera from patients with CD at first diagnosis were 
demonstrated to have high levels of auto-antibodies recognising distinct 
functional domains of tTG. Analyzing the antigen-antibody recognition pattern 
in CD patients’sera it is possible to identify the presence of a complex and 
heterogeneous autoimmune response toward different tTG expressed 
constructs (both linear and related to the protein folding), mainly directed to 
conformation-dependent epitopes. This is a peculiarity of other autoimmune 
diseases having autoantibodies directed to multiple conformational epitopes of 
autoantigens such as GAD and IA-2 in diabetes mellitus and TPO antibodies 
in Hashimoto thyroiditis
59
. 
 
Figure 2.10. Linear and conformational epitopes. 
 
Antibodies of different celiac patients can recognise parts of the same 
conformational epitopes constituted by amino acids located in different 
portions of the protein sequence.Simon-Vecsei et al. demonstrated that coeliac 
antibodies directly bind to the tTG surface in the following positions Arg19-
                                                        
59 a) R. Finke, P. Seto and B. Rapoport, J. Ciln. Endocrin. Metab., 1990, 71, 53-59; b) K. 
Syren, L. Lindsay, B. Stoehrer, K. Jury, F. Luhder, S. Baekkeskov, W. Richter, J. 
Immunol., 1996, 157, 5208-5214; c) H. Xie, B. Zhang, Y. Matsumoto, Q. Li, A.L. 
Notkins, M.S. Lan, J. Immunol.,1997, 159, 3662-3667. 
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Glu153-Met659
60
. The identification of defined epitope boundaries suggests 
that these tTG regions may harbor amino-acid sequences of high 
immunogenicity, which could be crucially involved in the induction of 
autoimmunity in CD. Antibodies to tTG are able to recognize linear epitopes 
of the autoantigenic protein and these autoreactive domains are sex- and age- 
dependent
61
. The dominant epitopes are clustered in N- and C-terminal 
domains, one spanning from the N-terminus to the catalytic region and the 
other comprising the two C-terminal domains
62,63
. 
 
2.2 Epitope mapping of antigenic proteins 
Epitope mapping is an important tool in the selection and characterization of 
antibodies, particularly where epitope similarity or dissimilarity issues are 
involved. At their most elaborate epitope mapping techniques, e.g. X-ray 
crystallography, NMR, or electron microscopy, can provide detailed 
information on the amino acid residues in a protein antigen which is in direct 
contact with the antibody-binding site. “Functional” epitope mapping methods 
can be divided into four groups: (1) competition methods; (2) antigen 
modification methods; (3) fragmentation methods; and (4) the use of synthetic 
peptides or peptide libraries. Apart from its intrinsic value for understanding 
protein interactions, epitope mapping hasalso a practical value in generating 
antibody probes of defined specificity as research tools and in helping to 
define the immune response to pathogenic proteins and organisms. The term 
‘epitope mapping’ has also been used to describe the attempt to determine all 
                                                        
60Simon-Vecsei, Z.; Király, R.; Bagossi, P.; Tóth, B.; Dahlbom, I.; Caja, S.; Csősz, É.; 
Lindfors, K.; Sblattero, D.; Nemes, É.; Mäki, M.; Fésüs, L.; and Korponay-Szabóf, I.R., 
Proc Natl Acad Sci U S A., 2012,109(2),431-436. 
61C. Tiberti, F. Bao, M. Bonamico, A. Verrienti, A. Picarelli, M. Di Tola, M. Ferri, E. 
Vecci, F. Dotta, G.S. Eisenbarth, and U. Di Mario, Clin Immunol, 2003;109:318-324; 
62 Seissler,J.; Wohlrab,U.; Wuensche,C.; Scherbaum,W. A; and Bohem,B.O., Clin. Exp. 
Immunol., 2001, 125, 216-221. 
63 Nakachi, K.; Powell, M.; Swift,G.; Amoroso, M.A.; Ananieva-Jordanova, R.; Arnold, 
C.; Sanders, J.; Furmaniak, J.; and Smith, B.R., J. Autoimmunity, 2004; 22, 53-63. 
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major sites on a protein surface that can elicit an antibody response in mice or 
humans. This information might be very useful, for example, to someone 
wishing to produce antiviral vaccines or diagnostic antigens
64
.Overlapping 
peptide libraries are ideal for T-cell epitope searching, because T-cell epitopes 
are by nature short linear peptides of the primary protein sequence. They are 
also appropriate for scanning the primary sequence of proteins for linear, or 
“continuous”, B-cell (antibody-defined) epitope characterisation. 
Overlapping peptide libraries can be used for epitope mapping (linear and 
continuous epitopes), which can in turn be used to determine essential regions 
of a protein contributing to the bioactivity.   
 
 
Figure 2.11. Proteins epitope mapping by overlapping peptides.  
 
The library design is based on two  parameters: peptide fragment length, and 
offset number. The peptide fragment length is the length of each peptide to be 
generated in the library, and it is typically between 10 and 25 amino acids in 
length.  The offset number is the degree of overlap with regard to the 
following peptide fragment. 
 
Selecting epitopes 
Any accessible part of a molecule may be considered to be a potential 
antigen.In fact, for antibody-binding to an antigen, the specific epitope must be 
                                                        
64Morris,G.E.; Epitope Mapping: B-cell Epitopes, ENCYCLOPEDIA OF LIFE & 
SCIENCES,2007, John Wiley & Sons, doi: 10.1002/9780470015902.a0002624.pub2. 
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exposed on the molecular surface. There are a number of criteria that might 
affect the epitope position, such as: 
 the mobility of the protein region; 
 the nature of the primary sequence (in the case of protein antigens) 
where there is the possibility to form a loop or a turn, e.g. the presence 
of proline residues; 
 the hydrophilicity. 
With reference to the molecular mobility of an antigen, X-rays and NMR 
studies canallow the identification of the surface amino acid residues with 
higher mobility and areas on the molecule with the hydrophilic stretches found 
on the surface. Therefore highly hydrophilic sequences are likely to be on the 
surface of a molecular fold and thus are putative epitopes, particularly when 
used in conjunction with hydrophilicity parameters for each residue. 
When investigating the nature of the putative epitopes on a protein, several 
enzymatic method are available, e.g. digestion of the protein into smaller 
peptides fragments. Alternatively the use of synthetic probes is a valuable 
strategy. The purity of enzyme digestion requires consideration, that’s why the 
use of synthetic antigens can have several advantages if compared to biotech 
approaches, in particular to overcome bias due to the low quality of 
expressed/extracted antigens. Analysis of overlapping peptides can produce 
precise data. In 1984, Geysen et al.
65
 investigated possible ways of identifying 
epitopes on macromolecules like proteins and developed the Pepscan 
technique. Of course this method requires prior knowledge of the amino acid 
sequence for the protein of interest. Peptide libraries can be designed and 
synthesized overlapping the complete length of a protein (or the portion 
                                                        
65
H M Geysen, R H Meloen, and S J Barteling, PNAS, 1984, 81(13),3998-4002. 
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considered of interest) to be used in solid phase ELISA (SP-ELISA) to screen 
panels of antibodies for distinguishing linear B-cell epitopes
66
. 
 
2.2.1 Epitope mapping of tTG(1-230) 
The characterization of tTG antigenic domains is a crucial step in 
understanding the autoimmune role and onset in the CD’ pathogenesis, since 
the pathogenic role and exact binding properties of these autoantibodies to tTG 
are still unclear. Autoantigenic epitopes are formed, in the main part, into the 
N-terminal and C-terminal portion
62,63
. 
We performed an epitope mapping study based on the “Chemical Reverse 
Approach”24 previously set up in PeptLab to characterize linear putative 
autoantigenic epitopes present in the tTG N-terminal portion. A library of 23 
overlapping peptide epitopes, listed in Table 2.1, was generated reproducing 
tTG(1-230) fragments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
66 a) Olwyn, M.; Westwood,R.; and  Hay, F. C., Epitope Mapping: A Practical Approach, 
Oxford University Press, USA; 2001; b) Carter, J.M.; and Loomis‐Price, L., Curr. Prot. 
Immunol., 2004, DOI: 10.1002/0471142735.im0904s60. 
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Table 2.1Overlapping peptides of the tTG N-terminal portion, i.e. tTG(1-230). 
Peptide tTG Protein Fragment Protein Sequence 
I tTG(1-15) MAEEL VLERC DLELE 
II tTG(11-25) DLELE TNGRD HHTAD 
III tTG(21-35) HHTAD LCREK LVVRR 
IV tTG(31-45) LVVRR GQPFW LTLHF 
V tTG(41-55) LTLHF EGRNY EASVD 
VI tTG(51-65) EASVD SLTFS VVTGP 
VII tTG(61-75) VVTGP APSQE AGTKA 
VIII tTG(71-85) AGTKA RFPLR DAVEE 
IX tTG(81-95) DAVEE GDWTA TVVDQ 
X tTG(91-105) TVVDQ QDCTL SLQLT 
XI tTG(101-115) SLQLT TPANA  PIGLY 
XII tTG(111-125) PIGLY RLSLE ASTGY 
XIII tTG(121-135) ASTGY QGSSF VLGHF 
XIV tTG(131-145) VLGHF ILLFN AWCPA 
XV tTG(141-155) AWCPA DAVYL DSEEE 
XVI tTG(151-165) DSEEE RQEYV LTQQG 
XVII tTG(161-175) LTQQG FIYQG SAKFI 
XVIIII tTG(171-185) SAKFI KNIPW NFGQF 
XIX tTG(181-195) NFGQF EDGIL DICLI 
XX tTG(191-205) DICLI LLDVN PKFLK 
XXI tTG(201- 215) PKFLK NAGRD CSRRS 
XXII tTG(211-225) CSRRS SPVYV GRVVS 
XXIII tTG(216-230) SPVYV GRVVS GMVNC 
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2.2.2 Synthesis of the linear peptides 
Linear peptide fragments were synthesized using a Fmoc/tBu strategy starting 
from Fmoc-Rink Amide resin. 
 
 
Figure 2.12. Rink-linker structure. 
 
Chemically synthesized peptides carry free amino and carboxy termini, being 
electrically charged in general. In order to remove this electric charge, peptide 
ends were often modified by 
α
N-terminal acetylation and/or C-terminal 
amidation. Peptide ends are thus uncharged, compared to standard synthetic 
peptides, so they mimic natural peptides
67
. Moreover, permeability of cells 
increases, peptide ends are blocked against synthetase activities and acetylated 
peptides serve as optimized enzyme substrates. Moreover,amidation of 
peptides having acetylated 
α
N-terminus enhances activity of peptide hormones. 
These modifications are indicated especially for peptides to be used in ELISA 
to minimize influences of charged C- or N-termini with ELISA binding 
characteristics. 
The peptides reported in Table 2.1 were synthesized using a Fmoc/tBu 
protection scheme on the Advanced ChemTech Apex 396 synthesizer 
equipped with a 8-wells reaction block (0.16 scale), starting from Fmoc Rink-
Amide resin (Iris Biotech Gmbh), according to the General Procedure for the 
                                                        
67Lloyd-Williams,P.; Albericio,F.;and Giralt,E., “Chemical approaches to the synthesis 
of peptides and proteins”, CRC Press, 1997. 
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automatic SPPS described in details in the Experimental Part and using 
commercially available Fmoc-protected amino acids and TBTU/DIPEA 
activation. 
α
N-terminal acetylation was carried out as reported in the 
Experimental Part. Peptide cleavage from the resin and contemporary 
deprotection of the amino acids side chains was carried out for 3 h at room 
temperature with reagent K. The crude products were precipitated with diethyl 
ether, collected after centrifugation, dissolved in H2O and lyophilized.  
The products were purified and characterized by RP-HPLC ESI-MS. 
Analytical data are reported in Table 2.2. 
 
Table 2.2. Analytical data of peptides I-XXIII. 
Peptide 
tTG 
Fragment 
Sequence 
HPLC 
Rt(min) 
 
ESI-MS (m/z) 
[M+2H]
2+
 
Calc(found) 
I tTG(1-15) Ac-MAEELVLERCDLELE–NH2 4.52
f  916.94 (917.77) 
II tTG(11-25) Ac-DLELETNGRDHHTAD–NH2 3.67
a  882.40 (882.62) 
III tTG(21-35) Ac-HHTADLCREKLVVRR–NH2 3.64
a  937.51 (937.84) 
IV tTG(31-45) Ac-LVVRRGQPFWLTLHF–NH2 5.36
a  955.54 (956.29) 
V tTG(41-55) Ac-LTLHFEGRNYEASVD–NH2 3.86
b  896.43 (897.15) 
VI tTG(51-65) Ac-EASVDSLTFSVVTGP–NH2 4.18
b  775.39 (776.02) 
VII tTG(61-75) Ac-VVTGPAPSQEAGTKA–NH2 3.34
a  727.38 (727.52) 
VIII tTG(71-85) Ac-AGTKARFPLRDAVEE–NH2 4.02
a  850.95 (851.05) 
IX tTG(81-95) Ac-DAVEEGDWTATVVDQ–NH2 4.36
a  838.37 (838.91) 
X tTG(91-105) Ac-TVVDQQDCTLSLQLT–NH2 4.76
a  852.92 (853.38) 
XI tTG(101-115) Ac-SLQLTTPANAPIGLY–NH2 4.97
a  800.44 (800.98) 
XII tTG(111-125) Ac-PIGLYRLSLEASTGY–NH2 4.62
c  840.95 (841.68) 
XIII tTG(121-135) Ac-ASTGYQGSSFVLGHF–NH2 3.58
e  799.88 (800.53) 
XIV tTG(131-145) Ac-VLGHFILLFNAWCPA–NH2 2.51
g  871.46 (872.34) 
XV tTG(141-155) Ac-AWCPADAVYLDSEEE–NH2 3.94
a  869.86 (870.69) 
XVI tTG(151-165) Ac-DSEEERQEYVLTQQG–NH2 3.6
a  926.42 (927.21) 
XVII tTG(161-175) Ac-LTQQGFIYQGSAKFI–NH2 3.87
a  871.46 (872.27) 
XVIIII tTG(171-185) Ac-SAKFIKNIPWNFGQF–NH2 4.07
d  919.49 (920.46) 
XIX tTG(181-195) Ac-NFGQFEDGILDICLI–NH2 4.8
f  869.42 (869.77) 
XX tTG(191-205) Ac-DICLILLDVNPKFLK–NH2 4.76
e  893.02 (893.93) 
XXI tTG(201- 215) Ac-PKFLKNAGRDCSRRS–NH2 4.07
a  888.47 (889.21) 
XXII tTG(211-225) Ac-CSRRSSPVYVGRVVS–NH2 4.01
a  846.95 (847.76) 
XXIII tTG(216-230) Ac-SPVYVGRVVSGMVNC–NH2 4.26
e  804.40 (805.18) 
Analytical HPLC gradients at 1 mL min
-1
, solvents system are  A: 0.1% TFA in H2O, B: 0.1% TFA in 
CH3CN, 
a
10-60% B in 5 min, 
b
20-60% B in 5 min, 
c
 10-90% B in 5 min, 
d
 25-70% B in 5 min, 
e
 20-70% B in 
5 min, 
f
20-90%B in 5 min, 
g
30-80% B in 5 min. 
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2.3 Immunoassays: SP- and Inhibition- ELISA 
The collection of the 23 pentadecapeptides, I-XXIII, corresponding to the 
tissue transglutaminase N-terminal portion, tTG(1-230), was screened on 
coeliac disease patients’sera, at the diagnosis to recognize and characterize the 
possible epitopes. 
 
2.3.1 Inhibition experiments using Eu-tTG Aeskulisa 
 
We evaluated the ability of these I-XXIII peptides to try toinhibit the binding 
of anti-tTG(1-687) IgA antibodies present in CD patients’sera. This full length 
protein antigen is used in the commercial diagnostic ELISA kit (Eu-tTG IgA, 
Aeskulisa). We used two representative CD patients’ sera, displaying high and 
medium titer (CD++ and CD+), and one Normal Blood Donor (NBD), as 
control, in Solid-Phase ELISA (SP-ELISA). 
 
 
Figure 2.13. SP-ELISA performed with Eu-tTG IgA, Aeskulisa. 
 
The two positive sera and the healthy control (NBD) were then preincubated 
with the 23 different synthetic overlapping peptides and added to the Eu-tTG 
IgA, in the Aeskulisa plate.  
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Figure 2.14.Competition-ELISA performed with the 2 CD patient’s sera. On the left is 
reported the reference value of the sample sera measured in SP-ELISA performed with 
Eu-tTG IgA, Aeskulisa 
 
We found that the peptides I, V, VI, XII, XVI, and XIX are able to inhibit the 
binding of the anti-tTG(1-687) IgA antibodies. Moreover, we found that these 
peptides do not cross-react if tested with the representative NBD serum. 
 
 
Figure 2.15.Competition-ELISA performed with NBD serum. On the left is reported 
the reference value of the sample serum  measured in SP-ELISA performed with Eu-
tTG IgA, Aeskulisa. 
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2.3.2 Solid Phase-ELISA experiments: screening of peptides I-XXIII 
SP-ELISA reflects essentially the antibody affinity, which depends on the 
exposure of the minimal epitope in the solid-phase conditions of the assay. 
Therefore, we evaluated by SP-ELISA the possible IgA and IgG recognition 
by the peptides I-XXIII using the representative CD patient's serum (CD++) 
positive to Eu-tTG IgA, Aeskulisa and compared with the results obtained 
with the representative NBD. In a first instance IgA and IgG were tested using 
as secondary antibody anti-human IgA and anti-human IgG conjugated to 
Horseradish Peroxidase enzyme (HRP). 
 
 
 
Figure 2.16. Screening of serum antibody recognition (IgA and IgG) using the 
peptides I-XXIII in SP-ELISA. 
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Data reported in the Figure 2.16 show some interesting results of IgA. This is 
in line with what is reported in the literature concerning the higher specificity 
of anti-tTG IgA compared to anti-tTG IgG. 
These preliminary data let us to select four peptides, i.e. I, V, VI, XVI that 
showed the better IgA antibody recognition both in inhibition- and SP-ELISA 
experiments.Therefore, we evaluated, by SP-ELISA, the possible antibody 
recognition with peptides I, V, VI, XVI in 8 CD patients’ sera and 3 NBDs, as 
controls. 
 
 
Figure 2.17. SP-ELISA on a selected cohort of patients. 
 
Sera CD5, CD20, CD22, CD40, and CD45 are from patients with severe 
mucosal damages, classified according Marsh criteria
46
 (3a-3c) and show high 
IgA values also with the commercial Aeskulisa. CD60 and CD62 sera are from 
patients with severe mucosal damages but display low titers even with the 
commercial Aeskulisa. CDstd is a pool of CD patients’ sera and displays a low 
titer when tested with the commercial Aeskulisa.Each serum was also used to 
obtain dilution curves. In Figure 2.18 we report as example the graph of the 
dilution curve obtained with CD20. 
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Figure 2.18. Dilution curve for serum CD20 measured with the peptides (I), (X), (VI), 
and (XVI). 
 
As shown in Figure 2.18, the four peptides, I, V, VI, and XVI display more or 
less the same activity in detecting autoantibodies in SP-ELISA in coeliac 
patients’ sera, at the diagnosis. 
 
2.3.3 Results and discussion 
The results obtained with the 23 synthetic overlapping peptides confirm that 
autoantibodies in patients with coeliac disease recognize precise linear peptide 
epitopes (continuous) present in tTG(1-230)
62,63
. 
 
Peptide I, ie tTG(1-15), includes the peptide epitope tTG(1-13). The most 
relevant N-terminal epitope requires the presence of the first 13 residues, and 
the truncation of the first 13 residues, completely abolishes antibody binding 
to all epitopes within the N-terminal part of the protein, as shown in Figure 
2.19. 
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Figure 2.19. Antibody reactivity to different fragments of tissue transglutaminase62. 
 
Peptide V, i.e. tTG(41-55) and Peptide VI, i.e. tTG(51-65), overlap the 
peptide fragment tTG(41-65) and both contain the protein fragment tTG(52-
54). The tripeptide Ala-Ser-Val, i.e. tTG(52-54) is characterized by a type I β-
turn conformation, as reported in the UNIPROT Data Base
68
. In particular, this 
type I β-turn was identified in the structure deposited in the PDB, by Pinkas et 
al.
56
, and more recently Lindemann et al.
69
 of the tTG in complex with two 
inhibitors, in the open conformation, that is the one considered having non-self 
antigen properties. The position of this tripeptide is slightly different from the 
one found in the inactive enzyme. 
 
 
                                                        
68 http://www.uniprot.org/uniprot/P21980. 
69 Lindemann, I.; Boettcher, J.; Oertel, K.; Weber, J.; Hils, M.; Pasternack, R.; Heine, A.; 
Klebe, G., To be published, 2012, DOI:10.2210/pdb3s3p/pdb. 
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Figure 2.20. Right, overlap of the two structures solved in presence of an inhibitor 
mimicking natural substrates of tTG. Left, overlap of the two structures solved by 
Pinkas and Lindemann (red and light blue ribbons) in comparison with the inactive 
enzyme (purple ribbon)56,69. 
 
β-Turn structures are secondary structures frequently associated with antigenic 
sites, particularly when they are adjacent to β-sheets or α-helical structures in 
hydrophilic regions and polypeptide chain flexibility. β-Turns usually occur on 
the exposed surface of proteins and hence likely represent antigenic sites or 
involve molecular recognition, as presumably occurs when tTG is in the open 
conformation. These considerations let us to hypothesize that the peptide 
tTG(41-65) is recognized as a linear epitope. 
 
Peptide XVI, i.e. tTG(151-165), overlaps a very hydrophilic part of the 
protein and contains a minimum of hydropathicity, [Position: 155 Score: -
3.067 (min), according to Kyte and Doolittle algorithm]. Highly hydrophilic 
sequences are likely to be on the surface of a molecular fold and thus they can 
be considered putative epitopes. 
 
 
Ala52-Ser53-Val54 
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Figure 2.21. Profile of hydropathicity calculated according to Kyte and Doolittle 
algorithm70. 
 
Moreover, the Peptide XVI contains a negatively charged sequence composed 
of Glu residues, tTG(153-155). Glu153 and Glu 154, as reported by Simon-
Vecsei et.al, are located on the first alpha-helix of the core domainand together 
with Arg19 on the first alpha-helix of the N-terminal domain and Met659 
constitute an important conformational epitope
60
. 
  
                                                        
70
http://www.uniprot.org/uniprot/P21980 
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2.4 Cross-linked peptide probes for the development of an in 
vitro diagnostics for Coeliac Disease 
Untreated CD patients have high levels of circulating IgAs and IgGs directed 
to different autoantigens, and in particular tTG, gliadin and endomysium 
(EMA) whose presence is strictly correlated with the gluten dietary intake. 
Moreover,they are directly involved in mucosal injury by inhibiting the 
differentiation of epithelial cells
40,71. Clinical evaluation and diagnosis of CD 
may require several years because of the large variety of associated symptoms 
and the low specificity and sensitivity of the available serological tests, thus 
leading to an increasing probability to develop additional disorders. Thus, 
reliable assays are necessary not only for an early diagnosis but also for 
monitoring the disease activity by evaluating antibodies, as specific 
biomarkers
72
. Up today the gold standard for the diagnosis of CD remains the 
bowel biopsy even though serological tests are in rapid development both in 
terms of specificity and sensitivity. Nevertheless, the bowel biopsy cannot be 
considered anymore as a routine diagnostics, particularly for infants. 
The improvement of the sensitivity of serological tests replacing extracted or 
recombinant antigens with synthetic peptide probes could assume a particular 
relevance if applied to a disease in which only the 20% of patients is thought 
to be diagnosed as exemplified by the model of the coeliac iceberg in  
Figure 2.22. 
                                                        
71 Halttunen,T. ; and Mäki, M., Gastroenterology, 1999, 116, 566-572. 
72
 Roland, P.; Atkinson, J.A.; and Lesko, L.J., Clin. Pharm. Ther., 2003, 73, 284-291. 
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Figure 2.22. The coeliac Iceberg. 
 
Therefore, it could be of relevant importance the desing and synthesis of 
peptides mimicking aberrant modifications occurring in protein antigen (tTG) 
involved in the coeliac disease pathogenesis in order to dissect the mechanisms 
of the autoimmune response and developing new diagnostic tools. Recently, it 
has been reported the introduction in the coeliac disease diagnostics a new 
generation of diagnostic tools based on tissue transglutaminase-gliadin 
constructs formed in vivo
73
. 
 
 
Figure 2.23. tTG-gliadin constructs. 
 
This new generation of kit uses a unique antigen approach based on human 
tTG antigens crosslinked with deamidated gliadin specific peptides coated on 
the ELISA plate wells. The antigen used up to now for detecting CD-
                                                        
73
 Matthias, T.; Not, T.; and  Selmi, C., Clinic Rev Allerg Immunol, 2010, 38, 298–301. 
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associated antibodies is the purified cross-linked complex which is formed 
under in vivo physiological conditions, designed to detect IgA and IgG 
antibodies to tTG. Transamidation can be considered the aberrant PTM 
triggering autoantibodies in CD. Therefore, cross-linked peptides between 
Lys- and Glu- side-chains of tTG and Gliadin peptide epitopes could be 
innovative tools to develop peptide-based in vitro diagnostics for CD. 
Synthetic cross-linked peptide probes could replace protein extracts thus 
giving rise to a new class of even more sensitive and specific diagnostic tools . 
 
2.4.1 Tissue Transglutaminase’ fragments selection 
Digested peptides forming covalent complexes between tTG and gliadin were 
characterized investigating the chemical nature of the linkage. In order to 
trigger an autoantibody response via a hapten carrier-like model in coeliac 
sprue, ‘neo-epitopes’ as tTG–gliadin adducts shold be relatively stable. 
Gliadin peptides can be covalently linked to the enzyme either via thioester 
bond to the active site cysteine or via isopeptide bond to particular lysine 
residues of the enzyme. The ispopetide form dominates when more than one 
peptide is linked to tTG, rather than the deamidation reaction, thus presumably 
is the most common form in the case of patients with active and undiagnosed 
CD following a gluten-rich diet.  
In these conditions, at high molar excess of gliadin peptides, 6 Lys 
residues were identified as participating residues in isopeptide bonds 
formation to the targeted Gln residues giving important insights on how 
antibodies to tTG are formed in CD. These acyl acceptor residues were 
univocally identified by mass spectrometry experiments applied to the 
proteolytic digested tTG-gliadin in vivo formed adducts, as reported by 
Fleckenstein et al
74
, and shown in Table 2.3. 
 
 
PART A 
55 
 
 
Table 2.3. tTG-derived peptides. 
   
 Entry tTG-derived peptides cross-linked to a 
representative  peptide  
Lys no.  Molar 
ratio to 
tTG 
1:150  
1 
2 
EDITHTYKYPEGSSEER 
DCLTESNLIKVR 
Lys-444 
Lys-562 
(+) 
++ 
3 DLYLENPEIKIR Lys-590 ++ 
4 QKRK Lys-600 + 
5 TVEIPDPVEAGEEVKVR Lys-649 + 
6 AVKGFR Lys-677 ++ 
The signals for the tTG-derived peptides I–VI covalently linked to the represenative were found with very 
low, (+),  intermediate, +, or high intensities, ++, in the MALDI-TOF and ESI mass spectra. 
 
 
Lys-590, Lys-600, Lys-649, and Lys-677 are all located in the C-terminal 
domain 4, Lys-444, and Lys-562 are situated in domain 2. Interestingly, Lys-
677 is located at the interface of domain 2 and 4, rather buried in the interior of 
the protein exposed at the surface. Also, Lys-562 appears to be partly buried, 
whereas the other four lysine residues are clearly exposed to the surface of the 
protein
74
. 
 
                                                        
74Fleckenstein, B.; Qiao, S.-W.; Larsen, M.R.; Jung, G.; Roepstorff, P.; and Sollid, L.M., 
J. Biol. Chem., 2004, 279(17), 17607–17616. 
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Figure 2.24. Data Bank file, shows thelocation of the identified acyl acceptor Lys 
residues within the three-dimensional protein structure. Only the side chains of the six 
Lys residues (space-fill model) participating in the isopeptide bond formation and 
those of the catalytic triad (ball and sticks) are illustrated. The backbone of domains 
1–4 is colored in blue, green, orange, and red, respectively74. 
  
On the basis of these experimental findings we selected the more 
representatives tTG fragments. From Table2.3 we selected, as tTG epitopes, 
peptide fragments. II, III and VI that sowed a higher frequency in giving the 
isopeptide bonds in comparison to the other listed. More precisely we 
considered the following fragments: 
 
1) DCLTESNLIK562VR, tTG(553-564), containing K562 (in bold); 
2) DLYLENPEIK590IR, tTG(581-592), containing K590 (in bold); 
3) AVK677GFR, tTG(675-680), containing K677 (in bold). 
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2.4.2 Identification of the possibleantigenic gliadin epitopes 
Regiospecific deamidation and transamidation of the immunogenic gliadin 
peptides by tTG increases their affinity for HLA, both DQ2 and DQ8, as well 
as the potency with which they activate patients-derived gluten-specific CD4+ 
T-cells
75
.These T-cells usually recognize gluten peptides that have been post-
translationally modified by tTG
76,77
. Although the propensity for either of the 
two modifications may differ slightly for some peptide substrates, the substrate 
specificity for deamidation and transamidation seems to be very similar
78
. In 
addition, it has been proved that these two post-translational modifications can 
occur on distinct Gln residues within the same peptide. The majority of the 
identified transamidated peptides, whose isopeptide bonds are not susceptible 
to the proteolytic cleavage that hydolyze normal peptide bonds
79
, contain 
intact known T-cells epitopes (9mer core regions) or their truncated 
versions
80
.The stability of the fragments generated by brush border enzyme 
degradation, associated with their remarkable resistance to proteolysis is 
reported as one of the driving forces in the selection of epitopes in CD for 
gluten T-cell response. The majority of gluten T-cell epitopes identified in 
celiac disease so far are derived from α- and γ-gliadins. Epitopes derived from 
α-gliadin have been shown to be recognized by T cells isolated from nearly all 
                                                        
75 Molberg, O.; Kett, K.; Scott, H.; Thorsby, E.; Sollid, L. M.; and Lundin, K. E., Scand. J. 
Immunol, 1997, 46, 103–109. 
76Molberg, O.; McAdam, S. N.; Korner, R.; Quarsten, H.; Kristiansen, C.; Madsen, L.; 
Fugger, L.; Scott, H.; Noren, O.; Roepstorff, P.; Lundin, K. E.; Sjostrom, H.; and Sollid, L. 
M. Nat. Med. 1998, 4, 713– 717. 
77
van der Wal, Y.; Kooy, Y.; van Veelen, P. A.; Pena, S.; Mearin, L.; Papadopoulos, G.; 
and Koning, F. J. Immunol. 1998, 161, 1585–1588. 
78 Stamnaes,  J.; Fleckenstein, B.; and Sollid, L.M., Biochim Biophys Acta., 2008, 
1784(11), 1804-11. 
79Miller, M.L.; and  Johnson, G.W., J Chromatogr., 1999, 732, 65–72. 
80 Dørum, S.; Arntzen, M.Ø.; Qiao,S.-W.; Holm, A.; Koehler, C.J.; Thiede, B.; Sollid, 
L.M.; and Fleckenstein, S.-W., PlosOne, 2010, 5(11), e14056. 
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CD patients, whereas responses against γ-epitopes are less frequently 
observed
81,82
. 
It is possible to identify several gliadin epitopes that appear to account for 
most of the α-gliadin specific recognition by CD4+ T-cells from celiac 
subjects. The so called “33mer” α2-gliadin fragment, the peptide 
LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF, α2-gliadin (57-89), 
deriving from the proteolityc digestion of gliadin from food sources as wheat, 
barley and rye has been identified as the major antigen leading to the 
activation of the T-cell mediated response in genetically predisposed subjects. 
This peptide is of particular interest because it is the most noteworthy of the 
digestive products. Three distinct patients'-specific T cell epitopes previously 
identified in T cell proliferation assays, are present in this peptide, namely, 
PFPQPQLPY, PQPQLPYPQ (three copies), and PYPQPQLPY (two copies). 
In addition to this Gln- and Pro-rich 33-mer, the peptide WQIPEQSR has been 
also identified
57. 
Recently, Dørum and coworkers reported a fine analysis investigating the 
preferred substrates for tTG. Thanks to a mass spectrometry method based on 
centroid mass determination, they observed large variations in the degree of 
deamidation in differet gliadin derived epitopes
83
, as well as for the 
transamidation reaction
80. 
Concerning the deamidation reaction, they were able to demonstrate that Gln 
residues within the same peptide exhibit different levels of deamidation and, 
not only the position of the residue has importance but also the entire peptide 
length can have a role in the tTG substrates’ selection. Data collected were 
validated studying the T-cell response to these DQ2 and DQ8 resctricted 
                                                        
81Marti, T.; Molberg, O.; Li, Q.; Gray, G. M.; Khosla, C.; and Sollid, L. M., J. Pharmacol. 
Exp. Ther.,2005, 312, 19–26. 
82Qiao, S. W.; Bergseng, E.; Molberg, O.; Jung, G.; Fleckenstein, B.; and Sollid, L. M., 
J.Immunol., 2005, 175, 254–261. 
83Dørum, S.; Qiao, S.-W.; Sollid, L.M.;and Fleckenstein, B., J. Prot. Res., 2009, 8, 1748–
1755. 
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epitopes.The epitope selection presumably deals with the anchoring position 
positively charged in HLA. In addition, it is possible to establish a deep 
correlation between the rate of deamidation of the different epitopes and their 
T-cell immunostimulatory capacity
83. 
The more representative CD4+T-cell epitopes identified in α2-Gliadin fraction 
of wheat gluten are listed below (their importance is established on the basis of 
the CD4+T-cell response): 
 
1) PFPQPQLPY (DQ2-α2-I), [α2-Glia(61-69), 9mer]; 
2) PQPQLPYPQ (DQ2-α2-II), [α2-Glia(63-71), 9mer]; 
3) PYPQPQLPY (DQ2-α2-III), [α2-Glia(68-76), 9mer]; 
4) LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF [α2-Glia(57-89), 
33mer]. 
Underlined Gln residues are those expected to be targeted by the enzyme 
 
Gliadin peptides 1), 2), and 3) are the identified T- cell epitopes in wheat 
gluten (9 mer core regions), these three peptides derive from the super antigen, 
sequence no. 4. It has been demonstrated that such shorter version can be as 
potent as the 33 mer in stimulating intestinal T-cell response
84
. 
 
2.5 Peptide-based cross linked antigens design and synthesis 
Following our “Chemical Reverse Approach”24, we selected three tTG peptide 
epitopes, e.g., tTG(553-564), tTG(581-592), and tTG(675-680) and three α2-
Gliadin peptide epitopes, e.g., α2-Glia(61-69), α2-Glia(63-71), and α2-
Glia(68-76) to design nine peptides containing cross-links between Lys- and 
Glu side-chains in tTG and α2-Glia linear fragments, respectively. 
 
                                                        
84Camarca, A.; Anderson, R.P.; Mamone, G.; Fierro, O.; Facchiano A, et al. J Immunol, 
2009, 182, 4158–4166. 
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Table 2.4. tTG and α2-gliadin protein fragments. 
Protein Fragment Sequence Target 
Residue 
tTG (553-564) DCLTESNLIKVR Lys562 
tTG (581-592) DLYLENPEIKIR Lys590 
tTG (675-680) AVKGFR Lys677 
α2-Gliadin (61-69) PFPQPQLPY Gln66 
α2-Gliadin (63-71) PQPQLPYPQ Gln66 
α2-Gliadin (68-76) PYPQPQLPY Gln73 
 
The nine cross- linked peptides were synthesized by Fmoc/tBu SPPS and the 
target Gln residues were replaced with Glu, for synthetic requirements to 
generate the new cross linked peptides. In particular the peptides were 
synthesized starting from a Rink-Amide Resin and were acetylated on the 
α
N-
terminus. 
Table 2.5. tTG and α2-gliadin peptides. 
Peptide Sequence 
tTGI Ac-DCLTESNLIKVR–NH
2
 
tTGII Ac-DLYLENPEIKIR–NH
2
 
tTGIII Ac-AVKGFR–NH
2
 
DQ2(I) Ac-PFPQPELPY–NH
2
 
DQ2(II) Ac-PQPELPYPQ–NH
2
 
DQ2(III) Ac-PYPQELPY–NH
2
 
 
Coupling reactions were performed in heterogeneous phase with the tTG 
fragments still anchored on the resin, and α2-gliadin peptides coupled in 
solution. The neo-epitopes were tested in ELISA to evaluate the IgA and IgG 
response to tTG-α2Glia constructs in coeliac patients’ sera, at the diagnosis, to 
develop a new ELISA based on peptides as an even more powerful diagnostic 
tool in terms of specificity and sensitivity. 
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Table 2.6. tTG and α2-gliadin cross-linked peptides. 
 
Cross-linked 
Peptides 
 
Cross-linked protein 
fragments  
 
 
Sequence 
tTGI-DQ2(I) 
 
tTG (553-564)-α2Glia(61-69) 
 Ac- DCLTESNLIKVR–NH
2
 
                               | 
         Ac- PFPQPELPY –NH
2
 
tTGI-DQ2(II) 
 
tTG (553-564)-α2Glia(63-71) 
 Ac- DCLTESNLIKVR –NH
2
 
                              | 
              Ac- PQPELPYPQ –NH
2
 
tTGI-DQ2(III) 
 
tTG (553-564)-α2Glia(68-76) 
 Ac- DCLTESNLIKVR –NH
2
 
                              |                                                                                                             
         Ac- PYPQPELPY –NH
2
 
tTGII-DQ2(I) 
 
tTG (581-592)-α2Glia(61-69) 
 Ac- DLYLENPEIKIR –NH
2
 
                              | 
         Ac- PFPQPELPY –NH
2
 
tTGII-DQ2(II) 
 
tTG (581-592)-α2Glia(63-71) 
 Ac- DLYLENPEIKIR –NH
2
 
                               | 
               Ac- PQPELPYPQ –NH
2
 
tTGII-DQ2(III) 
 
tTG (581-592)-α2Glia(68-76) 
 Ac- DLYLENPEIKIR –NH
2
 
                               |                                                                                                             
          Ac- PYPQPELPY –NH
2
 
tTGIII-DQ2(I) 
 
tTG (675-680)-α2Glia(61-69) 
               Ac- AVKGFR –NH
2
 
                             | 
         Ac- PFPQPELPY –NH
2
 
tTGIII-DQ2(II) 
 
tTG (675-680)-α2Glia(63-71) 
               Ac- AVKGFR –NH
2
 
                             | 
              Ac- PQPELPYPQ –NH
2
 
tTGIII-DQ2(III) 
 
tTG (675-680)-α2Glia(68-76) 
               Ac-AVKGFR –NH
2
 
                             |                                                                                                             
         Ac- PYPQPELPY –NH
2
 
 
 
 
2.5.1 Automatic synthesis of linear gliadin peptides: DQ2(I), DQ2(II), 
and DQ2(III) 
The three α2-Gliadin-derived peptides, i.e. DQ2(I) Ac-PFPQPELPY-NH2, 
DQ2(II) Ac-PQPELPYPQ-NH2, and DQ2(III) Ac-PYPQPELPY-NH2, were 
synthesized by Fmoc/tBu SPPS using an automatic peptide synthesizer, Apex 
396 equipped with a 8-wells reaction block (0.16 scale), starting from Fmoc 
Rink-Amide resin (Iris Biotech Gmbh), according to the general procedure for 
the SPPS described in details in the Experimental Part and using th 
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commercially available Fmoc-protected amino acids and TBTU/DIPEA 
activation. 
Table 2.7. Synthesis of α2-gliadin-derived peptides. 
Peptide Protein Fragment Sequence 
DQ2(I) α2-Gliadin (61-69) Ac-PFPQPELPY-NH2 
DQ2(II) α2-Gliadin (63-71) Ac-PQPELPYPQ-NH2 
DQ2(III) α2-Gliadin (68-76) Ac-PYPQPELPY-NH2 
 
The three α2-Gliadin-deriving peptides were modified replacing Gln target 
residues (present in the native sequence) with Glu residues at positions 66 in 
α2-Gliadin (61-69) and in, α2-Gliadin (63-71), at position 72 in α2-Gliadin 
(68-76) to perform the cross coupling reaction with the target Lys residues on 
the tTG peptide-fragments. The peptides were acetylated on the 
α
N-terminal 
function and cleaved from the resin as described in the general procedure 
reported in the Experimental Part. After cleavage of the linear peptides from 
the resin and deprotection of the amino-acid side chains, the crude products 
were purified by SLFC and characterized by RP-HPLC ESI-MS. Analytical 
data are reported in Table 2.8.  
 
Table 2.8. Analytical data of the peptides 
DQ2(I), DQ2(II)and DQ2(III). 
Peptide 
Rt 
(min)
a 
ESI-MS [M+H]
+
 
(m/z) 
calc(found) 
DQ2(I) 4.10 1128.8 (1128.6) 
DQ2(II) 2.81 1109.9 (1109.6) 
DQ2(III) 3.42 1144.8 (1144.7) 
a
Analytical HPLC gradients at 0.6 mL min
-1
, 
a 
20-70% B in 5 min,  
solvent system are A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
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2.5.2 Manual synthesis of the peptide tTGI, a case study. 
The synthesis of the tTGI peptide, Ac-DCLTESNLIKVR-NH2, presented 
difficult couplings at the level of the N-terminal tetrapeptide DCLT.  
 
Table 2.9 Peptide reproducing selected tTG protein fragment. 
Peptide Sequence Target Residue 
tTGI Ac-DCLTESNLIKVR-NH2 Lys 562 
 
The first attempt to obtain the peptide tTGI was performed using the manual 
peptide synthesizer PLS ChemTech starting from theFmoc Rink-Amide resin 
(Iris Biotech Gmbh, 0.63 mmol/g loading) and via TBTU/NMM activation. 
This approach was unsuccessful. Therefore, we decided to use a lower loaded 
Fmoc Rink-Amide resin (Iris Biotech Gmbh, 0.14 mmol/g loading). In order to 
identify the critical steps of the synthesis, each coupling reaction was 
monitored by the Kaiser test and a micro-cleavage (monitored by RP-HPLC 
ESI-MS) was performed each four residues as described in details in the 
Experimental Part. In particular, we found deletion sequences at the level of 
the four N-terminal coupling steps. To overcome these synthetic problems we 
performed a systematic study for the coupling reactions using different 
activating agents (TBTU/NMM, HATU/NMM, DIC/HOBt, and TBCR/NMM) 
in different reaction conditions, e.g. we performed the couplings both at room 
temperature, at 40 °C, and assisted by microwaves (35 Watt and 70 °C).  
 
Coupling reactions using HATU at room temperature, at 40°C, and assisted 
by microwave irradiation 
We used the most performing 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyl uronium hexafluorophosphate methanaminium (HATU) as a 
coupling reagent instead of TBTU. The HATU/NMM activation system was 
applied in the case of the last 4 coupling steps of the manual peptide synthesis. 
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HATU is a HOAt–based reagent developed by Carpino in 1994, who 
demonstrated increased reactivity when the activating agent presented strongly 
electronegative heteroatoms (i.e., nitrogen or oxygen) as in the 
azabenzotriazolyl ring. In fact, the withdrawing effect of nitrogen can decrease 
electron density at the carbon atom of the ester group linked to the ring in the 
activated form of the amino acid, increasing its reactivity towards 
nucleophiles. The difference in activities of these coupling reagents compared 
to the corresponding HOBt-based reagents could be explained by the hydrogen 
bond formed between the additional nitrogen atom in HOAt and HATU, 
stabilising the activated ester intermediate via an anchimeric assistance effect. 
Moreover, the possible transition state energy is lowered thus resulting in a 
higher coupling rate
85
. 
 
 
Figure 2.25. Commercially available HOBt (blue), HOAt, and HATU [both HOAt-
based (red) coupling reagents]. 
 
 
Notwithstanding the use of this more potent reagent, the final yield of the 
crude tTGI resulted lower than 5% by RP-HPLC ESI-MS analysis of the 
crude performed after micro-cleavage. 
Therefore HATU activation was coupled with the microwave irradiation (35 
Watt and 70 °C) during the coupling reactions. Kinetic problems due to 
                                                        
85 a) Carpino, L.A.; El-Faham, A.; Albericio, F. Tetrahedron Lett., 1994, 35, 2279-2282; 
b) L. A. Carpino, J.Am. Chem. Soc.,1993; 115: 4397; c) L. A. Carpino, J. Am. Chem. 
Soc.,1993, 115: 4397 –4398; d) L. A. Carpino, A. J. El-Faham, Org. Chem., 1995, 60, 
3561 –3564;e) L. A. Carpino, F. J. Ferrer, Org. Lett., 2001; 3: 2793–2795. 
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intermolecular aggregation or steric hindrance of protecting groups 
cangenerate premature termination of the sequence (causing deletion 
sequences) during the different steps of the SPPS. Recently, the use of 
microwave energy has been proposed to fulfill the requirement to couple a 
high-speed technology with an efficient solid-phase synthetic strategy. In 
particular, microwave irradiation allows homogeneous heating of the reaction 
vessel. Although conventional SPPS remains the principal strategy for peptide 
synthesis, the use of microwave energy in SPPS represents an important 
breakthrough in difficult couplings of numerous peptides (hydrophobic, 
sterically hindered sequences, i.e. polyArg; etc.), in terms of decreasing chain 
aggregation and improving the coupling rates during the syntheses, as reported 
by Rizzolo et al. for microwave assisted synthesis of the antibiotic peptide 
gramicidin A
86
. 
 
Figure 2.26. Advantages of heating by microwave 
irradiation. 
 
The last four couplings of the synthesis of tTGI, Ac-DCLTESNLIKVR-NH2, 
were performed using the standard microwave protocol reported in Table 2.10 
using HATU/NMM activation. Unfortunately no improvement in final yield of 
the peptide tTGI was achieved. 
 
                                                        
86 Rizzolo, F.; Sabatino, G.; Chelli, M.; Rovero P.; and Papini A.M., Int. J. of Pept. Res. 
and Ther.,2007, 13(1-2), 203-208. 
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Table 2.10 Microwave-assisted coupling conditions. 
Step Temp(°C) MW Power (W) Time (sec) 
Coupling of all aa 70 35 300 
Coupling of 
Fmoc-Cys554(Trt)-OH 
35 30 300 
 
 
The synthesis of the entire sequence of the peptide tTGI was repeated 
performing the coupling reaction at 40°C, using HATU/NMM activation. We 
failed once again, and in particular in this case we observed Ser558 
epimerization. 
 
 
Figure 2.27 RP-HPLC profile of Fmoc-Glu-Ser-Asn-Leu-Ile-Lys-Val-Arg-NH2 after 
microcleavage. 
 
In the general conditions of the SPPS (large excess of the reagents and fast 
coupling reactions) the racemization is usually reduced, but this can be a 
serious problem during the coupling of peptide fragments in the presence of 
Cys, His, Phe, and Ser residues as an example
87
. 
 
DIC/HOBt activation strategy 
tTGI, i.e. Ac-DCLTESNLIKVR-NH2, was therefore synthesized again using 
DIC/HOBt as activation system. At the end of the synthesis, the peptide was 
acetylated at the N-terminus following the general procedure described in the 
Experimental Part. Then the Dde protecting group on the side chain of Lys562 
was removed as described in the general procedure using 2% v/v hydrazine in 
                                                        
87a) Di Fenza A.; Tancredi M.; Galoppini C.; Rovero P., Tetr. Lett., 1998, 39, 8529-8532; 
b) Di Fenza, A.; Rovero, P. Lett. Pept. Sci., 2002, 9, 125-129. 
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DMF for 3-5 minutes.The peptide purity was checked by RP-HPLC ESI-MS 
after micro-cleavage as described in the Experimental Part. 
 
Table 2.11. RP-HPLC-ESI MS characterization of tTGI after micro-cleavage 
 
Peptide 
 
Sequence 
 
Rt 
(min)
a
 
[M+2H]
2+
 (m/z) 
Calc.(found) 
 
HPLC 
Crude Purity 
tTGI Ac-DCLTESNLIKVR-NH2 3.7
 b 
716.4 
(716.7) 
<10% 
a
 Analytical HPLC gradients at 0.6 mL min
-1
, 
b
20-60% B in 5 min,  
solvent system are A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
 
We tried to synthesize tTGI using DIC/HOBt as activation system coupled to 
a microwave assisted protocol using the same coupling conditions described in 
Table 2.10 without obtaining the peptide in acceptable purity (data not shown). 
 
TBCRs-based strategy 
Because of the bad results obtained using as coupling reagents TBTU/NMM, 
HATU/NMM, and DIC/HOBt, we decided to switch to the Triazine Based 
Coupling Reagents (TBCRs) previously developed by Kaminski et al. and 
successfully applied and validated for SPPS
88
. TBCRs structurally derive from 
the commercially available and unstable 2-chloro-4,6-dimethoxy-1,3,5-triazine 
(CDMT) that was demonstrated not to be useful in SPPS. 
 
                                                        
88(a) Kaminski, Z.J.; Kolesinska, B.; Kolesinska, J.; Sabatino, G.; Chelli, M.; Rovero, P.; 
Blaszczyk, M.; Glowka, M.L.; Papini, A.M. J. Am. Chem, Soc. 2005, 127, 16912. (b) 
“Process for the preparation of N-triazinylammonium salts”. Filing date 07/11/2005. 
Applicant: Italvelluti S.p.a. Inventors: Z. Kaminski, A. M. Papini, B. Kolesinska, J. 
Kolesinska, K. Jastrzabek, G. Sabatino, R. Bianchini. PCT/EP2005/055793 , 2005.  
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Figure 2.28. TBCR·BF4 structure. 
 
On the contrary acylation of amino acids in SPPS by the most stable and 
soluble TBCR, the tetrafluoroborate of 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methyl morpholinium (Figure 2.28), can take advantage of the stepwise 
mechanism of amide bond formation via TBCRs in which the tetrahedral 
intermediate is formed after the nucleophilic attack of the amino function, 
followed by expulsion of the leaving group (Figure 2.29). 
 
Figure 2.29. Mechanism of amide bond formation via TBCRs. 
 
In fact, the concept of “superactive esters”89via TBCRs, lowering the energy of 
the amide formation transition state below the energy of the transition state 
relative to tetrahedral intermediate formation, is justified by a favoured process 
                                                        
89
Kaminski, Z. J., Biopolymers, 2000, 55, 140-165. 
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associated with the departure of the leaving groups releasing an additional 
energy (Figure 2.30). 
 
 
Figure 2.30.Energetic profile of amine acylation by active ester (left side) and 
“superactive ester” (right side). 
 
The energetically favoured process by TBCRs, of prototropic rearrangement of 
the enol to the more stable keto form contributes with a sufficient driving force 
changing the energetic profile of the coupling reaction. Since their inception
90
, 
TBCRs have been considered promising coupling reagents, particularly 
suitable for peptide synthesis. Triazine esters have already been found more 
reactive than any other acylating reagent, including N-hydroxybenzotriazole 
esters. Moreover, many authors used successfully triazine reagents for the 
synthesis of peptides, carboxylic acid esters, amides, pholic acid antagonists, 
α-lactames, carotenoids, fullerenes, and other compounds. 
TBTU/NMM activation was replaced byTBCR·BF4/NMM to synthesize tTGI, 
i.e. Ac-DCLTESNLIKVR-NH2. A solution of TBCR•BF4 in CH3CN, was 
added of the Fmoc-protected amino acids pre-dissolved in DMF and NMM. 
The reaction mixture was stirred for 30min before adding to the resin. The 
coupling mixture was left overnight at room temperature or, alternatively 1min 
and 30’’ + 3min in the case of microwave-assisted couplings (reaction 
conditions summarized in Table 2.12). 
                                                        
90
Kamiński, Z.J., Int. J. Pept. Protein Res.,1994, 43, 312-319. 
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RP-HPLC-ESI-MS of the crude product after microcleavage from the resin 
showed no improvement even in the case of this strategy. A particular critical 
step in the peptide chain elongation resulted the coupling of the penultimate 
residue Fmoc-Cys554(Trt)-OH. 
 
Use of ChemMatrix resin and replacement of Fmoc-Ser(tBu)-OH with Fmoc-
Ser(Trt)-OH 
We decided to use in the peptide synthesis Fmoc-Ser-(Trt)-OH bearing the 
more hindered trityl protecting group instead of the conventionally used Fmoc-
Ser(tBu)-OH. This was to try to overcome some possible aggregation effects 
usually drammatically affecting final yield. Moreover, the synthesis of tTGI, 
Ac-Asp-Cys-Leu-Thr-Glu-Ser-Asn-Leu-Ile-Lys-Val-Arg-NH2, was performed 
starting from a Fmoc-Rink-Amide Chem Matrix
®
resin according to the General 
Procedure for the SPPS described in details in the Experimental Part and using 
the commercially available Fmoc-protected amino acids and TBTU/NMM 
activation. Chem Matrix
®
 resins (Figure 2.31) are polyethyleneglycol-based 
resins and the solid support is exclusively composed of primary ether bonds 
and, therefore, it is claimed to have higher chemical stability. Its usefulness 
has been reported in several recent papers for the synthesis of complex, long, 
and highly hydrophobic peptides. 
 
Figure 2.31. Chemical structure of the polymeric polyethilenglycol support of 
ChemMatrix® resins. 
 
This synthetic process let us to obtain finally the tTGI peptide in acceptable 
purity(75%) as evaluated by RP-HPLC of the crude after micro-cleavage. In 
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Table 2.12 are summarised the different strategies performed to arrive to an 
optimised synthetic protocol to obtain tTGI. 
Table 2.12. Comparison of the different synthetic strategies performed during the 
optimization of the synthesis of tTGI 
Entry Coupling 
reagent 
Temp. 
°C 
Time 
min 
MW 
W 
Yield 
% 
 
Fmoc-Rink-
Amide-Y 
Resin  
Fmoc- 
Ser558(X)-
OH 
1 TBTU/NMM 20 20 - <5% Y=PS Resin X=tBu 
2 HATU/NMM 20 20 - <5% Y=PS Resin X=tBu 
3 HATU/NMM 70 5 35 <5% Y=PS Resin X=tBu 
4 HATU/NMM 40 20 - <5% Y=PS Resin X=tBu 
5 DIC/HOBt 20 20 - <10% Y=PS Resin X=tBu 
6 DIC/HOBt 70 5 35 <5% Y=PS Resin X=tBu 
7 TBCR/NMM 20 O.N. - <5% Y=PS Resin X=tBu 
8 TBCR/NMM 70 1.5+3 100 <5% Y=PS Resin X=tBu 
9 TBTU/NMM 20 20 - 75% Y=Chem 
Matrix® Resin 
X=Trt 
 
The Peptide tTGI was then acetylated on the 
α
N-terminal function as 
described in the general procedure reported in the Experimental Part.The target 
Lys side-chains in tTGI peptide sequence, Lys562 was protected by 1-(4,4-
dimethyl-2,6-dioxacyclohexylidene)ethyl (Dde)
91
 that was orthogonally 
removed to react regioselectively with the Glu side chains in α2-Gliadin 
peptide fragments, as reported in details in the Experimental Part. Dde is easily 
removed under nucleophilic conditions treating the resin with 2% v/v 
hydrazine in DMF for 3-5 minutes.The deprotection reaction was followed by 
UV detection at 290nm because of the formation of 3,6,6-trimethyl-4-oxo-
                                                        
91Nash, I.A.; Bycroft, B.W.; and Chan, W.C., Tetrahedron Letters, 1996, 37(15), 2625–
2628. 
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4,5,6,7-tetrahydro-1H-indazole. Dde is stable under Fmoc- and Boc-
deprotection conditions. On the contrary Fmoc is readily deprotected with 2% 
v/v hydrazine in DMF. Therefore Dde has to be removed only at the end of the 
synthesis after introducing the last amino acid protected as Boc on the N-
terminus or after acetylation with acetic anhydride in the presence of NMM, as 
in our case. The peptide purity was checked by RP-HPLC ESI-MS after micro-
cleavage from the resin as described in the Experimental Part.  
Analytical data are reported in Table 2.13. 
Table 2.13. Analytical data of the peptide tTGI. 
 
Peptide 
 
Sequence 
 
Rt 
(min)
a
 
[M+2H]
2+
 (m/z) 
Calc. (found) 
 
HPLC 
Purity 
tTGI Ac-DCLTESNLIKVR-NH2 3.62
b
 716.4 
(716.7) 
75% 
a
 Analytical HPLC gradient at 0.6 mL min
-1
, 
b
20-60% B in 5 min,  
solvent system are A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
 
 
2.5.3 Manual synthesis of the linear peptides tTGII and tTGIII 
The peptides, tTGII, Ac-DLYLENPEIKIR-NH2,  and tTGIII, Ac-AVKGFR- 
NH2 were synthesized by Fmoc/tBu SPPS using the manual peptide 
synthesizer PLS ChemTech starting from Fmoc-Rink-Amide resin (Iris 
Biotech Gmbh), according to the general procedure for the SPPS described in 
details in the Experimental Part and using the commercially available Fmoc-
protected amino acids and TBTU/NMM activation. 
 
Table 2.14. Peptides reproducing the selected tTG protein fragments. 
Peptide Sequence Target Residue 
tTGII Ac-DLYLENPEIKIR-NH2 Lys590 
tTGIII Ac-AVKGFR- NH2 Lys677 
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Each coupling step was monitored by the Kaiser test in order to follow the 
coupling reactions. The peptides were acetylated on the 
α
N-terminal function 
as described in the general procedure reported in the Experimental Part.  
The target Lys side chains in the tTGII and tTGIII peptide sequences, 
Lys590 e Lys677 respectively, were protected by Dde. Therefore the Lys side 
chains were orthogonally deprotectedwith 2% v/v hydrazine in DMF at the end 
of the synthesis to react regioselectively with the Glu side chains in α2- 
Gliadin peptide fragments, as reported in details in the Experimental Part. 
Peptides purity was checked by RP-HPLC ESI-MS after micro-cleavage as 
described in the Experimental Part. Analytical data are reported inTable 2.15. 
Table 2.15. Analytical data for the peptides tTGII and tTGIII. 
 
Peptide 
 
Sequence 
 
Rt 
(min)
 a 
 
ESI-MS 
[M+2H]
2+
 
(m/z) 
Calc(found) 
 
HPLC 
Purity 
tTG II Ac-DLYLENPEIKIR-NH2 3.9
b 772. 4 
(772.7) 
95% 
tTG III Ac-AVKGFR-NH2 3.5
c 359.7 
(359.8) 
80% 
a
 Analytical HPLC gradients at 0.6 mL min-1, 
b
20-60% B in 5 min, , 
c
10-60% B in 5 min;solvent system are 
A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
 
 
2.5.4 Synthesis of the nine cross-linked tTG-Gliadin peptides: 
tTGI-DQ2(I), tTGI-DQ2(II), tTGI-DQ2(III), tTGII-
DQ2(I),tTGII-DQ2(II), tTGII-DQ2(III), tTGIII-DQ2(I), 
tTGIII-DQ2(II), and tTGIII-DQ2(III). 
The nine cross-linked peptides were obtained starting from the linear tTGI, 
tTGII, and tTGIII and the α2-Gliadin peptides, DQ2(I), DQ2(II), and 
DQ2(III) obtained as described in the previous sections. Coupling reactions 
were performed in heterogeneous phase with the tTG peptide fragments still 
anchored on the resin, adding solutions ofthe α2-Gliadin peptides. α2-Gliadin 
peptides were purified up to 95% purity before the cross-linking reaction. 
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Figure 2.32. Cross-linking reaction in heterogeneous phase. 
 
100mg of resin (1 eq.) bearing each tTG peptide fragment, i.e. Rink-Amide 
Polystirene Resin for the tTGII and tTGIII peptides andRink-Amide Chem-
Matrix Resin for the tTGI peptide,were swollen in DMF before performing 
the cross-coupling, as reported in details in the Experimental Part. α2- Gliadin 
peptides (2.5 eq.), i.e., DQ2(I), DQ2(II),and DQ2(III), were added in a 
solution of DMF/NMP 2:1. The coupling reactions were performed at room 
temperature for 1h in HATU/DIPEA activation system. 
The coupling reaction was monitored by the Kaiser test and by micro-cleavage 
according to the general procedure reported in the Experimental Part. After 
cleavage of the cross-linked peptides from the resin and contemporary 
deprotection of amino-acids side chains of tTG peptide fragments, the crude 
products were purified by semipreparative RP-HPLC and characterized by RP-
HPLC ESI-MS. Analytical data are reported in Table 2.16. 
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Table 2.16. Analytical data of the cross-linked peptides. 
Cross-linked 
peptide 
Sequence 
ESI-MS 
[M+2H]
2+
 (m/z) 
Calc (found) 
HPLC 
(Rt,min)
a
 
tTGI-DQ2(I)  Ac- DCLTESNLIKVR–NH2 
                               | 
           Ac- PFPQPELPY –NH
2
 
1271.1 
(1271.02) 
3.31
b
 
tTGI-DQ2(II)  Ac- DCLTESNLIKVR –NH2 
                              | 
              Ac- PQPELPYPQ –NH
2
 
1261.61 
(1261.4) 
3.67
 d
 
tTGI-DQ2(III)  Ac- DCLTESNLIKVR –NH2 
                              |                                                                                                             
         Ac- PYPQPELPY –NH
2
 
1279.1 
(1279.02) 
2.86
b
 
tTGII-DQ2(I)  Ac- DLYLENPEIKIR –NH2 
                              | 
          Ac- PFPQPELPY –NH
2
 
1327.2  
(1327.6) 
3.99
b
 
tTGII-DQ2(II)  Ac- DLYLENPEIKIR –NH2 
                               | 
               Ac- PQPELPYPQ –NH
2
 
1317.71 
(1318.2) 
2.75
b
 
tTGII-DQ2(III)  Ac- DLYLENPEIKIR –NH2 
                               |                                                                                                             
          Ac- PYPQPELPY –NH
2
 
1335.21 
(1335.2) 
3.51
b
 
tTGIII-DQ2(I)                Ac- AVKGFR –NH2 
                             | 
         Ac- PFPQPELPY –NH
2
 
914.50 
 (915.19) 
3.46
b
 
tTGIII-DQ2(II)                Ac- AVKGFR –NH2 
                             | 
              Ac- PQPELPYPQ –NH
2
 
905.01 
(905.67) 
3.51
c
 
tTGIII-DQ2(III)                Ac-AVKGFR –NH2 
                             |                                                                                                             
         Ac- PYPQPELPY –NH
2
 
922.50 
(923.22) 
4.01
c
 
a
Analytical HPLC gradients at 0.6 mL min
-1
 solvent systems are: A (0.1% TFA in H2O MilliQ) and B (0.1 % 
TFA in CH3CN), 
b
30-70% B in 5 min ,
c
20-60% B in 5 min, 
d
25-65% B in 5 min. 
 
2.6 SP-ELISA using the nine cross-linked peptides as synthetic 
antigens 
The nine cross-linked peptides, i.e., tTGI-DQ2(I), tTGI-DQ2(II), tTGI-
DQ2(III), tTGII-DQ2(I), tTGII-DQ2(II), tTGII-DQ2(III), tTGIII-
DQ2(I),tTGIII-DQ2(II), and tTGIII-DQ2(III) were tested in SP-ELISA to 
evaluate IgA and IgG antibody titre in 48 CD patients’ sera at the diagnosis, 
and 36 normal blood donors (NBDs) as controls. 
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SP-ELISA experiments were performed using as secondary antibody, anti-
human IgA and anti-human IgG conjugated to Alkaline Phosphatase (AP). IgA 
displayed only low titers. On the contrary, IgG antibodies displayed higher 
titers. In particular, we selected the two cross-linked peptides, ie., tTGI-
DQ2(I) and tTGI -DQ2(II), after screening 48 CD patients' sera versus 36 
NBDs (Figure 2.33). 
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Figure 2.33. Dispersion diagrams generated for tTGI-DQ2(I)and tTGI-DQ2(II). 
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We generated the two ROC curves
92
reported below for the anti-cross-linked 
peptide tTGI-DQ2(I) and anti-tTGI -DQ2(II) IgG antibodies in 48 CD versus 
36 NBDs. 
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Figure 2.34.  ROC analysis calculated for anti-tTGI-DQ2(I)and anti-tTGI-DQ2(II) 
IgG in 48 CD versus 36 NBD. 
In analyzing the ROC curves there are some parameters that have to be taken 
into account. The parameters calculated for the two ROC curves corresponding 
                                                        
92Receiver Operating Characteristic (ROC) curves are often used in medicine to 
determine a cutoff value for a clinical test. In a Receiver Operating Characteristic 
(ROC) curve the true positive rate (Sensitivity, y‐axis) is plotted in function of the false 
positive rate (100-Specificity, x‐axis) for different cut-off points. Each point on the 
ROC curve represents a sensitivity/specificity pair corresponding to a particular 
decision threshold. A test with perfect discrimination (no overlap in the two 
distributions) has a ROC curve that passes through the upper left corner (100% 
sensitivity, 100% specificity). Therefore the closer the ROC curve is to the upper left 
corner, the higher the overall accuracy of the test. Zweig & Campbell, 1993. 
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to the IgG antibodies to the two selected cross-linked peptides are reported in 
Table 2.17. 
 
Table 2.17. ROC parameters 
Parameters  Peptide 
tTGI-DQ2(I) 
Peptide 
tTGI-DQ2(II) 
Area under the ROC curve 0.7428 0.7928 
Std. error 
 
0.05477 
 
0.04838 
95% confidence interval 0.6354- 0.8501 
 
0.6980 - 0.8877 
 
P value 0.0001513 < 0.0001 
 
In particular, the area under the ROC curve (AUC) and the P value allow to 
measure the overall ability of the test to discriminate between CD patients and 
healthy controls
93
.  
In conclusion, the peptide tTGI -DQ2(II) displayed the best performance in 
detecting autoantibodies in CD patients’ sera at the diagnosis and the analysis 
of the ROC curve allowed us to determine the cut-off of the clinical assay (IgG 
Abs> 0.3 OD) using tTGI -DQ2(II) as a synthetic antigen in SP-ELISA. 
                                                        
93The area under the ROC curve quantifies the overall ability of the assay to 
discriminate between those individuals with the disease and those without the 
disease.ROC curve areas are typically between 0.5 and 1.0. The maximum possible 
AUC of an ideal test is 1.00. The software we used for data analysis calculates the P 
value from the z ratio, z as (Area - 0.5)/(SE Area). The P value tests the null 
hypothesis that the test has no skill at distinguishing patients from controls. The 
Significance level or P-value is the probability that the observed sample Area under 
the ROC curve is found when in fact, the true (population) Area under the ROC curve 
is 0.5 (null hypothesis: Area = 0.5). The smaller the P value is, the higher will be the 
ability of the assay to distinguish between the two groups, i.e. CD patients and healthy 
controls.  
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Figure 2.35. Results obtained from SP-ELISA using the peptide tTGI-DQ2(II). 
 
In conclusion the cross-linked peptide tTGI-DQ2(II) is able torecognize 
circulating IgG autoantibodies in coeliac patients'sera with 56% speciticity and 
89% sensitivity (percentage of CD patients).  
 
2.6.1 Investigation of the nature of the antigen-antibody 
recognition by the cross-linked peptide  tTGI-DQ2(I) in 
SP-ELISA 
We investigated the role of the linear peptide fragments by a comparison with 
the cross-linked adduct tTGI-DQ2(II). To this end, we performed SP-ELISA 
experiments using the tTGI peptide,i.e. tTG(553-564), the DQ2(II) peptide, 
i.e.α2-Gliadin(63-71), a mixture of both the linear sequences tTGI and 
DQ2(II), and the cross-linked peptide tTGI-DQ2(II) in a screening on 30 CD 
patients’ sera and 24 NBDs, using as secondary antibody anti-human IgG 
conjugated to AP. 
 
PART A 
80 
tTGI
NBD CD
0.00
0.25
0.50
0.75
1.00
1.25
1.50
Sample Sera
A
b
s
 1
:1
0
0
 (
4
5
0
n
m
)
DQ2(II)
NBD CD
0.00
0.25
0.50
0.75
1.00
1.25
1.50
Sample Sera
A
b
s
 1
:1
0
0
 (
4
5
0
n
m
)
 
 
tTGI + DQ2(II)
NBD CD
0.00
0.25
0.50
0.75
1.00
1.25
1.50
Sample Sera
A
b
s
 1
:1
0
0
 (
4
5
0
n
m
)
tTGI-DQ2(II)
1H_DS 1H_CD
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
Sample Sera
A
b
s
 
Figure 2.36. Dispersion diagrams generated for the linear peptides tTGI and 
DQ2(II), a mixture of them, and the cross-linked adduct tTGI-DQ2(II). 
 
The results reported in Figure 2.36 confirm the importance of the cross-link in 
the new peptide probe tTGI-DQ2(II) in recognizing IgG antibodies in CD 
patients' sera compared to NBDs. 
 
2.6.2 Results and discussion 
Thanks to the innovative "Chemical Reverse Approach" previously developed 
in PeptLab of the University of Florence, we were able to select the cross-
linked peptide tTGI-DQ2(II) as the most promising tool to recognize 
circulating IgG autoantibodies in sera of coeliac patients, at the diagnosis. 
Antibody recognition obtained using the syntehtic cross-link tTGI-DQ2(II) 
confirm the previously reported results indicating protein fragments formed in 
vivo
73
.In particular,univocally characterised synthetic probes reproducing these 
fragments could mimic the in vivo formed antigens and can be used to set-up 
and validate peptide-based ELISA for CD early diagnosis. Moreover this result 
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underlines the importance of the criteria used to drive epitope selection since 
the tTGI peptide fragment is exposed on the surface of tTG when it is in the 
open conformation
74,56,69
. Finally we found that among the 9-mer epitopes of 
the 33-mer super-antigen α2-Glia(57-89), the best non-self antigen is α2-
Glia(63-71), reproduced in the DQ2(II) synthetic peptide. 
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PART B: Glycopeptidomimetic-based immunoassays for 
Multiple Sclerosis 
 
3 Multiple Sclerosis: an overview 
Multiple Sclerosis was described for the first time by the french neurologist 
Jean Martin Charcot, in 1868. Charcot observed the accumulation of 
inflammatory cells in a perivascular distribution within the brain and spinal 
cord white matter in patients with intermittent episodes of neurologic 
dysfunction
94. This led to the term “sclérose en plaques disseminées”, or 
Multiple Sclerosis. Later, in 1948, Elvin Kabat’s observation of increased 
oligoclonal immunoglobulin in the cerebrospinal fluid of patients with MS 
provided further evidence of an inflammatory nature of the disease
95
. MS twin 
studies demonstrated a strong genetic basis for this clinical-pathological 
entity
96
. In 1933, Thomas Rivers demonstrated that repeated injections of 
rabbit brain and spinal cord (CNS myelin) into primates developed a 
demyelinating disease (experimental autoimmune encephalomyelitis, e.g. 
EAE) and led to the generally accepted concept that MS is an autoimmune 
disease
97
. 
MS is a chronic, inflammatory, demyelinating disease of the CNS that affects 
brain and spinal cord and its name comes from the numerous “sclerotic” areas 
observable by microscopical examination of the brain. Usually, the disease is 
mild, but some people lose the ability to write, speak or walk. Typical 
symptoms of MS are, visual disturbances, muscle weakness, trouble with 
                                                        
94
a) Charcot, J.. Gazette des Hôpitaux. 1868, 41, 554–566; b) Charcot, J.,The New 
Sydenham Society. London, United Kingdom., 1877, 157–222. 
95
 Kabat, E. A.; Glusman, M.; and Knaub, V., Am. J. Med., 1948, 4, 653-662. 
96
a) Mackay, R. P., Arch. Neurol. 1966, 15, 449–462; b) Williams, A., Eldridge, R.; 
McFarland, H.,  Neurology. 1980, 30, 1139–1147. 
97
Rivers, T. M. Sprunt, D.H.; and Berry, G.P., J. Exp. Med.1933, 58, 39–53. 
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coordination and balance, sensations such as numbness, prickling, or "pins and 
needles" and thinking and memory problems. 
 
 
Figure 3.1. MS shorts out the flow of information within the brain and between the 
brain and body, similar to how a stripped electrical wire can short out an appliance. 
 
MS represents the first cause of neurological disability in adult Caucasians. 
Today there is no cure for MS, but medicines may slow it down and help 
control symptoms. Physical and occupational therapy may also help. 
 
Clinical subtypes of Multiple Sclerosis 
MS onset generally occurs from the adolescence and around the age of 35. 
Epidemiologically, it hits women more commonly than men (2:1). The disease 
shows a definite relationship with latitude. The four are the clinical subtypes of 
MS, based on temporal profile are described below. 
 
1) Progressive relapsing MS (PR-MS).PR-MS is defined as progressive 
disease from onset, with clear acute relapses, with or without full recovery. 
2) Secondary progressive MS (SP-MS).SP-MS is defined as a disease that 
has an initial relapsing-remitting disease course followed by progression with 
or without occasional relapses, minor remissions, and plateaus. 
PART B 
84 
3) Primary progressive MS (PP-MS).PP-MS is defined as the disease 
progression from the onset with occasional plateaus and temporary minor 
improvements. 
4) Relapsing-remitting MS (RR-MS).RR-MS is characterized by clearly 
defined disease relapses with full recovery or with sequelae and residual 
deficit upon recovery. In the period between disease relapses patients are 
stable with lack of disease progression
98
. 
 
 
Figure 3.2. Clinical subtypes of MS; a) Progressive relapsing MS, b) Secondary 
progressive MS, c) Primary progressive MS, d) Relapsing-remitting MS. 
 
Pathogenesis of Multiple Sclerosis 
On the basis of myelin protein loss, the geography and extension of plaques, 
the patterns of oligodendrocyte destruction, and the immunopathological 
evidence of complement activation, Lucchinetti. et al. proposed four distinct 
patterns of MS pathology: 1) cell-mediated demyelination; 2) antibody-
                                                        
98
 Lublin, F.D.; and Reingold, S.C., Neurology, 1996, 46, 907-911. 
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mediated demyelination; 3) active myelin destruction; 4) oligodendrogliopathy 
or oligodendrocyte dystrophy
99
. 
Two patterns (1 and 2) show close similarities to T-cell–mediated or T-cell 
with Ab–mediated autoimmune encephalomyelitis, respectively. The other 
patterns (3 and 4) are highly suggestive of a primary oligodendrocyte 
dystrophy, reminiscent of virus or toxin induced demyelination rather than 
autoimmunity. This study demonstrated that most cases share in common the 
T cell and macrophage dominated inflammatory reaction, lesions segregated 
into those with close similarities to autoimmune encephalomyelitis (i.e. 
patterns 1 and 2) and those with signs of oligodendrocyte dystrophy (i.e. 
patterns 3 and 4)
100
. The idea that MS is caused by an infectious agent has 
been controversial for almost a century. According to this hypothesis, MS is 
caused by primary infection of the CNS with intact or mutant virus, whereas 
an inadequate immune response probably contributes to disease progression. 
During the first phase of the disease, the virus replicates rapidly in the CNS 
and induces variable degrees of demyelination. After a few days, increasing 
mononuclear cell infiltrates targeting the virus infection are observed. 
Predominantly CD8
+
 T cells, but also CD4
+
 T cells, are crucial for controlling 
the virus, whereas B cells and Abs seem to be less important in the acute 
disease stage
101
. 
 
Role of the oxidative stress  
Oxidative stress refers to a state in which free radicals and their products are in 
excess of antioxidant defense mechanisms. Reactive Oxygen Species (ROS) 
and Reactive Nitrogen Species (RNS) include superoxide ions, hydrogen 
peroxide, nitric oxide, and peroxynitrite and are generated as part of normal 
cellular physiology. Overproduction of ROS can cause damage to lipids, 
                                                        
99 Lucchinetti, C.;Bruck, W.; Parisi, J.; Scheithauer, B.; Rodriguez, M.; and Lassmann, 
H., Ann. Neurol., 2000, 47, 707-717. 
100 Lassmann, H.; Bruck, W.; and Lucchinetti, C., Trends Mol. Med., 2001, 7, 115-121. 
101
 Hemmer, B.; Archelos, J.J.; and Hartung, H.P., Nat Rev Neurosci , 2002, 3, 291-301. 
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proteins, and nucleic acids and may lead to cell death. ROS cause damage to 
cell function with aging and are involved in a number of age-related disorders 
playing a crucial role in neurodegenerative diseases. Extensive evidence 
implies increased ROS production in inflammatory demyelinating diseases. 
Human microglia are one of the most potent producers of superoxides
102
, and it 
is accepted that during inflammatory demyelinating diseases, cells such as 
these are recruited to lesions within the CNS. Neurons can also produce 
ROS
103
 in response to electrical activity following eicosanoid production 
driven by calcium cellular influx
104
. Direct evidence of lipid peroxidation has 
been demonstrated in postmortem brain tissue with findings pointing to a 
pivotal role in early plaque evolution. There is also evidence for increased 
ROS production in EAE
105
. A link between fatty acid oxidation and 
autoimmune inflammation of CNS has been demonstrated in an animal model 
of MS. Shriver et al. demonstrated that inhibition of Carnitine 
palmitoyltransferase 1 (CPT-1) resulted in less severe EAE, reduced 
inflammation, and demyelination
106
.  
 
Figure 3.3. Importation of Fatty Acids into the Mitochondria. 
The coordinated immune attacks in the CNS are undoubtedly the most 
important factor in the early phase of RR-MS while the chronic progressive 
phase of MS is dominated by non-immune mediated mechanisms. ROS and 
                                                        
102
 Loane, D.J.; and Byrnes, K.R., Neurotherapeutics,2010, 7, 366-377. 
103 He, Y.,Cui, J.; Lee, J.C‑M.; Ding, S.; Chalimoniuk, M.; Simonyi, A.; Sun, a.Y.; Gu, Z.; 
Weisman, G.A.; Gibson Wood, W.; and Sun, G.Y., ASN Neuro,2011, 3, e00050. 
104 Windelborn, J.A.; and Lipton, P., J Neurochem,2008, 106, 56-69. 
105Ruuls, S.R.;Bauer, J.; Sontrop, K.; Huitinga, I.; 't Hart, B.A.;and Dijkstra, C.D.,J 
Neuroimmunol., 1995, 56, 207-217. 
106
 Shriver, L.P.; and Manchester, M. Nature, 2011, doi:10.1038/srep00079. 
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RNS produced as part of the inflammatory response can have a potential role 
in tissue damage in MS.  
 
Autoimmune features 
The underlying immunological abnormalities in MS lead to various 
neurological and autoimmune manifestations. There is strong evidence that 
MS is, at least in part, an immune-mediated disease, whereas there is less 
evidence that MS is a classical autoimmune disease, even though many 
authors state this in the description of the disease
107
. 
 
 
Figure 3.4. Immune response in multiple sclerosis108. 
Multiple Sclerosis is thought to be  an autoimmune disease in which CD4+ and 
CD8+ T-cells enter the CNS and initiate an inflammatory response directed 
against myelin and other components of CNS. Over several years, a more 
complex pathophysiology in which numerous cells are involved in the 
development of MS plaques emerged. These cells are CD8+ T lymphocytes, 
                                                        
107Wootla, B.; Eriguchi, M.; and Rodriguez, M., Autoimm. Dis., 2012, 
doi:10.1155/2012/969657. 
108
Hemmer, B. ; Archelos, J.J.; Hartung, H-P.,Neuroscience. 2002, 3,291-301. 
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B-cells, and Th17 cells (a population of T helper cells that secrete 
inflammatory cytokine IL-17). MS has classically been thought as a T-cell-
dependent process associated with macrophage-mediated demyelination driven 
by myelin-specific auto-Ags
109
. In the presence of APCs, such as dendritic 
cells, efficient B- and T- cell responses are initiated. After priming, these cells 
cross the blood–brain barrier, migrate to the site of Ag exposure and develop 
effector functions. CNS specific autoreactive T-cells initiate an inflammatory 
process that results in CNS demyelination and cross the blood brain barrier by 
diapedesis. After entering the CNS, these T-cells re-encounter the specific 
Ag(s) and cause inflammation. These APCs express MHC class I and MHC 
class-II Ags, which increase the local inflammatory response causing the 
damage of saltatory conduction, which leads to MS symptoms. 
The role of B-cells, plasma cells, and Abs is complex and may be involved in 
pathogenic, regulatory and reparative phases of MS. A possible mechanism is 
that the intratechal Ab response in MS patients is due to nonspecific 
immunodysregulation. Nevertheless autoAb production in MS patients might 
be driven or promoted by cross-reacting infectious Ags. To this sense 
molecular mimicry is an especially appealing concept with accumulating 
support. Abs seem to modulate the inflammatory response mediated by T cells 
in brain lesions. T lymphocytes disturb the blood brain barrier and start the 
inflammatory process by activating effector cells, such as macrophage and 
microglia. Although the cause of MS is still uncertain, many findings point 
towards the autoAb response to self antigenic proteins of the myelin family. 
Myelin oligodendrocyte glycoprotein (MOG), even if its role in the 
pathogenesis of MS has remained controversial, has been considered as one of 
the potential self protein Ag in MS. Studies demonstrated the serological 
and/or CSF presence of antibodies directed against MBP and/or MOG in MS 
patients. Moreover, specific Abs against MOG gain access to their target Ag 
on the surface of myelin sheaths and initiate myelin destruction in the model of 
                                                        
109
 Goverman, J.M., J.Immunol Rev2011, 241, 228-240. 
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MOG induced autoimmune encephalomyelitis
110
. In a recent study, it is 
claimed that anti-MOG Abs are also responsible of demyelination in CNS 
demyelinating diseases
111
. 
3.1 The N-Glucosylated peptide CSF114(Glc) for the diagnosis of 
MS 
Different self-proteins of myelin have been investigated as potent targets for 
T- or B-cells in MS, e.g. MOG. In the Laboratory of Peptide & Protein 
Chemistry & Biology of the University of Florence, the N-glucosylated 
peptide [Asn
31
(Glc)hMOG(30-50)] was demonstrated for the first time in 1999 
to be able to detect autoantibodies in MS patients’ sera, in ELISA 
experiments
112
. It was then observed that the ability of the glucosylated peptide 
to recognize autoantibodies in MS was related not only to its conformation but 
to a specific N-linked glucosyl moiety in the autoantibody binding site on 
MOG glycopeptide
113
. 
                                                        
110Lalive, P.H.; Molnarfi, N.; Benkhoucha, M.; Weber, M.S.; and Santiago-Raber, M.L., 
J. Neuroimmunol. , 2011, 240-241, 28-33. 
111Olsson, T.,Nat Rev Neurol., 2011, 7, 248-249. 
112Mazzucco, S.; Mata, S.; Vergelli, M.; Fioresi, R.; Nardi, E.; Mazzanti, B.; Chelli, M.; 
Lolli, F.; Ginanneschi, M.; Pinto, F.; Massacesi, L.; Papini, A. M. Bioorg. Med. Chem. 
Lett.,1999, 9, 167-172. 
113Carotenuto, A.; D’Ursi, A.M.; Nardi, E.; Papini, A.M.; Rovero, P. J. Med.Chem,2001, 
44, 2378-2381. 
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Figure 3.5. Calculated structures of CSF114(Glc). Ribbon diagram of the lowest 
energy conformer of 200 calculated structures of CSF114(Glc) derived from NMR data. 
 
Hence, the recognition properties of the molecule were optimized through the 
design and screening of focused libraries of different glycopeptides by a 
“Chemical Reverse Approach”. A family of specific antigenic probes, termed 
CSF114(Glc) and characterized by type I' β-turn structures, was developed to 
identify autoantibodies, as biomarkers of MS, correlating with disease activity 
in a sub-population of MS patients. Glycopeptides based on the 
CSF114(Glc)structures
14,114
, are able to measure accurately high affinity 
autoantibodies in sera of a statistically significant patients’ population115,116 and 
are characterized by different types of β-turn structures bearing a β-D-
glucopyranosyl moiety linked to an Asn residue. It has been demonstrated that 
autoantibody detection by type I’β-turn CSF114(Glc) glucopeptide is strictly 
                                                        
114 Lolli, F.; Mazzanti, B.; Pazzagli, M.; Peroni, E.; Alcaro, M.C.; Sabatino, G.; Lanzillo, 
R.; Brescia Morra, V.; Santoro, L.; Gasperini, C.; Galgani, S.; D’Elios, M.M.; Zipoli, V.; 
Sotgiu, S.; Pugliatti, M.; Rovero, P.; Chelli, M.; Papini, A.M.,J 
Neuroimmunol.,2005,167, 131-137 
115Carotenuto, A.; D'Ursi, A. M.; Mulinacci, B.; Paolini, I.; Lolli, F.; Papini, A. M.; 
Novellino, E.; Rovero P., A. J. Med. Chem.2006, 49, 5072-5079. 
116Carotenuto, A.; Alcaro, M.C.; Saviello, M.R.; Peroni, E.; Nuti, F.; Papini, A.M.; 
Novellino, E.; Rovero, P., J. Med. Chem., 2008, 51, 5304–5309. 
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related to the β-D-glucopyranosyl moiety linked to the Asn residue117, since 
glycopeptides lacking Asn(Glc) display a negligible activity
118
. 
CSF114(Glc) represents an unconventional approach, since its structure is 
completely unrelated to MOG (or any other myelin derivative) and is not 
linked to any particular pathogenetic hypothesis. More than one of the myelin 
proteins could undergoes aberrant N-glucosylation thus creating a family of 
new autoantigens and CSF114(Glc) could be a mimetic of all those N-
glucosylated proteins. Recently, putative Ags present in rat brain, which 
recognize serum MS autoAbs purified through CSF114(Glc) affinity columns, 
termed “CSF114(Glc) Abs” were characterized. MALDI mass spectrometry 
analysis confirmed by ESI-MS, of the isolated Ags led to the identification of 
alpha actinin 1, a cytoskeletal protein abundant in CNS, as a principal MS-
related Ag. Detection of cytoskeletal protein alpha actinin 1 by autoAbs from 
MS patients, besides signaling its involvement in the pathology, implies a 
derangement of the barrier shield, leading to exposure of the neurovascular 
niche to further degenerative injuries
119
. It is evident that CSF114(Glc) is a 
valuable tool not only for MS diagnosis but even to elucidate the 
inflammatory/degenerative processes of MS
120
. 
Therefore, a further investigation of the possible molecular mechanisms 
involved in MS, and in particular the characterization of the native 
autoantigen(s) recognized by anti-CSF114(Glc) auto Abs, designing even 
more optimized tools may represent an important goal in the study of MS to 
develop simple diagnostic assays based on peptides. 
                                                        
117 Nuti, F.; Paolini, I.; Cardona, F.; Chelli, M.; Lolli, F.; Brandi, A.; Goti, A.; Rovero, P.; 
Papini, A.M. Bioorg. Med. Chem.2007,15, 3965-3973. 
118 Nuti, F.; Peroni, E., Real-Fernandez, F.; Bonache, M.A.; Le Chevalier-Isaad, A.; 
Chelli, M.; Lubin-Germain, N.; Uziel, J.; Rovero, P.; Lolli, F.; and Papini, A.M., 
Biopolymers, 2010, 94(6), 791-799. 
119Pandey, S.; Dioni, I.; Lambardi, D.; Real-Fernandez, F.; Peroni, E.; Pacini, G.; Lolli, F.; 
Seraglia, R.; Papini, A.M.; and Rovero, P., Mol. Cell. Proteom., 2012, In press 
120 Pandey, S.; Alcaro, M.C.; Scrima, M.; Peroni, E.; Paolini, I.; Di Marino,S.; Barbetti, 
F.; Carotenuto, A.; Novellino, E.; Papini, A.M.; D'Ursi, A.M.; and Rovero, P., J. Med. 
Chem., 2012, In press. 
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3.2 Glycopeptidomimetic-based diagnostics in MS 
Following the same approach that led to the generation of CSF114(Glc) 
multiple epitope peptides and gluco-cyclopeptide analogues were designed 
and synthesized. These synthetic probes were then tested by the use of our 
reverse approach to identify MS-specific autoatibodies as disease biomarkers 
in simple ELISA. 
 
3.2.1 Multivalent interactions in antigen-antibody recognition 
system 
The nature of the antigen-antibody interaction deals with the concept of the 
multivalency, i.e. the interaction between multivalent receptors and/or 
multivalent ligands. Nature provides us with numerous examples of molecules 
with low-intrinsic affinity binding sites that are capable of high-avidity 
interactions with their targets due to multivalent binding. An antibody 
molecule with high affinity for a target antigen does not usually exist in the 
primary naive antibody library, and antibody affinity usually increases during 
an immune response in vivo, called affinity maturation. Therefore, even if the 
intrinsic affinity of an antibody molecule toward various invaders (e.g. virus, 
and/or bacterial proteins) is relatively low, high avidity can overcome the low 
intrinsic affinity, leading to the production of antibody molecules with high 
intrinsic affinity for the target antigen through affinity maturation in the 
immune system
121
. All classes of antibodies have multiple equivalent receptor 
sites: two (IgD, IgE, IgG, IgA), four (IgA), six (IgA),and ten (IgM). Hence, the 
concept of avidity in terms of antibody binding is comparable to the 
multivalency one
122
. One of the most efficient ways to increase the binding 
activity of an antibody to a surface (e.g. cell surface) is to make use of the 
                                                        
121Kumagai, I.; Tsumoto, K. Encyclopedia of Life Sciences, Nature Publishing Group, 
2001. 
122Fasting, C.; Schalley, C.A.; Weber, M.; Seitz, O.; Hecht, S.; Koksch, B.; Dernedde, J.; 
Graf, C.; Knapp, E-W.; and Haag, R., Angew. Chem. Int. Ed., 2012, 51, 10472 – 10498 
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multivalency effect since multivalet interactions can be collectively much 
stronger than the sum of corresponding monovalent interactions
123
.  
In 1988, Dr. James Tam
124
 described the use of a multiple antigenic peptide 
(MAP) systemeliciting specific antibodies in rabbits. This system represented 
a novel approach based on a small immunologically inert core molecule of 
radially branching lysine dendrites onto which a number of peptide antigens 
are anchored. 
 
Figure 3.6. Branched structure of a MAP. 
The result is a large macromolecule which has a high molar ratio of peptide 
antigen to core molecule and does not require further conjugation to a carrier 
protein. MAPs containing defined B-and/or T-cell epitopes of one or more 
antigens constitute a useful chemically unambiguous system to explore 
antigen-antibody interaction. Because of their shape and physical 
characteristics, MAPs are referred to as dendrimers and are viewed as protein 
mimetics and are being pursued as protein-like materials for biotechnological 
applications since the architecture of a multivalent ligand is a key parameter in 
determining its activity
125
. Therefore, in the context of Multiple Sclerosis it 
appears important the design of multivalent ligands termed Multiple Epitope 
peptides (MEps), bearing multiple copies of CSF114(Glc) minimal epitopes, 
                                                        
123
 Mammen, M.; Choi, S.K.; and Whitesides, G.M., Angew. Chem. Int. Ed., 1998, 37, 
2754 -2794. 
124
a)Tam, J.P P.N.A.S., 1988, 85, 5409-5413; b) Tam, P.J J. of Immunol. M,1996, 1, 17–
32. 
 
125Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen,K.A.; and Kiessling, L.L., J.A.C.S., 
2002, 124, 14922-14933. 
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i.e. Asn(Glc), to characterize the immunological responses in MS patients' 
sera. 
 
3.2.2 Synthesis of Multiple Epitope peptides 
A collection of six Lys branched structures, MEps, was designed and 
synthesized with spacers of different length on the dendrimeric core and 
different peptide sequences as epitopes surrounding the sugar moiety 
Asn(Glc). 
 
 
Figure 3.7. Collection of MEps synthesized. The 20-atoms-spacer is -HN-(CH2)3-(O-
CH2-CH2)3-CH2-HN-CO-(CH2)2-CO-, the 9-atoms-spacer is -HN-(CH2-CH2-O)2-CH2-
CO-. 
 
MEps were synthesized by Fmoc/tBu SPPS starting from Fmoc4-Lys2-Lys-β-
Ala-Wang resin, according to the General Procedure for the SPPS described in 
details in the Experimental Part and using commercially available Fmoc-
protected amino acids and HATU/NMM activation. The Fmoc-
Asn(βGlcAc4)-OH building block was synthesized according to the method 
developed by Paolini et al.
126
. 
 
                                                        
126 Paolini, I.; Nuti, F.; Pozo-Carrero, M.C.; Barbetti, F.; Kolesinska, B.; Kaminski, Z.J.; 
Chelli, M.; Papini, A.M. Tetrahedron, 2007, 48, 2901-2904. 
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Scheme 1. Synthesis of Fmoc-Asn(GlcOAc4)-OH building block according to Paolini 
et al.126. 
We synthesized the MEps reported in Table 3.1 based on a Lys tetrameric core 
bearing the different spacers, β-Alanine, 3,6-dioxa-octanoic acid (introducing 
in SPPS Fmoc-HN-(CH2-CH2-O)2-CH2-COOH, Fmoc-Ado-OH) or 1,13-
diamino-4,7,10-trioxatridecan-succinamic acid (introducing in SPPS Fmoc-
HN-(CH2)3-(O-CH2-CH2)3-CH2-HN-CO-(CH2)2-COOH; Fmoc-TTDS-OH), 
and specific peptide sequences, e.g. a N-glucosylated β-hairpin pentapeptide 
(CT32, CT33), an N-glucosylated hexapeptide (CT34) and an N-glucosylated 
consensus sequence (CT38), or to the simple sugar amino acid Asn(Glc) 
anchored to a spacer (CT21 and CT35). 
 
 
Table 3.1Sequences of the synthesized MEps 
MEp  MEp sequence 
CT21 (Ac-N(Glc)-βA)4-K2-K-βA 
CT35 (Ac-N(Glc)-spacer TTDS)4-K2-K-βA 
CT32 (Ac-E-R-N(Glc)-G-H-spacer Ado)4-K2-K-βA 
CT33 (Ac-E-R-N(Glc)-G-H-spacer TTDS)4-K2-K-βA 
CT34 (Ac-E-R-N(Glc)-G-H-S)4-K2-K-βA 
CT38 (Ac-N(Glc)-H-T-spacer TTDS)4-K2-K-βA 
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Each coupling step was monitored by the Kaiser test in order to follow  the 
synthetic process. MEps were acetylated on the 
α
N-terminal function as 
described in the general procedure reported in the Experimental Part. After 
cleavage of the MEps from the resin and deprotection of the amino-acid side 
chains, deprotection of the hydroxyl functions of the sugar was performed as 
described in details in the Experimental Part using MeONa/MeOH. All the 
MEps were purified by semi-preparative RP-HPLC, and characterized by RP-
HPLC ESI-MS.  
Analytical data are summarized in Table 3.2. 
Table 3.2Analytical data of MEps 
MEPs Rt (min)
a
 
ESI-MS (m/z) 
 calculated (found) 
CT21 3.94
b
 1017.98 1016.42 [M+2H]
2+
 
CT35 3.96
c
 1480.28 1479.35 [M+2H]
2+
 
CT32 3.96
d
 1418.12 1416.63 [M+3H]
3+
 
CT33 4.52
e
 1220.87 1219.93 [M+4H]
4+
 
CT34 4.01
f
 1339.28 1338.81 [M+3H]
3+
 
CT38 4.01
g
 1306.35 1304.38 [M+3H]
3+
 
a
Analytical RP-HPLC gradients at 0.6 mL min
-1 
in 5 min; solvent 
system A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
b
02-35% B in 
5min, 
c
07-35% B in 5 min, 
d
05-40% B in 5 min, 
e
07-40% B  in 5 min, 
f
03-25% B in 5 min, 
g
10-35% B in 5 min. 
 
 
3.3 Immunochemical assays with MEPs 
The antibody recognition of  the six synthetic MEps synthesized was evaluated 
by solid-phase and competitive-ELISA on Multiple Sclerosis patients’ sera. 
We evaluated by SP-ELISA, IgG serum antibodies to the MEps in a group 
of16 MS patients positive to the original N-glucosylated type I’ β-turn peptide 
structure CSF114(Glc) and compared to the 14 selected negative healthy blood 
donors. IgM and IgG responses were detected using as secondary antibody 
anti-human IgMs and anti-human IgGs conjugated to alkaline phosphatase 
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(AP). In particular, SP-ELISA absorbance values for patients and blood donors 
measured for the collection of MEps (data not shown) let us to select CT35 as 
the most valuable tool. This result underlines the importance of the presence of 
Asn(Glc) as minimal epitope recognized by autoantibodies, suggesting that the 
surrounding amino acids, e.g. the N-glucosylated β-hairpin hexapeptide of  
CSF114(Glc) in CT34, the N-glucosylated β-hairpin pentapeptide of 
CSF114(Glc) in CT32 and CT33, and the N-glycosylation consensus 
sequence (sequon) in CT38 play a minor role. Moreover, the spacer seems to 
play a role in modulating the antigen-antibody interaction. In fact, in CT35 we 
introduced the 1,13-diamino-4,7,10-trioxatridecan-succinamic acid as a spacer 
between the tetrameric Lys core and the Asn(Glc) whereas in its analogue 
CT21 a β-alanine was employed as a spacer. This behavior could be associated 
to the higher flexibility of the 20 atoms spacer, compared to β-Ala, that could 
facilitate the antigen-antibody interaction. 
 
Figure 3.8 Branched structure of CT35. 
Figure 3.9. Dispersion diagrams obtainedfrom data collected in SP-ELISA 
experiments for CT35 in comparison with CSF114(Glc) for MS patiens (MS) and 
normal blood donors (BD) at 1:100 serum dilution. Horizontal lines indicate the 
medium values. 
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Data reported in Figure 3.9 indicate that CT35 is able to bind IgG 
autoantibodies in MS patients’ sera even if the N-glucosylated peptide 
CSF114(Glc) shows the highest ability to detect disease-specific 
autoantibodies in the MS patients’sera tested. 
Competitive ELISA was used to analyze the anti CSF 114(Glc) autoantibody 
binding affinities in solution with the newly designed MEp, CT35. Data 
shown in Figure 3.10 indicate that CT35 shows partial inhibition of anti-
CSF114(Glc) IgGs in a significant reference MS patient’s serum positive to 
CSF114(Glc). 
 
Figure 3.10 Inhibition curves of anti-CSF114(Glc) antibodies with MEp CT35 
compared with CSF 114(Glc) in a competitive ELISA. The results are expressed as the 
percentage of inhibition of a representative MS serum (ordinate axis). 
 
From the inhibition curves we calculated the half maximal inhibitory 
concentration (IC50) as a measure of the effectiveness of the peptide in 
inhibiting biological or biochemical function
127
.  
 
IC50 CT35 = 8,88 μM. 
IC50CSF114(Glc) =0.371 μM. 
                                                        
127 In competition binding assays,  IC50 is the concentration of competing antigen in 
fluid phase which displaces 50% of the specific binding of the antigen coated in the 
ELISA plate. 
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CT35 shows similar, but lower, affinity to autoantibodies present in Multiple 
Sclerosis patients’ sera compared to CSF114(Glc), confirming previous 
findings indicating the usefulness of the synthetic peptide probe CSF114(Glc) 
to detect antibodies as biomarkers of MS. 
 
3.3.1 Results and discussion 
In conclusion, this study reports for the first time that MEps, e.g. synthetic 
multivalent ligands, can be efficient antigenic probes to detect autoantibodies 
in MS. Moreover, we confirmed the importance of the N-glucosylated Asn 
residue as fundamental minimal epitope  necessary to detect the specific 
antibody recognition. 
 
3.4 Type I’ beta turn CSF114(Glc) cyclic analogues 
Cyclic peptides have been used in medicine as active ingredients of natural 
extracts for thousands of years. In modern medicine, their application was 
rediscovered in the middle of the last century, when the cyclic decapeptide 
antibiotic Gramicidin S was isolated together with linear gramicidins from the 
bacterium Bacillus brevis. Cyclic peptides have recently acquired the status of 
being referred to as privileged because of their ability to bind to multiple 
classes of biological targets with high affinity. This led, in the past few years, 
to the production of combinatorial libraries of natural and synthetic cyclic 
peptides. Cyclic peptides, compared to linear peptides, have been considered 
to have greater potential as therapeutic agents due to their increased chemical 
and enzymatic stability, receptor selectivity, and improved pharmacodynamic 
properties. They have been used as synthetic immunogens, transmembrane ion 
channels, antigens for Herpes Simplex Virus, potential immunotherapeutic 
vaccines for diabetes and EAE, inhibitors against alpha-amylase and as protein 
stabilizers
128
.  
                                                        
128 Katsara. M.; Tselios, T.; Deraos, S.; Deraos, G.; Matsoukas,  M.T.; Lazoura, E.; 
Matsoukas, J.; Apostolopoulos, V.; CurrMed Chem., 2006,13(19), 2221-32. 
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Cyclisation is a key step in small cyclic peptide synthesis. There are different 
ways to cyclise peptides, not only head-to-tail, but also side-chain-to-head, 
side-chain-to-tail and side-chain-to-side-chain bridges have been described. 
Moreover, in order to obtain cyclic peptides, sophisticated synthetic strategies 
have been developed. There are numerous possibilities for chemical alterations 
of a cyclic precursor molecule, such as insertion of a Cys residues, or modified 
non proteinogenic aminoacids, such as 2,3 diaminoproprionic acid, amino 
acids bearing alkinyl or azido moieties.  
 
 
Figure 3.11. Different modes of cyclization for peptides129. 
 
In light of the importance of specific sugars and conformation of epitopes 
involved in auto-Ab recognition in MS, we designed a synthetic 
cyclopeptide reproducing  the antibody specific target-epitope recognized in 
CSF114(Glc), i.e. Asn
7
(Glc), and the surrounding amino acids of the type I’ β-
turn and studied its capacity to recognize autoAbs in MS by ELISA. In 
particular, disulfide bridged containing cyclopeptides reported in Table 3.3 
were synthesized. 
 
 
                                                        
129 Jensen, K., Peptides and protein design for Biopharmaceutical Applications. J.Wiley 
Ed., 2009. 
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Table 3.3 Glycosylated and unglycosylated cyclic peptides 
Peptide Sequence 
MDP-I 
MDP-II 
Ac-c[Cys-Arg-Asn-Gly-His-Cys]-NH2 
Ac-c[Cys-Arg-Asn(Glc)-Gly-His-Cys]-NH2 
 
For immunochemical application purposes, both the glucosylated cyclopeptide 
and the unglycosylated one as control, were synthesized. 
Intra- and inter-molecular multiple disulfide bonds with the correct Cys 
connectivities can be generated either by simple oxidative refolding after 
removal of a single-type thiol protecting group from synthetic precursors or by 
regioselective methods based on orthogonal thiol protection schemes
130,131
. For 
the synthesis of the cyclised peptide we employed as oxidizing agent the 2,2′-
dithiodipyridine (DTDP), a specific lipophilic oxidizer of thiol groups suitable 
even to be used with unprotected glycopeptides
132
. 
 
3.4.1 Synthesis of MDP-I: Ac-c[Cys-Arg-Asn-Gly-His-Cys]-NH2 
Linear precursor of MDP-I was synthesized by Fmoc/tBu SPPS using a 
manual peptide synthesizer, PLS ChemTech starting from Fmoc Rink-Amide 
MBHA resin (Iris Biotech Gmbh), according to the General Procedure for the 
SPPS described in details in the Experimental Part and using commercially 
available Fmoc-protected amino-acids and HBTU/NMM activation. 
Table 3.4 Linear unglycosylated peptide sequence 
Peptide Sequence 
Lin-MDP-I Ac-Cys-Arg-Asn-Gly-His-Cys-NH2 
 
                                                        
130 Andreu, D.; Albericio, F.; Solé, N.A.; Munson, M.C.;  Ferrer, M.; and Barany, G., 
Introd. Meth. Mol.Biol., 1994, 35, 91-169 
131 Boulègue, C.; Musiol, H.; M.; Prasad, V.; Mododer, L., Chemistry Today,2006, 24(4), 
24-36 
132
Hoffmann, R.; Otvos L.Jr., Lett. Pept. Sci.,1996, 3, 371-377. 
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Each coupling step was monitored by Kaiser test in order to optimize the 
synthetic process. Peptide was acetylated on the 
α
N-terminal function as 
described in the general procedure reported in the Experimental Part. After 
cleavage of the linear peptide from the resin and concomitant deprotection of 
amino-acid side chains, crude product was characterized by RP-HPLC and 
MALDI-TOF. 
Analytical data are reported in Table 3.5. 
Table 3.5Analytical data of linear peptide MDP-I 
Peptide HPLC (Rt,min)
a
 
MALDI-TOF-MS [M+H]
 +
 
Calc (found) 
Lin_MDP-I 13.2 730.29 (730.44) 
                                a
Analytical HPLC gradient at 1 mL min
-1
, 03-15% B in 30 min, solvent 
system A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
 
 
Crude lyophilized product was solved in 0.1% of TFA in MilliQ water 
(1mL/mg) and then a solution of DTDP 1,2mg/mL in 0.1% of TFA in MilliQ 
water was added. The solution was vigorously stirred at r.t. and the formation 
of the intramolecular disulfide bridge was monitored by RP-HPLC. After 3 
hours the reaction was quenched. 
 
Scheme 2. Cyclization reaction of MDP-I mediated by DTDP. 
 
The lyophilized cyclised peptide was then purified by semi-preparative RP-
HPLC and characterized by RP-HPLC and MALDI-TOF. 
Analytical data are reported in Table 3.6. 
Table 3.6Analytical data of cyclic peptide MDP I 
Peptide 
HPLC 
(Rt,min)
a
 
MALDI-TOF-MS 
[M+H]
 +
 
Calc (found) 
MDP-I 14.9 728.29 (728.18) 
                                        a
Analytical HPLC gradients at 1 mL min
-1
, 03-15% B in 30 min, solvent 
system A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
 
Ac-Cys-Arg-Asn-Gly-His-Cys-NH
2
 Ac-c[Cys-Arg-Asn-Gly-His-Cys]-NH
2
 DTDP 
3h, r.t. 
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3.4.2 Synthesis of MDP-II: Ac-c[Cys-Arg-Asn(Glc)-Gly-His-Cys]-NH2 
Linear precursor of MDP-II was synthesized by Fmoc/tBu SPPS using a 
manual peptide synthesizer, PLS ChemTech starting from Fmoc Rink-Amide 
MBHA resin (Iris Biotech Gmbh) according to the General Procedure for the 
SPPS described in details in the Experimental Part and using commercially 
available Fmoc-protected amino acids and HBTU/NMM activation.  
 
Table 3.7. Linear glucosylated peptide sequence of Lin MDP-II. 
Peptide Sequence 
Lin MDP-II Ac-Cys-Arg-Asn(Glc)-Gly-His-Cys-NH2 
 
The Fmoc-Asn(βGlcAc4)-OH building block was prepared according to the 
method developed by Ibatullin et al.
133
 as described in details in the 
experimental part and introduced during the stepwise synthesis using 
HATU/NMM activation. 
 
 
 
Scheme 3. Synthesis of Fmoc-Asn(GlcOAc4)-OH building block according to Ibatullin 
et al133. 
Each coupling step was monitored by the Kaiser test in order to optimize the 
synthetic process. The peptide was acetylated on the 
α
N-terminal function as 
described in the general procedure reported in the Experimental Part. 
Deprotection of the acetyl groups on the sugar moiety was carried with the 
peptide still anchored to the resin using a solution of N2H4 in MeOH (4:1) as 
described in details in the Experimental Part. After cleavage of the linear 
                                                        
133
 Ibatullin , F.M.; Selivanov, S.I., Tetrahedron Lett.,2009, 50, 6351–6354. 
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peptide from the resin and concomitant deprotection of amino-acid side chains, 
the crude product was characterized by RP-HPLC ESI-MS. 
Analytical data are reported in Table 3.8. 
Table 3.8. Analytical data of the linear peptide Lin MDP-II. 
Peptide HPLC (Rt,min)
a
 
ESI-MS [M+H]
 +
 
Calc (found) 
Lin MDP-II 2.37 892.67 (892.72) 
                                     a
Analytical HPLC gradients at 0.6 mL min
-1
, 03-15% B in 5 min, solvent 
system A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
 
Crude lyophilized product was solved in 0.1% of TFA in MilliQ water 
(1mL/mg) and then a solution of DTDP 1,2mg/mL in 0.1% of TFA in MilliQ 
water was added. The solution was vigorously stirred at r.t. and the formation 
of intramolecular disulfide bridge was monitored by RP-HPLC. After 3 hours 
the reaction was quenched. 
 
 
Scheme 4. Cyclization reaction of MDP-II mediated by DTDP. 
The lyophilized cyclized peptide was then purified by semi-preparative RP 
HPLC and characterized by RP-HPLC ESI-MS. 
Analytical data are reported in Table 3.9. 
Table 3.9. Analytical data of the cyclic peptide MDP-II. 
Peptide 
HPLC 
(Rt,min)
a
 
ESI-MS [M+H]
 +
 
Calc (found) 
MDP-II 3.16 890.67 (890.72) 
                                           a
Analytical HPLC gradients at 0.6 mL min
-1
, 03-25% B in 5 min, solvent 
system A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
 
3.5 Immunochemical assays with cyclic glycopeptides 
The antibody recognition using the type I’ β-turnCSF114(Glc) cyclic 
glycopeptide analogue MDP-II and the unglycosylated one MDP-I, as 
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control, was evaluated by solid phase and competitive-ELISA on Multiple 
Sclerosis patients’ sera. 
We evaluated, by SP-ELISA, IgG serum antibodies to the cyclic glycopeptide 
MDP-II andthe unglycosylated analogue MDP-I in a group of MS patients 
and compared the results with Normal Blood Donors’ sera (NBDs). IgM (data 
not shown) and IgG responses were detected using as secondary antibodies 
anti-human IgMs and anti-human IgGs conjugated to alkaline phosphatase. 
IgG MDP-I  MDP-II
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Figure 3.12. Antibody titre in MS patients to the cyclopeptides MDP-I and MDP-II. 
The glycopeptide MDP-II displays higher antibody recognition if 
compared to the unglycosylated MDP-I indicating the importance of the 
β-D-glucopyranosyl moiety linked to the Asn residue and confirming the result 
found for MEps. 
Competitive ELISA was used to analyze the anti-CSF 114(Glc) autoantibody 
binding affinities of the newly synthesized peptides. Data represented in 
Figure 3.13 indicate that the glycosylated peptide shows partial inhibition of 
anti-CSF114(Glc) IgGs in a significant reference MS patient’s serum, while 
the unglycosylated control shows no inhibition activity. 
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Figure 3.13. Inhibition curves of anti-CSF114(Glc) antibodies with peptides MDP-I 
and MDP-II compared with CSF 114(Glc) in a competitive ELISA. The results are 
expressed as the percentage of inhibition of a representative MS serum (ordinate axis). 
From the inhibition curves we calculated the IC50 as a measure of the 
effectiveness of  the peptide in inhibiting biological or biochemical function
134
.  
 
IC50 MDP-II = 3,39 μM 
IC50CSF114(Glc) =0.371 μM 
 
3.5.1 Results and discussion 
In conclusion, the cyclic glycopeptide containing the Asn(Glc) residue, i.e. 
MDP-II, shows similar, but lower, affinity to autoantibodies present in 
Multiple Sclerosis patients’ sera, confirming previous finding indicating the 
usefulness of the synthetic peptide probe CSF114(Glc) to detect 
autoantibodies as biomarker of MS. 
 
3.6 Side chain to side chain cyclic peptides by Glaser-coupling 
In 1869, Carl Glaser observed the historic acetylenic coupling of Copper(I) 
phenylacetylide to diphenyldiacetylene under smooth aerobic conditions
135
. 
 
                                                        
134 IC50 is the concentration of competing antigen in fluid phase which displaces 50% 
of the specific binding of the antigen coated in the ELISA plate. 
135 a) Glaser, C., Ber.Dtsc h.Chem. Ges. 1869, 2, 422; b) Glaser, C., Ann.Chem. 
Pharm.1870, 154, 137. 
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Figure 3.14. The first acetylenic coupling described by Glaser. 
The classical Glaser type coupling is an oxidative acetylenic coupling reaction 
that takes place in mild conditions. Because of to the high functional group 
tolerance of homocoupling, the Glaser reaction has been used as a key step in 
the modification of complex molecules as well as for the synthesis of 
diacetylenic macrocycles, valuable highly conjugated molecules for electronic 
or photonic devices. Eglinton and Galbraith improved the procedure of Glaser 
coupling under homogeneous conditions using a stoichiometric amount of 
Copper(II) acetate in pyridine
136. N,N,N’,N’-tetramethylethylenediamine 
(TMEDA) was used as the co-complexing agent in Hay’s procedure for the 
Copper(I)-catalyzed homocoupling of terminal alkynes in the presence of 
oxygen as an oxidant with pyridine as a solvent
137
. Other methods for the 
synthesis of 1,4-disubstituted 1,3-diynes include the Cadiot-Chodkiewiczand 
the Sonogashira couplings
138
. More recently, it has been shown that the 
oxidative homocoupling of terminal alkynes can be accomplished by a 
combination of a Pd catalyst and a Cu(I) salt
139
. Oxidative alkyne–alkyne 
coupling is a good candidate for the synthesis of 1,3- diyne derivatives. 1,3-
Diyne derivatives are very important materials in biological, polymer, and 
                                                        
136
 Eglinton, G.; Galbraith, A. R. Chem. Ind. (London) 1956,737.  
137 a) A. S. Hay, J.Org .Chem. 1960, 25, 1275; b) A. S. Hay, J.Org . Chem. 1962, 27, 
3320. 
138 a)Cadiot, P.; Chodkiewicz, W. In Chemistry of Acetylenes; Viehe, H. G., Ed.; Marcel 
Dekker: New York, 1969; p 597; b) Sonogashira, K.; Tohda, Y.; Hagihara, N. 
Tetrahedron Lett. 1975, 16, 4467. 
139
 Rossi, R.; Carpita, A.; Bigelli, C. TetrahedronLett. 1985, 26, 523. 
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materials science because they can be converted into various structural entities, 
especially substituted heterocyclic compounds
140
. 
 
Mechanistic investigations of the oxidative coupling 
The classical oxidative alkyne couplings have been the most extensively 
studies, among the alkyne couplings, yet their exact mechanism remains 
unknown, and the existence of several hypotheses regarding the oxidation state 
and structure of the postulated intermediary copper acetylides have generated 
considerable discussion. 
The earliest mechanistic proposals postulated the formation of acetylenic 
radicals, which would then recombine to afford the corresponding diynes. An 
early kinetic investigation by Klesansky et al.
141
 demonstrated that Copper(II) 
ions served as direct oxidizing agent. They also noted that the rate of coupling 
was faster in basic media for more acidic terminal alkynes. In light of these 
findings, the homolytic bond cleavage proposed earlier by Zalkind and 
Fundyler
142
 was discarded in favor of a heterolytic cleavage followed by the 
transfer of a single electron to the Copper(II) salt. 
 
Figure 3.15Early proposal for the mechanism of oxidative acetylenic coupling 
Clifford and Waters in 1963 proposed the formation of Copper(I) acetylides, 
using Cu(OAc)2 in pyridine in absence of O2, which were rapidly oxidized by 
the transfer of a single electron to Copper(II) through an acetate ligand bridge. 
                                                        
140
 a) F. Bohlmann, T. Burkhardt, C. Zdero, Naturally Occurring Acetylenes, Academic 
Press, London, 1973; b) L. Hansen, P. M. Boll, Phytochem., 1986, 25, 285; c) H. 
Matsunaga, M. Katano, H. Yamamoto, H. Fujito, M. Mori, K. Takata, Chem.Pharm. 
Bull.1990, 38, 3480. 
141 Klebansky, A.L.; Grachev, I.V.; Kuznetsova, J., J Gen Chem USSR, 1957, 27, 3008-
3013 
142
 Zalkind, Y.S.; Fundyler, B.M., J. Gen Chem USSR, 1939, 9, 1725-1728. 
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Decomposition of the resultant Copper(II) acetylide and recombination of the 
free radicals would give the coupled products. 
 
Figure 3.16. Mechanism proposed by Clifford and Waters,(pyridine molecules are 
omitted). 
 
 On the basis of the observed second-order dependence of the coupling rate on 
alkyne concentration, Bolhman et al. proposed in 1964
143
 a mechanism in 
which a dinuclear Cu(II) acetylide complex is involved. This intermediate is 
supposed to collapse directly to the coupled product. The low experimentally 
determined activation energy of 21 kcalmol
-1
 provides an argument against 
radical mechanism in favor of the simultaneous oxidation and the C-C bond 
formation formerly proposed by Bohlmann
144
. 
 
Figure 3.17. Mechanism proposed by Bohlmann.Dimeric copper acetylides are 
proposed as intermediates in the oxidative acetylenic coupling.B in as N ligand, X is a 
Cl- or a OAc-. 
 
                                                        
143 Bohlmann, F.; Schoenowsky, H.; Inhoffen, E.; Grau, G. Chemische Berichte, 1964, 
97, 794. 
144 Siemsen, P.;  Livingstone, R.C.; Diederich, F., Angew Chem It. Ed, 2000, 39, 2632-
2657. 
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More recently a detailed mechanism of the Glaser reaction based on DFT has 
been proposed. The mechanism involves Cu(I)/Cu(III)/Cu(II)/Cu(I) catalytic 
cycle for this transformation. The key step for this reaction is the dioxygen 
activation occurring on the complexation of two molecules of acetylides with 
molecular oxygen giving Cu(III) complex
145
. 
We can resume the most important experimental observations: (1) the presence 
of amines is indispensable for the reaction to occur; (2) copper acetylides 
produce diacetylenes when oxidized by molecular oxygen; (3) the reaction 
often takes place at room temperature that implies low activation energies for 
each step of condensation. 
It can be concluded that the mechanism proposed in 1964 by Bohlmann et al. 
still provides the most reasonable and most accepted picture. 
 
Naturally Occurring Diynes 
The copper-mediated acetylenic coupling is a venerable reaction that has 
found applications in numerous research fields spanning from total synthesis 
of polyyne natural products
146
. Over the past fifty years, hundreds of di and 
polyyne compounds have been isolated from nature. Cu-catalyzed, oxidative 
acetylenic homo- and hetero-coupling reactions are a very useful tool to 
assemble the polyyne framework. Naturally occurring polyynes feature a wide 
range of structural diversity and display an equally broad array of biological 
properties
147
. 
 
                                                        
145 Fomina, L.; Vazquez, B.; Tkatchouk, E.; Fomine, S., Tetrahedron, 2002, 58, 6741–
6747. 
146 Evano, G.; Blanchard, N.; Toumi, M.,Chem. Rev. 2008, 108, 3054–3131. 
147 a) Angew Chem Int Ed. Engl 2006, 45(7), 1034-57; b) Nature Chemistry  
2010;2:967–971 2; c) Comptes Rendus Chimie 2009, 12(3-4), 341–358; d) Lipids 
2006;41(10):883-924. 
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Figure 3.18. Examples of naturally occurring diynes. 
 
 
3.6.1 On resin Glaser cyclization of peptides 
Copper(II) salt catalyzed oxidative coupling has proved to be of great value 
since its discovery, but it has gained importance only in recent years. 
Copper(II) acetate catalyzed homo- and hetero-couplings of terminal alkynes 
take place under mild reaction conditions
148
. The outcome of the oxidative 
coupling critically depends on the proper choice of the base and ligand as well 
as reaction conditions
149
. 
Developing a methodology for the oxidative coupling of alkynes, using 
inexpensive Copper(II) salts in the presence of a base with no further additives 
such as co-catalysts and co-oxidants, or oxygen atmosphere at room 
temperature, is highly desirable. This is true in particular in the case of 
coupling reactions performed in solution for which numerous examples of 
symmetrical and unsymmetrical 1,3 diynes are obtained in quantitative yields 
using Cu(OAc)2 under aerobic conditions. Different yields are obtained 
performing the reaction on resin. In fact, the presence of more sterically 
                                                        
148 Balaraman, K.; Kesavan, V., Synthesis, 2010, 20, 3461-3466. 
149
 Adimurthy, S.; Malakar, C.C.; Beifuss, U., J.O.C., 2009, 74(15), 5648–5651. 
Anti cancer activity 
Used to treat skin infections 
obtained from the soldier beetle  
Anti bacterial 
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hindered alkinyl moieties and the possible formation of intermolecular 1,3 
diyne derivatives might dramatically reduce yields. Despite these possible 
limitations, solid-phase oxidative coupling of terminal alkynes has potential to 
generate numerous molecules of diverse functionalities relying on solid-phase 
combinatorial chemistry to generate new libraries of compounds for biological 
testing. The choice to perform the reaction with the peptide still attached to the 
resin in a more constrained environment deals with the larger applications of 
such an optimized method. In fact, in this approach it is possible, after the 
formation of the cycle, to perform the synthetic process and to avoid further 
steps after the cleavage of the peptide from the resin. 
We developed an optimized on-resin Glaser-type reaction between the side 
chains of two propargyl glycine residues inserted at the beginning and at the 
end of the peptide sequence of two peptides Fmoc-Pra-Arg(Pbf)-Asn(Trt)-Gly-
His(Trt)-Pra-RinkAmidePSResin, and between the side chains of two N-
propargyl glycine residues in Fmoc-NPra-Arg(Pbf)-Asn(Trt)-Gly-His(Trt)-
NPra-RinkAmidePSResin to obtain the final products MDP-IIIand MDP-IV. 
The homocoupling of terminal alkynes of the propargyl moiety to 1,3-diynes 
gave the cyclized compound. The cyclization reaction was performed in the 
presence of the Fmoc protecting group of the 
α
N-terminal function.Our initial 
studies focused on the development of an optimum set of reaction conditions 
for the coupling of the two propargyl moieties on the Pra and NPra side chains. 
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Figure 3.19. Cyclic peptides MDP-III and MDP-IV. 
 
 
3.6.2 Optimization of the Glaser-type reaction to synthesize Ac-c[Pra-
Arg-Asn-Gly-His-Pra]-NH2 
We performed a systematic study to optimize the on-resin oxidative coupling 
of the propargyl moieties synthesizing a 1,3 diyne bond to give a side-chain to 
side-chain cyclic peptide Fmoc-c[Pra-Arg-Asn-Gly-His-Pra]-
RinkAmidePSResin. 
 
 
Scheme 5.On resin peptide cyclization by copper catalyzed 1,3 diyne bond formation 
of MDP-III. 
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The first reaction was performed at room temperature using Cu(OAc)2 as 
Copper complex in DCM and MeOH as solvent, and CH3CN as a source of 
nitrogen atoms that are thought to be involved in the formation of the 
intermediate complex according to the mechanism proposed by Bohlmann. 
DCM was chosen because is a suitable solvent in which the polystyrene resin 
can be swollen. MeOH was used to solve the copper acetate. 
Before adding the copper complex, the resin was swollen for 2 hours in DCM 
in order to facilitate the intramolecular reaction rather than the intermolecular 
one. RP-HPLC monitoring gave a 40:60 cyclic to linear ratio after 16h (entry 
4, Table3.10). In order to improve the cyclization yield we decided to switch 
to a microwave assisted cyclization. 
Today microwaves are commonly applied in several areas of the synthetic 
chemistry from MW-assisted SPPS to organic synthesis
150
. The use of 
microwaves irradiation allowed us not only to shorten the reaction times of 
several hours, from 16 h to 1h or 1h and 30’ (entry 5-11, Table3.10), but also 
to obtain higher yields of cyclization. This is reported even in the case of other 
syntheses of carbocyclic peptides, i.e. the microwave assisted ring closing 
metathesis
151
. On the contrary, irradiation of microwave energy allows to a 
larger number of side reactions to overcome the activation energy barrier so 
that the result is a crude product with more impurities.  
In the optimization process, several reaction conditions were applied. In 
particular, the solvent DCM was replaced with CHCl3 because the latter has an 
increased performance in transferring the microwave energy and has a higher 
boiling point than DCM.Attempts to perform the microwave-assisted Hay 
                                                        
150
 a) Lidstrom, P.; Tierney, J.; Wathey, B.; Wetsman, J., Thetrahedron, 2001, 57, 9225; 
b) Kappe, C.O., Agew. Chem. Int Ed., 2004, 43, 6250. 
151a) Robinson, A.; Elaridi, J.; Van Lierop, B.J.; Mujcinovic, S.;  and Jackson, W.R.,  J. 
Pept. Sci., 2007, 13, 280–285; b) D’Addona, D.; Carotenuto, A.; Novellino, E.; Piccand, 
V.; Reubi,J.C.; Di Cianni,A.; Gori, F.; Papini, A.M.;  and Ginanneschi, M., J. Med. Chem, 
2008, 51(3), 512-520. 
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coupling and Eglington coupling using NMP and DMF as solvents, led to 
reagents degradation (entry 1-3, Table3.10), possibly because of radical 
reactions.  
The Copper(II) complex was used in stoichiometric rather than catalytic 
amounts, 5 and 10 excess equivalents . Such high excess is typical of on resin 
synthetic strategies, i.e. SPPS.Best results were observed with the conditions 
reported in entry 11 of Table3.10 (see 95:5 cyclic/linear ratio yield in the case 
of the small scale, e.g. the reaction performed on 20mg resin in two steps, 
30’+1h, to induce a double activation of the reaction system. 
 
Table3.10Comparison of the different reaction conditions 
Entry Catalyst Eq
. 
Temp. 
(max) 
°C 
Time Solvents MW 
(W) 
Cooli
ng 
Av. 
Power 
(W) 
Cyc./ 
Lin. 
 
1 Cu(OAc)
2
.
H
2O 
5 100 1h 10%Py in DMF 200 yes 50 _ 
2 Cu(OAc)
2
.
H
2O 
5 100 1h 10%Py in NMP 200 yes 30 _ 
3 CuCl 5 100 30min DMF + 10eq 
TMEDA 
200 yes 30 _ 
4 Cu(OAc)
2
.
H
2O 
5 R.T 16h DCM/MeOH(3%)
/ CH
3
CN(5%) 
_ _ _ 40:60 
5 Cu(OAc)
2
.
H
2O 
5 70 1h DCM/MeOH(3%)
/ CH
3
CN(5%) 
25 no 15 70:30 
6 Cu(OAc)
2
.
H
2O 
5 70 1h DCM
/
 CH
3
CN 
(20%) 
200 no 25 70 :30 
7 Cu(OAc)
2
.
H
2O 
5 70 1h CHCl
3/
 CH
3
CN 
(20%) 
200 no 8 75:25 
8 Cu(OAc)
2
.
H
2O 
10 70 1h CHCl
3/
 CH
3
CN 
(20%) 
200 no 8 85:15 
9 Cu(OAc)
2
.
H
2O 
5  70 1h CHCl
3/
 CH
3
CN 
(20%) 
150 yes 110 90 :10 
10 Cu(OAc)
2
.
H
2O 
10 70 1h CHCl
3/
 CH
3
CN 
(20%) 
150 yes 110 60:40 
11 Cu(OAc)
2
.
H
2O 
5 70 30min+
1h 
CHCl
3/
 CH
3
CN 
(20%) 
150 yes 110 95 :5 
 
 
Formation of the 1,3 diyne bond leading to the the cyclic hexapeptide on resin 
was performed in absence of a base. We can hypothesize that this was possible 
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because of proton withdrawing by AcO
-
 of Cu(OAc)2
.
H2O, since the bases are 
absolutely necessary in the process of coupling of terminal alkynes. The 
oxidative coupling cannot occur using weak basic copper salt catalysts such as 
CuBr, CuCl, or CuI in the absence of bases or additives, such as DMSO. Very 
recently Niu et al. proposed a mechanism in which AcO
-
 of Cu(OAc)2
.
H2O 
catalyst may take the role of the base
152
. According to this hypothesis, the 
alkinyl copper intermediate A is formed by the reaction of the terminal alkyne 
and Cu(OAc)2, and then it undergoes smooth oxidative dimerization with air to 
the sp–sp homocoupling product and water. Cu(OAc)2 is then recycled. 
 
Figure 3.20 Mechanism proposed by Niu. 
 
The optimized conditions were used to perform the synthesis of peptide MDP-
III. 
Table 3.11 Sequence of cyclic peptide MDP-III 
Peptide Sequence 
MDP-III Ac-c[Pra-Arg-Asn-Gly-His-Pra]-NH2 
 
The inear precursor of MDPIII, Fmoc-Pra-Arg-Asn-Gly-His-Pra-Rink-
AmideResin was synthesized by Fmoc/tBu SPPS using a manual peptide 
synthesizer, PLS ChemTech starting from Fmoc Rink-AmideMBHA resin 
(Iris Biotech Gmbh), according to the general procedure for the SPPS 
described in details in the Experimental Part and using the commercially 
                                                        
152
 Niu, X.; Li, C.; Li, J.; Jia, X.,  TetrahedronLett, 2012, 53, 5559–5561. 
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available Fmoc-protected amino acids and HBTU/NMM activation. Side-chain 
to side-chain cyclization was achieved performing the 1,3 diyne bond 
formation according the reaction conditions reported in Table 3.12. 
 
Table 3.12 Large Scale cyclization peptide MDP-III 
 
Catalyst Eq 
T (max) 
°C 
Time Solvents 
MW 
(W) 
Cooling 
Average 
(W) 
Cyc 
/Lin 
Resin 
(mg) 
 Cu(OAc)
2
.
H2O 
5 70 
30min+
1h 
CHCl3/CH3CN 
(20%) 
150 yes 110 95 :5 100 
 
To remove the copper, resin was washed with a solution of 
dithiodicarbamate/DIPEA in DMF. After the side-chain to side-chain on resin 
cyclization the Fmoc protecting group was removed from the 
α
N terminus and 
the free amino function was acetylated according to the general procedure 
described in the Experimental Part. The crude product was lyophilized and 
purified by semi-preparative RP-HPLC. Analytical data are reported in Table 
3.13. 
Table 3.13 Analytical data of peptide MDP-III 
Peptide 
HPLC  
(Rt,min)
a
 
ESI-MS 
[M+H]
+
 
Calc(found) 
MDP-III 3.76 
712.71 
(712.66) 
                                           a
Analytical HPLC gradient at 0.6 mL min
-1
, 03-15% B in 5 min, 
                           solvent system A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. 
 
 
3.6.3 Optimization of the Glaser-type reaction to synthesize MDP-IV 
Ac-c[NPra-Arg-Asn-Gly-His-NPra]-NH2 
We tested the reaction conditions optimized for the cyclization of the peptide 
MDP-III, (entry 11, Table3.10), for the oxidative coupling between the two 
propargyl side chains in NPra. 
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Scheme 6. On resin peptide cyclization by copper catalyzed 1,3 diyne bond formation 
of MDP-IV 
 
We found that these conditions did not work with the NPra analogue, (entry 1, 
Table 3.14). Moreover, at 70°C we observed the reagents degradation under 
microwave-assisted coupling conditions indicating that this peptide is more 
sensitive to higher temperature. In the second experiment, (entry 2, Table 
3.14), we decreased the maximum temperature achieved in the microwave 
cavity to 40°C, and we registered a low conversion from the linear to the 
cyclic product. 
Finally, we optimized the 1,3 diyne bond formation reaction in the case of the 
small scale, e.g. the reaction performed on 20mg resin, up to 80:20 
cyclic/linear ratio (entry 4, Table 3.14), adding pyridine (3%) as a base 
 
Table 3.14 Optimization of the reaction conditions for MDP-IV 
Entry Catalyst Eq. 
Excess 
Temp. 
(max) 
°C 
Time Solvents MW 
(W) 
Cooling Av. 
Power 
(W) 
Cyc./Lin. 
 
1 Cu(OAc)
2
.
H2O 5 70 30min+1h CHCl
3/ CH3CN 
(20%)  
150 yes 100 - 
2 Cu(OAc)
2
.
H2O 10 40 30min+1h CHCl
3/ CH3CN 
(20%)  
100 yes 60 20 :80 
3 Cu(OAc)
2
.
H2O 10 60 1h CHCl
3/ CH3CN 
(20%)  
100 yes 50 50 :50 
4 Cu(OAc)
2
.
H2O 10 60 1h CHCl
3/ CH3CN 
(20%)/Py(3%) 
100 yes 60 80:20 
 
 
Pyridine is the preferred organic base to be used in Copper(II) acetate 
oxidative coupling of terminal alkynes. We preferred the use of this tertiary 
amine rather than other secondary amines as additives since we performed the 
cyclization with the 
α
N terminus still protected as Fmoc. Piperidine is reported 
as an excellent additive for the catalysis of homo- and hetero-couplings but it 
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is well known that this secondary amine readily cleaves Fmoc group, thus 
deprotecting the amine function. 
The lower yield in cyclization achieved for the peptide MDP-IV, compared to 
the 95:5 cyclic vs. linear ratio for MDP-III could be due to the more 
constrained environment of the 1,3 diyne bond formation reaction. In fact, the 
propargyl moiety is linked to the same nitrogen atom bearing the Fmoc 
protecting group.  
 
The optimized reaction conditions were used to perform the synthesis of the 
peptide MDP-IV. 
Table 3.15 Sequence of the cyclic peptide MDP-IV 
Peptide Sequence 
MDP-IV Ac-c[NPra-Arg-Asn-Gly-His-NPra]-NH2 
 
The linear precursor of MDP-IV,Fmoc-NPra-Arg-Asn-Gly-His-NPra-Rink-
AmideResin, was synthesized by Fmoc/tBu SPPS using a manual peptide 
synthesizer, PLS ChemTech starting from the Fmoc Rink-Amide MBHA resin 
(Iris Biotech Gmbh), according to the general procedure for the SPPS 
described in details in the Experimental Part and using the commercially 
available Fmoc-protected amino acids and HBTU/NMM activation. Fmoc-N-
Propargyl glycine building block was synthesized starting from 
propargylamine according to the procedure showed in Scheme 7 as described 
in details in the experimental part and introduced during the stepwise synthesis 
using HATU/NMM activation. 
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Scheme 7. Synthesis of Fmoc-N-Propargylglycine153. 
The reaction conditions optimized on 20mg resin, (entry 4, Table 3.14), were 
reported to a larger scale, e.g. 100mg resin. Unexpectedly, we found only 50% 
yield for the cyclization reaction (entry 1, Table 3.16). 
 
Table 3.16. Large scalecyclization ofthe peptide MDP IV. 
Entry Catalyst 
Eq. 
exc. 
Temp 
(max) 
°C 
Time Solvents 
MW 
(W) 
Cooling 
Av. 
Power 
(W) 
Cyc./
Lin. 
 
resin 
(mg) 
1 
Cu(OAc)
2
.
H2O 
10 60° 1h 
CHCl3/CH3CN 
(20%)/Py(3%) 
100 yes 60 50:50 100 
2 
Cu(OAc)
2
.
H2O 
10 60 
30mi
n+1h 
CHCl3/CH3CN 
(20%)/Py(3%) 
100 yes 60 90:10 75 
 
Inthe last experiment, (entry 2, Table 3.16) we increased again the reaction 
time and we performed the reaction in a small reaction vessel with the same 
amount of solvents used in the small scale reaction. These reaction conditions 
allowed us to obtain a 90:10 cyclic vs. linear ratio for the peptide Fmoc-NPra-
Arg(Pbf)-Asn(Trt)-Gly-His(Trt)-NPra-RinkAmideResin. To remove the copper 
in excess, the resin was washed with a solution of ditiodicarbamate/DIPEA in 
DMF. After the side-chain to side-chain on resin cyclization, the Fmoc 
protecting group was removed from the 
α
N terminus and the free amino 
                                                        
153Norgren, S.A.; Budke, C.; Majer, Z.; Heggemann, C.; Koop, T.; Sewald, 
N.,Synthesis2009, 3, 0488–0494.x..x.20 
PART B 
121 
function was acetylated according to the general procedure described in the 
Experimental Part. The crude product was lyophilized and purified by semi-
preparative RP-HPLC. Analytical data are reported in Table 3.17. 
Table 3.17Analytical data of the cyclic peptide MDP IV 
Peptide 
HPLC  
(Rt,min)
a
 
ESI-MS 
[M+H]
+
 
Calc.(found) 
MDP IV 3.46 
712.71 
(712.59) 
                                           a
Analytical HPLC gradient at 0.6 mL min
-1
, 03-15% B in 5 min, 
                           solvent system A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN; 
 
3.6.4 Results and discussion 
In summary, we developed a method to perform a microwave-assisted on-resin 
Glaser-type reaction to obtain side-chain to side-chain cyclic peptides that 
have Pra or NPra residues in their sequence. The Copper(II) acetate 
monohydrate catalysis allowed to perform coupling of terminal alkynes either 
in the presence or in absence of a base with very good cyclization yield (e.g. 
95:5 and 90:10 cyclic vs. linear ratio for MDP-III and MDP-IV, respectively) 
without any other additives such as a co-catalyst or oxygen atmosphere. The 
on-resin approach allowed cyclisation optimisation via a simple workup 
procedure. Moreover, unreacted copper catalyst could be easily removed 
compared to the liquid-phase approach. 
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4. Conclusions 
Peptides are unique and versatile chemical molecules with a huge 
pharmaceutical potential as active drugs and diagnostics in several areas of 
Medicinal and Clinical Chemistry. They can be produced by efficient synthetic 
strategies as univocally characterised molecules controlling primary, 
secondary tertiary, and quaternary structures. In the context of immune-
mediated diseases, the use of such synthetic peptides reproducing antigens 
involved in vivo in triggering autoantibodies can guarantee specificity and 
selectivity of recognition overcoming limitations demonstrated in the case of 
the use of recombinant proteins or protein extracts. This hypothesis has 
recently assumed a particular relevance for the characterisation of disease-
specific biomarkers (i.e., autoantibodies) setting up specific peptide-based 
diagnostic immunoassays and to explore the antigen-antibody interactions by 
using synthetic peptide probes selected by the"Chemical Reverse Approach". 
 
In this PhD research project, we demonstrated for the first time, in the case of 
Coeliac Disease, how synthetic peptides can be useful because mimicking 
aberrant modifications presumably involved in the disease pathogenesis. In 
fact, by the strategy of overlapping peptide synthesis it was possible to develop 
four new synthetic peptides tTG(1-15), tTG(41-55), tTG(51-65), and 
tTG(151-165) reproducing protein fragments of the native N-terminal portion 
tTG(1-230), giving important insights on the nature of the Ag-Ab interaction 
identifying minimal linear epitopes. Moreover, studying the molecular 
mechanisms at the basis of the pathogenesis of CD it was possible to design 
and select by the use of the reverse approach a very promising diagnostic tool, 
i.e, the cross-linked peptide probe tTGI-DQ2(II) reproducing the aberrant 
modification occurring invivo. 
In the case of Multiple Sclerosis, we started from the observation that aberrant 
post-translational modifications of protein antigens, such as N-glycosylation, 
could play a fundamental role in triggering an autoimmune mechanism 
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mediated by antibodies. We developed innovative peptide probes, e-g., 
Multiple Epitope Peptides and a new disufide cyclopeptide bearing the 
previously recognised minimal epitope Asn(-Glc) residue. Investigation of 
these two different systems confirmed previous results that led to the selection 
of the first specific antigenic probe for MS, a family of beta-turn structures 
termed CSF114(Glc), indicating for the first time the utility of synthetic 
peptide secondary structures in detecting autoantibodies as biomarkers of MS.  
In the context of developing efficient peptide synthesis to obtain new scaffolds 
to be used to build up collections of new peptides as diagnostics, we set up a 
method to perform a microwave-assisted on-resin Glaser-type reaction to side-
chain to side-chain cyclic peptides via 1,3-diyne bond formation. This part of 
the PhD research was performed during the last 4 months at the Ecole Normale 
Supérieure in Paris under the supervision of Prof. S. Lavielle, in the context of 
a cooperation with PeptLab. 
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5. Experimental Part A 
 
5.1 Materials and Methods 
The chemicals were purchased from Sigma-Aldrich and used without further 
purification. Peptide-synthesis grade N,N-dimethylformamide (DMF) was 
from Scharlau (Barcelona, Spain). HPLC-grade MeCN was purchased from 
Carlo Erba (Italy). Protected amino acids and resins were obtained from Iris 
Biotech AG (Germany). HATU, TBTU, HOBt and DIC were purchased from 
Advanced Biotech Italia (Milano, Italy). Activation product containing triazine 
was obtained from EspiKem (Firenze). 
Microwave assisted reactions and micro-cleavages were performed with a 
microwave apparatus CEM EXPLORER 48® (CEM Corporation). 
Spot Liquid Chromatography Flashwas performed using a Li-Chroprep C-
18column on an Armen Instrument working at 20 mL/min using as solvent 
systemsH2O (MilliQ) and CH3CN. Semi-preparative purifications via RP-
HPLC were performed by a Phenomenex Jupiter C-18 (250 × 4.6 mm) column 
at 28 °C using an Waters instrument (Sepation Module 2695, detector diode 
array 2996) working at 4 mL/min, with the indicated linear gradients. The 
solvent systems used were: A (0.1% TFA in H2O) and B (0.1 % TFA in 
CH3CN).Peptides were characterized by RP-HPLC ESI-MS. HPLC system is 
an Alliance Chromatography (Waters) with a Phenomenex Kinetex C-18 
column 2.6μm (100 × 3.0 mm) working at 0.6 mL/min, with the indicated 
linear gradients,coupled to a single quadrupole ESI-MS (Micromass ZQ).The 
solvent systems used were: A (0.1% TFA in H2O) and B (0.1 % TFA in 
CH3CN).Peptides were lyophilized using a Edward Modulyo lyophilizer.  
All the compounds were purified by RP-HPLC (>95%) to be used for 
autoantibody detection. 
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SP-ELISA assays were performed using 96 wells plates NUNC Maxisorp 
(Sigma) or Enhanced Binding (EB, Labsystem, Thermo Scientific). Washings 
steps were done with Hydroflex microplate washer (Tecan). Anti-hIgG and 
Anti-hIgA−Alkaline Posphatase used in ELISA are by Sigma, PNPP is by 
Fluka (System A). Anti-hIgG and Anti-hIgA−Horseradish Peroxidase used in 
ELISA and TMB are by Diesse Ricerche(System B). Absorbance values were 
measured using  a Sunrise Tecan ELISA plate reader at 405nm or at 450nm. 
Competitive ELISA was performed using a commercial kitEu-tTG-
IgA,Aeskulisa(code 9105, 96 test). The Eu-tTG IgA is an in vitro diagnostic 
enzyme immunoassay for qualitative ELISA test for the semi-quantitative 
diagnostic detection of IgA specific antibodies directed against the 
recombinant enzymetissue transglutaminase (tTG) inhuman serum
.
 
 
5.2 Solid Phase Peptide Synthesis 
 
5.2.1 General procedure for in batch SPPS on the manual PLS 4x4 
synthesizer 
Peptides are synthesized on a manual batch synthesizer (PLS 44, Advanced 
ChemTech) using a Teflon reactor (20 or 10 mL), following the Fmoc/tBu 
SPPS procedure. The resin is placed in the Teflon reactor, equipped with a 
filter. Mixing is provided by vortex, while filtration is performed connecting 
the reactor to a vacuum pump. The resin is swollen for 40 min with DMF (1 
mL/100 mg of resin) before use. Each amino-acid cycle is characterized by the 
following four steps: 
 
• Fmoc-deprotection: Resin is stirred twice (1 × 5 min + 1 × 15 min) 
with a solution of 20% piperidine in DMF (1 mL/100 mg of resin). 
• Washings: DMF (3 × 3 min). 
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• Coupling reaction: Fmoc-protected amino acid in DMF (1 mL/100 mg 
resin), TBTU/NMM  or HATU/NMM, or DIC/HOBt od TBCR
. 
BF4/NMMas coupling system for 20 min. 
• Washings: DMF (3 × 3 min) and DCM (2 × 3 min). 
Deprotection of the second residue should be performed by a fast protocol to 
avoid DKP formation (3 × 5 min). For the couplingstep a solution of the 
Fmoc-amino acid (5 equiv), TBTU (5 equiv), and NMM (7 equiv) in DMF (1 
mL × 100 mg resin) or HATU (5 equiv), and NMM (7 equiv) in DMF (1 mL × 
100 mg resin); orthe Fmoc-amino acid (4 equiv)DIC (4 equiv), and HOBt (4 
equiv) in DMF (1 mL × 100 mg resin)is added to the resin. After DCM 
washings each coupling reaction is monitored by Kaiser test
154
.After the last 
Fmoc-removal the resin is washed with DCM and dried under vacuum. 
Preparation of the peptide bond: typical procedure via TBCR
.
BF4 
To the vigorously stirred solution of TBCR
.
BF4(4quiv.) solved in the minimal 
amount of CH3CN, cooled to 0
o
C for 30', NMM (4equiv) and appropriate 
Fmoc-protected amino acid (4equiv) solved in DMF is added. The stirring is 
continued for additional 60 min, at 0
o
C. Then the mixture is let to achieve 
room temperature, added to the deprotected resin and the coupling system is 
stirrend for 1.5+3min in the case of microwave assisted coupling or overnight 
at room temperature.Then the resin is then filtered, washed in DMF(3x2min), 
DCM (3x2min), and dried. 
 
 
5.2.2 General procedure for in batch SPPS on an automatic peptide 
synthesizer 
All the reactions are performed in Advanced ChemTech Apex 396 synthesizer 
using a Fmoc/tBu protection scheme equipped with a 8-wells reaction block 
                                                        
154 Kaiser, E.; Colescott, R.L.; Bossinger, C.D.; Cook, P.I., Anal Biochem, 1970, 34, 595-
598. 
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(0.16 scale), starting from Fmoc-Rink Amide AM-PS resin (0.35 g, 0.63 
mmol/g). A robotic needle-like arm allows the distribution of reagents  
predissolved (0.5 M amino acids and coupling reagent, TBTU, in DMF) and 
2M DIPEA in NMP. Fmoc-deprotection is achieved with a solution of 20% 
piperidine in DMF (1 mL/100 mg of resin).The resin is swollen for 40 min. 
Each amino-acid cycle is characterized by the following four steps: 
 
• Fmoc-deprotection: Resin is stirred twice (1 × 5 min + 1 × 15 min)  
• Washings: with DMF (3×2 min). 
• Coupling reaction: (1 x 20 min). 
• Washings: with DMF (3×2 min). 
Deprotection of the second residue should be performed by a fast protocol to 
avoid DKP formation (3 × 5 min). For the coupling reaction a 0.5 M solution 
of the Fmoc-protected amino acid(5 equiv) in DMF, 0.5 M solution of 
TBTU(5 equiv) in DMF, and 2 M solution of DIPEA (7 equiv) in NMP are 
used. After removal of the last Fmoc-residue, the resin is washed with DCM 
and dried under N2 flow for 30 min. 
 
5.2.3 General procedure for peptides αN-terminal acetylation 
Acetylation of the 
α
N-terminal is carried out after Fmoc protecting group 
removal on the alfa amino function of the last residue anchored to the resin 
according the following procedure.   
• Resin is swollen for 20min in DCM and filtered. 
• Resin is stirred in a solution of Ac2O (20eq) and NMM (20 eq) in 
DCM (1mL/100mg of resin) at room temperature for 2 hours (2x1h). 
• Resin is then washed with DCM (3x3min) and dried. 
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5.2.4 General procedure for Dde protecting group removal 
Lys side chain 
ε
amino group orthogonally protected with 1-(4,4’-dimethyl-2,6-
dioxocyclohexylidene) ethyl group (Dde) is selectively deblocked with a 
solution of 2% hydrazine in DMF
155
following steps reported below: 
• Resin is swollen for 20min in DMF and filtered. 
• Resin in vigorously stirred with a solution of 2% N2H4 in DMF 
(3x3min). 
• Resin is then washed with DMF (3X3min) and DCM (3x3min) and 
dried. 
 
5.2.5 General procedure for cross-coupling reactions 
Cross-linking reactions are performed in heterogeneous phase with the tTG 
fragments still anchored on the resin, and α2-Glia peptides coupled in solution 
following the procedure reported below: 
Resin is swollen for 40min in DMF and filtered. 
• Coupling reaction: purified peptides DQ2(I), DQ2(II) and DQ2(III) 
(2.5 equiv) are pre-dissolved in a solution of DMF:NMP/2:1 (1 mL × 
100 mg resin), then HATU (2.5 equiv), and NMM (5 equiv) are added. 
The mixture is added to the resin and stirred at room temperature for 
1h. 
• Washings: DMF (3 × 3 min) and DCM (2 × 3 min). 
After DCM washings each the cross coupling is monitored by a Kaiser test and 
the resin is washed with DCM and dried under vacuum. 
 
5.2.6 General procedure for cleavage 
                                                        
155
 Rohwedder, B.; Mutti, Y.; and Mutter, M. Tetrahed Lett,1998, 39, 1175. 
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Peptides are cleaved from the resin using as cleavage mixture 
TFA/EDT/thioanisole/H2O/phenol (82.5:5:2.5:5:5) (reagent K) or 
TFA/H2O/TIS (95:2.5:2.5), as indicated for each compound. The peptide-resin 
is treated for 3 h with cleavage mixture (1 mL × 100 mg of resin) at room 
temperature. The resin is filtered off and the solution is concentrated flushing 
with N2. The peptide is precipitated from cold Et2O, centrifuged and 
lyophilized.Micro-cleavages are a useful tool to monitor stepwise syntheses. 
They can be performed at room temperature or alternatively microwave 
assisted to reduce reaction times. Microwave assisted micro-cleavages were 
performer using Discover
TM
 (CEM Corporation, Matthews, NC) as reported in 
the Table 5.1. 
Table 5.1. Microwave assisted micro-cleavages. 
Reaction Temp. (°C) MW Power (W) Time (min) 
Micro-cleavage 50 35 10 
 
The resin is filtered off and the solution is concentrated flushing with N2. The 
peptide is precipitated from cold Et2O or isopropyl ether, centrifuged and 
lyophilized.  
 
5.2.7 General procedure for purification by Spot Liquid 
Chromatography Flash 
Spot Liquid Chromatography Flash (SLCF) is performed on RP-C18 
LiChroprep columns on an automatic Armen Instrument. Main steps are 
reported here: Column washings with MeOH (3 column volumes) and CH3CN 
(3 column volumes); column conditioning with H2O (3 column volumes); 
dissolving the peptide in H2O (1 column volume), checking the pH that should 
be neutral. Peptides solved in water are absorbed and eluted as reported in 
Table 5.2 with different H2O/ CH3CN gradients. Fractions are checked by 
analytical RP-HPLC ESI-MS to homogeneous ones, and then lyophilized. 
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Table 5.2. Peptides purification by SLCF. 
Step Time(min) Flow (mL/min) %H2O %CH3CN 
1 0 20 100 0 
2 07 20 100 0 
3 12 20 80 20 
4 32 20 30 50 
5 33 20 0 100 
6 38 25 0 100 
 
 
Purification: AllPeptides are further purified by semipreparative RP-HPLC using 
methods and solvent system reported in tables. Fractions are checked by RP-
HPLCESI-MS to homogeneous ones. 
 
5.2.8 Synthesis of peptides DQ2(I), DQ2(II), DQ2(III) 
Peptides DQ2(I), DQ2(II), and DQ2(III), were synthesized using a Fmoc/tBu 
protection scheme on the multiple Apex 396 synthesizer (Advanced 
ChemTech) equipped with a 8-wells reaction block (0.16 scale), as reported in 
the general procedure, starting from Fmoc-Rink Amide AM-PS resin (350 mg, 
0.63 mmol/g). The Acetylation of the 
α
N-terminal was carried as reported in 
the general procedure. Peptide cleavage from the resin and contemporary 
deprotection of the amino acids side chains was carried out using TFA/ 
H2O/TIS (95:2.5:2.5) as cleavage mixture, as reported in the general 
procedure. The crude products were purified by Spot Liquid Chromatography 
Flash and characterized by RP-HPLC-ESI-MS. After lyophilization and 
purification, compound DQ2(I)was obtained in 29% yield, DQ2(II) was 
obtained in 23% yield, and DQ2(III) was obtained in 30% yield. Analytical 
data are reported inTable 2.8. 
 
5.2.9 Synthesis of peptide tTGI 
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Peptide tTGI was synthesized on a PLS 4x4 synthesizer, as described in the 
general procedure, starting froma FmocRink-Amide Chem-Matrix®resin, 
(300mg, 0,56 mmol/g) and using TBTU(5equiv.) and NMM(7equiv.). Fomc-
Ser(Trt)-OH instead of the commonly used Fomc-Ser(tBu)-OH was inserted in 
position 558 to overcome aggregation/formation of secondary structures thus 
improving the synthesis yields. Each coupling step was monitored by Kaiser 
test and the synthesis was monitored each 4 aminoacids by micro-cleavages as 
well as at the end of the peptide synthesis.The final deprotection is followed 
by on-resin acetylation, and orthogonal Dde-deprotection of 
ε
NH2 of Lys(562), 
each step was carried out, as described in the general procedure. The presence 
of the 
ε
free amino function was checked by Kaiser test and the peptide was 
further analyzed by micro-cleavage performed at room temperature. Purity of 
the peptide linked to the resin was evaluated by RP-HPLC, compound tTGI 
was obtained with 75% purity.Analytical data are reported in Table 2.11. 
 
5.2.10 Synthesis of tTGII, tTGIII 
Peptides tTGII and tTGIII were synthesized on a PLS 4x4 synthesizer, as 
described in the general procedure, starting from, starting fromFmoc-Rink 
Amide AM-PS resin(300mg,0.63 mmol/g)and using TBTU(5equiv.) and 
NMM(7equiv.). The final deprotection of tTGII and tTGIII is followed by on 
resin acetylation, and orthogonal Dde deprotection of 
ε
NH2 of Lys(590) and 
Lys(677) respectively, each step was carried out, as described in the general 
procedure. The presence of the free 
ε
amino function was checked by Kaiser 
test and the peptides were further analyzed by micro-cleavage performed at 
room temperature. Purity of the peptide linked to the resin was evaluated by 
RP-HPLC, compound tTGIIwas obtained with 95% purity, and compound 
tTGIIIwas obtained with 80% purity. .Analytical data are reported in Table 
2.15. 
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5.2.11 Synthesis of cross-linked peptides  
Cross linked peptides were synthesized according to the general procedure. 
Peptide cleavage from the resin and contemporary deprotection of the amino 
acids side chains was carried out using Reagent K as cleavage mixture as 
reported in the general procedure. After lyophilization, purifications were 
performed by semipreparative RP-HPLC and obtained as indicated in  
Table 5.3. Analytical data are reported in Table 2.16. 
 
Table 5.3. Semi-prep RP-HPLC and yields. 
Cross-Linked 
 peptide 
Semi-prep RP-HPLC 
 Method 
Yield 
tTG I-DQ2(I) 20-70% of B in 30 min 7% 
tTG I-DQ2(II) 25-65% of B in 30 min 6% 
tTG I-DQ2(III) 20-70% of B in 30 min 10% 
tTG II-DQ2(I) 25-70% of B in 30 min 9% 
tTG II-DQ2(II) 25-70% of B in 30 min 11% 
tTG II-DQ2(III) 25-70% of B in 30 min 4.5% 
tTG II-DQ2(I) 25-70% of B in 30 min 12% 
tTG III-DQ2(II) 25-70% of B in 30 min 24% 
tTG III-DQ2(III) 25-70% of B in 30 min 15% 
 
 
 
5.2.12 Synthesis of peptides I-XXIII 
Peptides I-XXIII were synthesized using a Fmoc/tBu protection scheme on 
the multiple Apex 396 synthesizer (Advanced ChemTech )equipped with a 8-
wells reaction block (0.16 scale), as reported in the general procedure, starting 
fromFmoc-Rink Amide AM-PS resin. Acetylation of the 
α
N-terminal was 
carried as reported in the general procedure. Peptide cleavage from the resin 
and contemporary deprotection of the amino acids side chains was carried out 
using TFA/H2O/TIS (95:2.5:2.5) as cleavage mixture as reported in the general 
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procedure. The crude products were purified by SLCF and characterized by 
RP-HPLC-ESI-MS. After lyophilization and purification, compounds were 
obtained in yields comprised between 5 and 10%. Analytical data are reported 
inTable 2.2. 
 
5.3 Immunoassays 
 
5.3.1 Solid-phase not competitive indirect ELISA (SP-ELISA) 
Serum was obtained for diagnostic purposes from patients and healthy blood 
donors who had given their informed consent, and stored at -20 ºC until use. 
Antibody responses were determined in SP-ELISA.  
System A) Ninety-six wells activated polystyrene ELISA plates (NUNC 
Maxisorp SIGMA) or Enhanced Binding (EB, Labsystem, Thermo Scientific) 
were coated with 1μg per 100μl of peptides per well in pure carbonate buffer 
0.05 M (pH 9.6) and incubated at 4 ºC overnight. After that, non specific 
binding sites were blocked by DILUENT2 (PBS/Brij/NewBorn/Methyl 
orange, Diesse Ricerche), 100μl per well, at room temperature for 60 min. Sera 
diluted 1:50, or 1:100 or from 1:100 o 1:6400 were applied at 37°C for 45min. 
After four washes, it was added 100μl of horseradish peroxidase conjugated 
anti-human IgA (diluted 1:215 in DT20, PBS/Tween/BSA/Metylorange, 
Diesse Ricerche) or IgG (diluted 1:2000 in DT20, PBS/Tween/BSA/Methyl 
orange, Diesse Ricerche) to each well. After 45min at 37°C incubation and 
five washes, 100 μl of substrate solution consisting of 0.26 mg/mL 3,3’,5,5’-
Tetramethylbenzidine(Diesse Ricerche) in 0,01% H2O2 in citrate buffer 0,05M 
at pH 3.8 (Diesse Ricerche) was applied. After 15 min, the reaction was 
stopped with 100 μl of 0.3M H2SO4 (Stop solution Enzywell, Diesse 
Ricerche), and the absorbance was read in a multichannel ELISA reader 
(Tecan Sunrise) at 450 nm. ELISA plates, coating conditions, reagent 
dilutions, buffers, and incubation times were tested in preliminary 
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experiments. The antibody levels are expressed as absorbance in arbitrary units 
at 450 nm. 
 
System B) Ninety-six wells activated polystyrene ELISA plates (NUNC 
Maxisorp SIGMA) were coated with 0.5 μg per 50 μl of peptides per well in 
pure carbonate buffer 0.05 M (pH 9.6) and incubated at 4 ºC overnight. After 
that, non specific binding sites were blocked by fetal calf serum (FCS), 10% in 
saline Tween 20 (50 μl per well) at room temperature for 60 min. Sera diluted 
1:100 were applied at 4 ºC overnight in saline/Tween 20/10% FCS. After five 
washes, it was added 50 μl of alkaline phosphatase conjugated anti-human IgA 
(diluted 1:1500 in saline/Tween 20/FCS) or IgG (diluted 1:8000 in saline/ 
Tween 20/FCS) (Sigma) to each well. After 3 h at room temperature 
incubation and five washes, 50 μl of substrate solution consisting of 1 mg/ml 
p-nitrophenyl phosphate (Sigma) in 10% diethanolamine buffer was applied. 
After 30 min, the reaction was stopped with 1M NaOH (25 μl), and the 
absorbance was read in a multichannel ELISA reader (Tecan Sunrise) at 405 
nm. ELISA plates, coating conditions, reagent dilutions, buffers, and 
incubation times were tested in preliminary experiments. The antibody levels 
are expressed as absorbance in arbitrary units at 405 nm (sample dilution 
1:100). 
 
5.3.2 Measurement of antibody affinity by competitive ELISA 
Antibody affinity was measured following the methods previously reported
156
. 
Sera diluted (1:1000) were preincubated with synthetic peptide antigen (0 
and2×10
-3
M) for 45min at room temperature. Unblocked Abs were revealed by 
ELISAat 450nm, Eu-tTG IgA, Aeskulisa, and the antigenic probe 
concentration-absorbance relationship was presented graphically. 
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 Rath, S.; Stanley, C. M.; Steward, M. W.,J. Immunol. Methods, 1988, 106, 245–249. 
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6. Experimental Part B 
 
 
6.1 Materials and Methods 
The chemicals were purchased from Sigma-Aldrich and used without further 
purification. Peptide-synthesis grade N,N-dimethylformamide (DMF) was 
from Scharlau (Barcelona, Spain). HPLC-grade MeCN was purchased from 
Carlo Erba (Italy). Protected amino acids and resins were obtained from 
Calbiochem-Novabiochem AG (Laufelfingen, Switzerland) or Iris Biotech 
Gmbh (Marktredwitz, Germany). HATU, TBTU, HBTU were purchased from 
Advanced Biotech Italia (Milano, Italy). TBCR
.
BF4was obtained from 
EspiKem (Firenze). Microwave assisted reactions were performed on a a 
microwave apparatus CEM EXPLORER 48® (CEM Corporation). 
TLC were carried out on silica gel precoated plates (Merck; 60 Å F254) and 
spots located with: (a) UV light (254 and 366 nm), (b) ninhydrin (solution in 
acetone), (c) Fluram (Fluka; fluorescamine, 4-phenyl-spyro[furan-2(3H),1’-
isobenzofuran]-3,3’-dione) in acetone,(d)CH2Cl2–MeOH–AcOH, 97:2.5:0.5. 
Flash Column Chromatography (FCC) was performed on Merck silica gel 60 
(230-400 mesh) according to Still et al
157
. 
1H and 13C NMR spectra were recorded at 400 and 100 MHz, and 200 and 50 MHz 
respectively, on a Varian spectrometer; or at  Bruker Avance III 500 MHz 
spectrometer equipped with a cryogenic TCI probe.in deuterated solutions and 
are reported in parts per million (ppm), with solvent resonance used as 
reference. Chemical shifts (δ) are reported in ppm relative to TMS and 
coupling constants (J) are reported in Hz. The multiplicity were marked as s 
=singlet, d = dublet, t = triplet, q = quartet, m = multiplet. Intensities of signals 
were estimated as vs = very strong, s = strong, m =medium, w = weak), b = 
broad. 
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Semi-preparative purifications via RP-HPLC were performed by a 
Phenomenex Jupiter C-18 (250 × 4.6 mm) column at 28 °C using an Waters 
instrument (Sepation Module 2695, detector diode array 2996) working at 4 
mL/min. The solvent systems used were: A (0.1% TFA in H2O) and B (0.1 % 
TFA in CH3CN). Peptides were characterized by RP-HPLC ESI-MS. HPLC 
system is an Alliance Chromatography (Waters) with a Phenomenex Kinetex 
C-18 column 2.6μm (100 × 3.0 mm) working at 0.6 mL/min, with UV 
detection at 215nm,coupled to a single quadrupole ESI-MS (Micromass 
ZQ).The solvent systems used were: A (0.1% TFA in H2O) and B (0.1 % TFA 
in CH3CN). 
Peptide MDP-I was purified by RP-HPLC on a ACE 5 C18-300" (250 × 10 
mm) column (Waters, Saint Quentin en Yvelines, France) at 28°C using an 
Waters instrument (Sepation Module 2695, detector diode array 2996)working at 
4 mL/min, with the indicated linear gradients. The solvent systems used were: A 
(0.1% TFA in H2O) and B (0.1 % TFA in CH3CN). Peptide MDP-I was 
characterized by RP-HPLC and MALDI-TOF-MS. HPLC system is an 
Alliance Chromatography (Waters) witha ACE 5 C18-300" (250 × 4.6 mm) 
columnworking at 1 mL/min, with UV detection at 220 and 280 nm. The solvent 
systems used were: A (0.1% TFA in H2O) and B (0.1 % TFA in CH3CN).  Mass 
spectral analysis was performed by MALDI-TOF (Voyager-DE
TM
 PRO 
Workstation, Applied Biosystems). 
The products were lyophilized with an Edwards apparatus, model Modulyo. 
All the compounds were purified by RP-HPLC (>95%) to be used for 
autoantibody detection. 
 
6.2 Synthesis of building blocks for SPPS 
 
6.2.1 2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosylamine(1) 
To a solution of commercially available 2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosyl azide (10 mmol) in MeOH, we added 20% Pd(OH)2/C. The 
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mixture was stirred for 24 h at r.t. under H2, checked by TLC [AcOEt/hexane, 
3:1; UV, fluorescamine, and vanilline], filtered over celite, washed with 
MeOH and concentrated. The desired compound 1 was re-crystallized from 
THF/hexane.  
2,3,4,6-tetra-O-acetyl-β-D-glucopyranosylamine (1), yield 98%. Rf = 0.37. 
1
H NMR (200 MHz, CDCl3) δ = 2.03 (s, 3H, OAc), 
2.04 (s, 6H, 2×OAc), 2.07 (s, 3H, OAc), 3.67-3.75 
(m, 1H, H-5), 4.03 (d, J = 12.2 Hz, 1H, H-6), 4.28 
(pd, J = 12.8 Hz, 1H, H-6’), 4.96 (t, J = 9.6 Hz, 1H, H-2), 5.12 (t, J = 10 Hz, 
1H, H-4), 5.27-5.36 (m, 2H, H-1 and H-3) ppm. 
 
6.2.2 Microwave assisted Synthesis of glucosylated asparagine 
The Asparagine derivative was prepared according to the following procedure 
for microwave-assisted synthesis. Fmoc-L-Asp-OtBu (60 mg, 0.144 mmol), 
2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl amine (1) (1 equiv), NMM (1 
equiv), and DMT-NMM/BF4
158,159
 (1 equiv) as coupling reagent were 
dissolved in acetonitrile (2 ml). The vessel was charged with the reaction 
mixture, sealed, and placed into the microwave synthesizer CEM EXPLORER 
48® applying the reaction conditions reported in Table 6.1. 
 
Table 6.1.MW-assisted coupling reaction. 
Reaction 
Temp 
(ºC)
 
Time 
(min) 
Power 
(W) 
Coupling reacion 70 5 100 
 
                                                        
158 [4-(4,6-dimethoxy-1,3,5-triazin-2-yl-)-4-methylmorpholinium tetrafluoroborate], 
“Process for the preparation of N-triazinylammonium salts”. Filing date 07/11/2005. 
Applicant: Italvelluti S.p.a. Inventors: Z. Kaminski, A. M. Papini, B. Kolesinska, J. 
Kolesinska, K. Jastrzabek, G. Sabatino, R. Bianchini. PCT/EP2005/055793 (2005). 
159 Z. J. Kamiński, B. Kolesińska, J. Kolesińska, G. Sabatino, M. Chelli, P. Rovero, M. 
Błaszczyk, M. L. Główka, A. M. Papini, J. Am. Chem. Soc., 2005, 127, 16912-16920. 
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The reaction tube was taken off after performing the coupling reaction. Then 
the mixture was transferred into a round bottom flask. The solvent was 
evaporated under reduced pressure, the residue was dissolved in CHCl3 and 
then washed with water, 0.5 M aqueous KHSO4, water, 0.5 M aqueous 
NaHCO3, and water again. Organic layer was dried over anhydrous Na2SO4, 
filtered off and concentrated to dryness. After purification of the residue by 
FCC (hexane/AcOEt, 1:1)we obtained compound 2as a white solid. (Rf = 0.30 
[AcOEt:Hexane, 1:1,(fluorescamine, vanilline)]; [α]D=22.94; ESI-MS: m/z 
calcd for C37H44O14N2 =740.28, found (M+H)
+
=741,73. 
Fmoc-L-Asn(βGlcAc4)-OtBu(2): yield 85%, 
1
H NMR (400 MHz, CDCl3) δ= 
1.46 (s, 9H, tBu), 1.99, 2.01 (2 s, 12H, 
4OAc), 2.84 (system ABMX, JAB = 
16.4 Hz, JAM = 4.4 Hz, JBM = 4.0 Hz, 
2H, Asn-β-CH2), 3.70 (pt, J = 4.8 Hz, 
1H, H-5), 4.04 (d, J = 12.4 Hz, 1H, H-6), 4.19 (t, J = 7.2 Hz, 1H, Fmoc-CH), 
4.23 (dd, J = 12.8 Hz, J = 4.4 Hz, 1H, H-6’), 4.31-4.42 (m, 2H, Fmoc-CH2), 
4.69-4.72 (m, 1H, Asn-α-CH), 4.98 (t, J = 9.6 Hz, 1H, H-2), 5.10 (t, J = 10 Hz, 
1H, H-4), 5.29-5.37 (m, 2H, H-1 and H-3), 6.09 (d, J = 8.0 Hz, 1H, Asn-α-
NH), 6.87 (d, J = 9.2 Hz, 1H, NH-1), 7.28 (app-t, 2H, Fmoc-Ar), 7.37 (app-t, 
2H, Fmoc-Ar), 7.57 (d, J = 7.2 Hz, 2H, Fmoc-Ar), 7.73 (d, J = 7.2 Hz, 2H, 
Fmoc-Ar) ppm. 
13
C NMR (100 MHz, CDCl3) δ = 20.5, 20.5, 20.6 (C(O)CH3), 
27.8 (C(CH3)), 37.9 (Cβ), 47.1(Fmoc CH), 50.9 (Cα), 61.5 (C-6), 67.1 (Fmoc-
CH2), 68.0, 70.5, 72.6, 73.6 (C-2,C-3,C-4,C-5), 78.0 (C-1), 82.4 (C(CH3)3), 
119.9, 125.1, 125.1, 127.0, 127.6, 141.2, 143.7, 143.8 (Ar-C), 156.1, 169.5, 
169.7, 169.8, 170.5, 170.7, 171.0 (C=O). Results were consistent with the data 
previously reported
160,126
. 
 
 
                                                        
160 Van Ameijde, J.; Albada, H.B.; Liskamp, R.; J. Chem. Soc. Perkin Trans., 2002,1, 
1042-1049. 
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6.2.3 tert-Butyl deprotection of Fmoc-protected amino acid 
The pure t-Bu ester was dissolved in TFA in DCM (1:1). The reaction mixture 
was stirred for 3 hours at r.t. The solvents were evaporated and after 
dissolution in water and freeze drying, compound 3was obtained. 
Fmoc-L-Asn(βGlcAc4)-OH (3): yield 95%. Rf = 0.19 (AcOEt/Hexane, 2:1, 
UV and vanilline). 
1
H NMR (400 MHz, 
CDCl3) δ = 2.00, 2.02 (2 s, 12H, 4×OAc), 
2.85 (system ABMX, JAB = 16.4 Hz, JAM 
= 4.4 Hz, JBM = 4.0 Hz, 2H, Asn-β-CH2), 
3.74 (pt, J = 4.8 Hz, 1H, H-5), 4.05 (d, J = 12.4 Hz, 1H, H-6), 4.19 (t, J = 7.2 
Hz, 1H, Fmoc-CH), 4.27 (dd, J = 12.8 Hz, J = 4.4 Hz, 1H, H-6’), 4.31-4.40 (m, 
2H, Fmoc-CH2), 4.59-4.61 (m, 1H, Asn-α-CH), 4.94 (t, J = 9.6 Hz, 1H, H-2), 
5.07 (t, J = 10 Hz, 1H, H-4), 5.27-5.35 (m, 2H, H-1 and H-3), 5.59 (broad s, 
1H, COOH), 6.25 (d, J = 8.0 Hz, 1H, Asn-α-NH), 7.06 (d, J = 9.2 Hz, 1H, NH-
1), 7.28 (app-t, 2H, Fmoc-Ar), 7.37 (app-t, 2H, Fmoc-Ar), 7.57 (d, J = 7.2 Hz, 
2H, Fmoc-Ar), 7.73 (d, J = 7.2 Hz, 2H, Fmoc-Ar) ppm. 
 
6.2.4 One step Synthesis of glucosylated asparagine 
To a stirred solution of acetylated glucosyl amine (5.0 mmol) in DMSO (3 
mL), N-Fmoc-aspartic anhydride (5.0 mmol) was added. The reaction mixture 
was kept at ambient temperature for one hour and then diluted with methanol. 
The precipitate was filtered and recrystallized from methanol. In the case of 
disaccharide derivatives, the product was isolated by dilution of the reaction 
mixture with water, followed by extraction with CHCl3. Evaporation and 
recrystallization from methanol afforded the pure product, 3.  
O
H
N
OAc
OAc
AcO
AcO
OH
O
O
NHFmoc
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Fmoc-L-Asn(βGlcAc4)-OH(3): yield 82%. 1H NMR (DMSO-d6, 500 MHz): 
d (ppm) 8.75 d 1H J1NH = 9.4 Hz, NH-
Glc), 7.88 (d, 2H, J = 7.5 Hz, HAr-Fmoc), 
7.70 (dd, 2H, J = 7.4 Hz, J = 7.4 Hz, HAr-
Fmoc), 7.57 (d, 1H, J = 8.4 Hz, NH-Asn), 
7.40 (t, 2H, J = 7.5 Hz, HAr-Fmoc), 7.32 (t, 2H, J = 7.4 Hz, HAr- Fmoc), 5.41 
(dd, 1H, J1,2 = 9.3 Hz, H-1), 5.33 (dd, 1H, J3,4 = 9.6 Hz, H-3), 4.91 (dd, 1H, 
J4,5 = 9.7 Hz, H-4), 4.82 (dd, 1H, J2,3 = 9.4 Hz, H-2), 4.38 (dt, 1H, J,1 = 6.1 
Hz, J,2 = 7.4 Hz, a-CH-Asn), 4.27 (d, 2H, a,b-CH2-Fmoc), 4.20 (dd, 1H, J = 
6.6 Hz, H-9 Fmoc), 4.16 (dd, 1H, J6a,6b = 12.3 Hz, H-6a), 4.09 (dq, 1H, J5,6a 
= 4.4 Hz, J5,6b = 2.2, H-5), 3.97 (dd, 1H, H-6b), 2.64 (dd, 1H, J1,2 = 15.8 Hz, 
b1-H-Asn), 2.52 (m, 1H, b2-H-Asn), 1.99, 1.98, 1.92, 1.89 (4s, each 3H, 4 _ 
CH3CO). 13C NMR (DMSO-d6, 125 MHz): d (ppm) 172.81 (COOH), 169.90 
(CO-NH), 169.63, 169.39, 169.20, 169.00 (CO-Ac), 155.73 (CO-Fmoc), 
143.70, 143.64, 140.59, 127.53, 126.98, 125.16, 120.00 (Ar-Fmoc), 76.70 (C-
1), 72.77 (C-3), 71.99 (C-5), 70.45 (C-2), 67.69 (C-4), 65.60 (CH2-Fmoc), 
61.62 (C-6), 50.12 (CH-Asn), 46.49 (CH-Fmoc), 20.41, 20.27, 20.21, 20.18 
(CH3-Ac). ESI FT-ICR HRMS (m/z): 707.2066 (707.2064 calculated for 
C33H36N2NaO14 [M+Na]
+
). 2,3,4,6-tetra-O-acetyl-N-[N-Fmoc-D-aspart-4-
oyl]-b-D-glucopyranosylamine. Results are consistent with previously reported 
data
133
. 
 
6.2.5 Synthesis of N-(Propargyl) Glycine 
Ethyl bromoacetate (100 mmol, 11.1 mL) in THF (30.0 mL) was added 
dropwise to a cooled (ice-bath) solution of propargylamine (100 mmol, 6.86 
mL) and Et3N (200 mmol, 27.9 mL) in anhydrous THF (30.0 mL). The ice-
bath was kept for 30 min before the reaction mixture was allowed to attain r.t. 
After stirring overnight, the mixture was filtered to remove ethylamine 
hydrobromide. The filtrate was washed repeatedly with Et2O and the organic 
O
H
N
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AcO
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O
O
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phase was removed under reduced pressure. The crude coompound, 4, did not 
require further purification before the next step. 
H-N-Pra-OEt(4): Yield 84%. 1H NMR (500 MHz, CDCl3): d = 4.20 (q, J = 
7.1 Hz, 2 H), 3.51 (s, 2 H), 3.49 (d, J 
= 2.4 Hz, 2 H), 2.24 (m, 1 H), 1.29 
(t,J = 7.1 Hz, 3 H). 13C NMR (125 
MHz, CDCl3): d = 171.9, 81.2, 72.0, 
60.9, 49.2, 37.7, 14.2. 
 
N-(9-Fluorenylmethoxycarbonyl)-N-(propargyl)glycine(5) 
Aq 4 M NaOH (20.0 mL) was added to a solution of 4 (84.0 mmol, 11.9 g) in 
dioxane (100 mL) and MeOH (35.0 mL). After stirring for 40 min, the reaction 
mixture was concentrated in vacuo. The resulting sodium salt was dissolved in 
H2O (80.0 mL) and the pH was adjusted to 9–9.5 with concd HCl. A solution 
of Fmoc-OSu (84.0 mmol, 28.3 g) in MeCN (130 mL) was subsequently added 
and the mixture was left to stir overnight at r.t.. The MeCN was removed 
under reduced pressure and the aqueous phase was acidified (pH 1– 2) with 
concd HCl. The aqueous phase was extracted with CH2Cl2 (2 × 100 mL) and 
the combined organic phases were washed with H2O (50 mL) and brine (50 
mL), dried (Na2SO4) and concentrated under reduced pressure. 
Recrystallization from EtOAc–hexane gave 5 as white crystals in 55% yield 
(45 mmol, 15.1 g); mp 130– 132 °C; Rf = 0.33 (CH2Cl2–MeOH–AcOH, 
97:2.5:0.5).  
Fmoc-N-Pra-OH (5): Yield 55%. IR (KBr): 3851 (s), 2959 (w), 2893 (w), 
1736 (s), 1678 (s), 1541 (w). 1479 (m), 1460 
(m), 1403 cm–1 (m). 1H NMR (500 MHz, 
DMSO-d6): d = 12.87 (s, 1 H), 7.89 (m, 2 H), 
7.72 (m, 1 H), 7.60 (m, 1 H), 7.35 (m, 4 H), 
4.30–4.00 (m, 7 H), 3.30 (m, 1 H). 13C NMR 
(125 MHz, DMSO-d6): d = 170.99/170.87, 155.48/155.45, 144.1, 
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141.19/141.15, 128.2, 127.6, 125.75/125.56, 120.6, 79.76/79.57, 68.0 (br), 
48.33/47.72, 46.98/46.89, 37.63/37.45. Results are consistent with previously 
reported data
153
. 
 
6.3 Solid Phase Peptide Synthesis 
 
6.3.1 General procedure for batch SPPS on the manual PLS 4x4 
synthesizer 
Peptides are synthesized on a manual batch synthesizer (PLS 44, Advanced 
ChemTech) using a Teflon reactor (20 or 10mL), following the Fmoc/tBu 
SPPS procedure. The resin is placed in the Teflon reactor, equipped with a 
filter. Mixing is provided by vortex, while filtration is performed connecting 
the reactor to a vacuum pump. The resin is swollen for 40 min with DMF (1 
mL/100 mg of resin) before use. Each amino-acid cycle is characterized by the 
following four steps:  
• Fmoc-deprotection: Resin is stirred twice (1 × 5 min + 1 × 15 min) 
with a solution of 20% piperidine in DMF (1 mL/100 mg of resin). 
• Washings: DMF (3 × 3 min). 
• Coupling reaction: Fmoc-protected amino acids in DMF (1 mL/100 
mg resin), TBTU/NMM or HBTU/NMM or HATU/NMM as coupling 
system for 30 min. 
• Washings: DMF (3 × 5 min) and DCM (2 × 5 min). 
Deprotection of the second residue should be performed by a fast protocol to 
avoid DKP formation (3 × 5 min). For the couplingstep a solution of the 
Fmoc-amino acid, TBTU/NMM, or HBTU/NMM or HATU/NMM in DMF (1 
mL × 100 mg resin) is added to the resin. Coupling conditions, in terms of 
equivalents of excess and coupling reagents used are specified for each 
product. After DCM washings each coupling reaction is monitored by Kaiser 
test
154
. After the last Fmoc-deprotection the resin is washed with DCM and 
dried under vacuum. 
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6.3.2 On-Resin Glaser cyclization 
The resin aliquots were swollen for 2 h in DCM before adding the pre-
dissolved copper catalyst and additives. The vessels were then transferred to 
the MW cavity of a manual CEM synthesizer. The cyclization reactions were 
performed according the conditions summarized in Table 3.12 and in Table 
3.16for each compound. The resin is washed using DMF (3 x 2 min), 0.5 % 
diethylthiocarbamate and 0.5% DIEA in DMF (3 x 10 min, or until brown 
coloration disappears), DMF (3 x 2 min) and DCM (3 x 2 min). 
 
6.3.3 General procedure for peptides αN-terminal acetylation 
Acetylation of the 
α
N-terminal is carried out after Fmoc-protecting group 
removal on the alfa amino function of the last residue anchored to the resin 
according the following procedure.   
• Resin is swollen for 20min in DCM and filtered. 
• Resin is stirred in a solution of Ac2O (20eq) and NMM (20 eq) in 
DCM (1mL/100mg of resin) at room temperature for 2 hours (2x1h). 
• Resin is then washed with DCM (3x3min) and dried. 
 
6.3.4 General procedure for cleavage  
Peptides and glycopeptides are cleaved from the resin using as cleavage 
mixture TFA/EDT/thioanisole/H2O/phenol (82.5:5:2.5:5:5) (reagent K) or 
TFA/H2O/TIS (95:2.5:2.5), as indicated for each compound. The peptide-resin 
is treated for different times with cleavage mixture (1 mL × 100 mg of resin) at 
room temperature, as indicated for each compound. The resin is filtered off 
and the solution is concentrated flushing with N2. The peptide is precipitated 
from cold Et2O, centrifuged and lyophilized. 
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6.3.5 General procedures for glycopeptide deacetylation 
A) Deacetylation of the sugar linked to the MEps is accomplished by adding 
0.1 M MeONa in MeOH to a solution of the raw material in dry MeOH until 
pH 12. After 5 h under stirring the reaction is quenched by adding conc. HCl 
to neutrality, the solvent is evaporated under vacuum and the residue 
lyophilized. 
B) Deacetylation of the sugar linked to the disulfide bridge cyclopeptideis 
accomplishedby stirring the resin in a solution of N2H4/MeOH 4:1 1h x2 times 
at room temperature. The resin is then filtered, washed with DMF (3x2min), 
DCM (3x2min) and dried. 
 
Purification: AllPeptides are purified by semipreparative RP-HPLC using 
methods and solvent system reported in tables. Fractions are checked by RP-
HPLC ESI-MS or MALDI-TOF to homogeneous ones. 
 
6.3.6 Synthesis of Multiple Epitope peptides, CT21, CT32, CT33, CT34, 
CT35 and CT38  
Multiple Epitope peptides were synthesized on a manual PLS 4x4 synthesizer, 
as described in the general procedure, starting fromFmoc4-Lys2-Lys-β-Ala-
Wang resin (100mg, 0.2 mmol/g) using HATU(5equiv.) and NMM(7equiv). 
Fmoc-LAsn(β-GlcAc4)-OH (2.5 equiv), Fmoc-Ado-OH (2.5 equiv), and 
Fmoc-TTDS-OH (2.5 equiv) were coupled with HATU (2.5 equiv) and NMM 
(5 equiv) in DMF for 1 h. MEPs were acetylated on the 
α
N-terminal as 
described in the general procedure. MEPs were cleaved from the resin and side 
chains were deprotected as described in the general procedure treating the 
resind with a cleavage solution ofTFA/ H2O/TIS (96:2:2), for 4h, at r.t.. 
Deprotection of the hydroxyl functions of sugars was performed as described 
in the general procedure, a), and the MEps were purified by semipreparative 
RP-HPLC with different gradients, as reported in Table6.2. 
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Table6.2.Semi-prep. purification of MEps. 
 
 
 
 
 
 
 
 
 
 
Characterization of the peptides was performed using analytical RP-HPLC and 
ESI-MS spectrometry. Analytical data are reported in Table 3.2. 
 
6.3.7 Synthesis of cyclopeptide MDP-I 
Linear peptide MDP-I wassynthesized on a manual PLS 4x4 synthesizer, as 
described in the general procedure, starting from Fmoc-RinkAmide (MBHA) 
PS Resin (100mg, 0.43mmol/g) using HBTU(5equiv.) and NMM(7equiv.). 
Acetylation of the 
α
N-terminal was carried out as indicated in the general 
procedure. Lin-MDP-I was cleaved from the resin and side chains were 
deprotected as described in the general procedure using as cleavage solution 
reagent K for 3h, at r.t..After lyophilization, the intramolecular disulfide bond 
formation was carried out solving the crude product, in a solution of 0.1% of 
TFA in MilliQ water (1mg/mL). Oxidation could be performed in presence of 
TFA thanks to ‘activation’ by 2,2′-dithiodipyridine. 100 μl of a 2,2′-
dithiodipyridine solution (1.2 mg/ml in distilled H2O) were added per milliliter 
of solution. The reaction progress was monitored analytical RP-HPLC. After 3 
hours crude oxidation reaction mixture was concentrated by rotary 
evaporation, freezed and lyophilized. 
MEP RP-HPLC Method 
 Yield 
(%) 
ct21 02-35% B in 30 min  1,5 
ct35 07-35% B in 30 min  1,7 
ct32 05-40% B in 30 min  2,1 
ct33 07-40% B  in 30 min  1,9 
ct34 03-25% B in 30 min  2,5 
ct38 10-35% B in 30 min  2,3 
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Lyophilized cyclic peptide was purified by semi-preparative RP-HPLC 03-
15% of B in 30min; HPLC gradient at 4 mL min
-1
, solvent system A: 0.1% 
TFA in H2O, B: 0.1% TFA in CH3CN. After lyophilization and purification 
the compound MDP-I was obtained in 27% yield. Analytical data are reported 
in Table 3.6. 
 
6.3.8 Synthesis of cyclopeptide MDP-II 
Linear peptide MDP-II wassynthesized on a manual PLS 4x4 synthesizer, as 
described in the general procedure, starting from Fmoc-RinkAmide (MBHA) 
PS Resin (100mg, 0.43mmol/g) using HBTU(5equiv.) and NMM(7equiv.). 
Fmoc-L-Asn(βGlcAc4)-OH (3 equiv) was coupled using HATU (3 equiv) and 
NMM (5 equiv) in DMF for 1 h. Acetylation of the 
α
N-terminal was carried 
out as indicated in the general procedure. Peptide Deprotection of the hydroxyl 
functions of sugar was performed as described in the general procedure, b). 
Lin-MDP-II was cleaved from the resin usingand side chains were 
deprotected as described in the general procedure as cleavage solution reagent 
K for 3h, at r.t..After lyophilization, the intramolecular disulfide bond 
formation was carried out solving the of the crude product, in a solution of 
0.1% of TFA in MilliQ water (1mg/mL). Oxidation could be performed in 
presence of TFA thanks to ‘activation’ by 2,2′-dithiodipyridine. 100 μl of a 
2,2′-dithiodipyridine solution (1.2 mg/ml in distilled H2O) were added per 
milliliter of solution. The reaction progress was monitored analytical HPLC. 
After 3 hours crude oxidation reaction mixture was concentrated by rotary 
evaporation, freezed and lyophilized. 
Lyophilized cyclic peptide was purified by semi-preparative RP-HPLC 03-
15% of B in 30min; HPLC gradient at 4 mL min
-1
, solvent system A: 0.1% 
TFA in H2O, B: 0.1% TFA in CH3CN. After lyophilization and purification 
the compound MDP-II was obtained in 13.5% yield.Analytical data are 
reported in Table 3.9. 
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6.3.9 Synthesis of cyclopeptide MDP-III 
Linear Fmoc-protected precursor of MDPIII was synthesized on a manual 
PLS 4x4 synthesizer, as described in the general procedure, starting from 
starting from Fmoc-RinkAmide (MBHA) PS Resin(100mg, 0.43mmol/g) and 
using Fmoc-protected amino acids (5equiv.), HBTU (5 equiv.) and NMM (7 
equiv.) in DMF for 30 min. Fmoc-Pra-OH(3 equiv.) was coupled using HBTU 
(3 equiv). and NMM (5 equiv.) in DMF for 45 min. Side chain to side chain 
cyclization was achieved performing the Glaser coupling as described in the 
general procedure according the reaction conditions reported in Table 3.12and 
the cyclization yield was evaluated by RP-HPLC. Acetylation of the 
α
N-
terminal was carried out as indicated in the general procedure.MDPIIIwas 
cleaved from the resin and side chains were deprotected as described in the 
general procedure using as cleavage solution TFA/H2O/TIS (95:2.5:2.5), for 
3h at r.t.. Crude lyophilized product was purified by semi-preparative RP-
HPLC 03-15% of B in 30min; HPLC gradients at 4 mL min
-1
, solvent system 
A: 0.1% TFA in H2O, B: 0.1% TFA in CH3CN. After lyophilization and 
purification the compound MDP-III was obtained in 23% yield. Analytical 
data are reported in Table 3.13. 
 
6.3.10 Synthesis of cyclopeptide MDP-IV 
Linear peptide MDP-IV wassynthesized on a manual PLS 4x4 synthesizer, as 
described in the general procedure, starting from Fmoc-RinkAmide (MBHA) 
PS Resin (100mg, 0.43mmol/g) and using Fmoc-protected amino acids 
(5equiv), HBTU (5 equiv) and NMM (7 equiv) in DMF for 30 min. Fmoc-N-
Pra-OH(3 equiv) was coupled using HBTU (3 equiv). and NMM (5 equiv) in 
DMF for 45 min.Side chain to side chain cyclization was achieved performing 
the Glaser coupling as described in the general procedure according the 
reaction conditions reported in Table 3.16and the cyclization yield was 
evaluated by RP-HPLC. Acetylation of the 
α
N-terminal was carried out as 
indicated in the general procedure.MDPIVwas cleaved from the resin and side 
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chains were deprotected as described in the general procedure using as 
cleavage solution TFA/H2O/TIS (95:2.5:2.5), for 3h, at r.t.. Crude lyophilized 
product was purified by semi-preparative RP-HPLC 03-15% of B in 30min; 
HPLC gradients at 4 mL min
-1
, solvent system A: 0.1% TFA in H2O, B: 0.1% 
TFA in CH3CN. After lyophilization and purification the compound MDP-IV 
was obtained in 8% yield. Analytical data are reported in Table 3.17. 
 
6.4 Immunochemical assays 
 
6.4.1 Solid-phase not competitive indirect ELISA (SP-ELISA) 
Serum was obtained for diagnostic purposes from patients and healthy blood 
donors who had given their informed consent, and stored at -20 ºC until use. 
Antibody responses were determined in SP-ELISA. Ninety-six wells activated 
polystyrene ELISA plates (NUNC Maxisorp SIGMA) were coated with 1 μg 
per 100 μl of peptides per well or glycopeptides in pure carbonate buffer 0.05 
M (pH 9.6) and incubated at 4 ºC overnight. After five washes with saline 
containing 0.05% Tween 20, non specific binding sites were blocked by fetal 
calf serum (FCS), 10% in saline Tween 20 (100 μl per well) at room 
temperature for 60 min. Sera diluted from 1:100 to 1:100.000 were applied at 4 
ºC overnight in saline/Tween 20/10% FCS. After five washes, it was added 
100 μl of alkaline phosphatase conjugated anti-human IgM (diluted 1:200 in 
saline/Tween 20/FCS) or IgG (diluted 1:8000 in saline/ Tween 20/FCS) 
(Sigma) to each well. After 3 h at room temperature incubation and five 
washes, 100 μl of substrate solution consisting of 1 mg/ml p-nitrophenyl 
phosphate (Sigma) in 10% diethanolamine buffer was applied. After 30 min, 
the reaction was stopped with 1M NaOH (50 μl), and the absorbance was read 
in a multichannel ELISA reader (Tecan Sunrise) at 405 nm. ELISA plates, 
coating conditions, reagent dilutions, buffers, and incubation times were tested 
in preliminary experimentsErrore. Il segnalibro non è definito.. The antibody 
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levels are expressed as absorbance in arbitrary units at 405 nm (sample 
dilution 1:100). 
 
6.4.2 Measurement of antibody affinity by competitive ELISA 
Antibody affinity was measured following the methods previously reported
156
. 
The semi-saturating sera dilution (1:600) was calculated from the preliminary 
titration curves (absorbance, 0.7). At this dilution, Abs were preincubated with 
increasing synthetic peptide antigen concentration (0; 2.7×10
-11
; 2.7×10
-10
; 
2.7×10
-9
; 2.7×10
-8
; 2.7×10
-7
; 2.7×10
-6
; 2.7×10
-5
;2.7×10
-4
;2.7×10
-3
) for 1 h at 
room temperature. Unblocked Abs were revealed by ELISA, and the antigenic 
probe concentration-absorbance relationship was presented graphically. 
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7. Abbreviations 
 
Ab: antibody; 
Ac: Acetyl; 
Ag: Antigen; 
AGA: anti gliadin antibodies; 
AP: alkaline phosphatase; 
APC: Antigen presenting cell; 
ATP: Adenosine triphosphate; 
Boc: tert-butoxycarbonyl; 
BSA: bovine serum albumine; 
CD: coeliac disease 
CNS: Central Nervous System 
DCM: dichloromethane; 
Dde: 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl; 
DIC: N,N’diisopropylcarbodiimide 
DIPEA: diisopropylethylamine; 
DMF: N,N dimethylformamide; 
EB: ennhanced binding; 
EDT: ethanedithiole; 
ELISA: enzyme-linked immunosorbent assay; 
EMA: endomysial antibodies; 
ESI-MS: electrospray ionization-mass spectrometry 
Fab: fragment antigen-binding; 
Fc: fragment crystallizable; 
FCC: flash column chromathography; 
FCS: fetal calf serum; 
Fmoc: 9-H-fluoren-9-ylmethoxycarbonyl; 
GAD: glutamic-acid decarboxylase; 
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Glia: Gliadin; 
GTP: Guanosine triphosphate; 
HATU:2-(1H-7-Azabenzotriazol-1-yl)--1,1,3,3-tetramethyl uronium 
hexafluorophosphate Methanaminium 
HLA:human leukocyte antigen 
HMW: high molecular weight;  
HOBt: 1-hydroxybenzotriazole; 
HPLC: high performance liquid chromatography; 
HRP: horseradish peroxidase; 
IA 2:  insulinoma antigen 2; 
Ig: immunoglobulin (IgE, IgG, etc.); 
IL: interleukin; 
IFN: interferon; 
LMW: low molecular weight; 
MALDI-TOF: matrix-assisted laser desorption ionization- time of flight; 
MAP: mutiple antigenic peptide; 
MEP: multiple epitope peptide; 
MHC: major histocompatibility complex; 
MMPs:matrix metalloproteinases; 
MOG: myelin oligodendrocyte glycoprotein; 
MS: Multiple Sclerosis; 
MW: microwaves; 
NBD’s: Normal Blood Donors: 
NK: natural killer cells; 
NMM: N-methyl morpholine; 
NMR: nuclear magnetic resonance; 
NMP:N-methyl-2-pyrrolidone; 
OT: oligosaccharil transferase; 
PBS: phosphate buffered saline; 
PDB: protein data bank; 
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PEG: polyethylene glycol;  
PNPP: para-nitrophenylphosphate; 
PS: polystyrene; 
RA: rheumatoid arthritis; 
RIA: radioimmunoassay; 
ROC: receiving operating characteristics; 
RS: rett syndrome 
SLCF: spot liquid chromatography flash; 
SP-ELISA: solid-phase enzyme-linked immunosorbent assay; 
SPPS: solid phase peptide synthesis; 
TBCR
. 
BF4: 4-(4,6-dimetoxy-1,3,5-triazin-2yl)-4-metylmorpholinium 
tetrafloroborate 
TBCRs: Triazine Based Coupling Reagents; 
TBTU: 2 - (1H-benzotriazole-1-yl) - 1,1,3,3 - tetramethyluronium; 
tetrafluoroborate; 
tBu: tert-butyl; 
TFA: trifluoroacetic acid; 
TIS: triisopropylsilane; 
TJ: tight junctions; 
TNF: tumor necrosis factor 
Th: T-helper cell; 
THF: tetrahydrofurane; 
TLC: Thin layer chromatography; 
TLR: toll-like receptor; 
TMS: trimethylsilylane; 
TPO: Thyroid Peroxidase;  
Trt: trityl; 
tTG: tissue Transglutaminase. 
